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Abstract 
 
The pathology of Alzheimer’s disease (AD) is characterised by progressive 
accumulation of misfolded proteins, which form senile plaques and 
neurofibrillary tangles, and chronic inflammation in the brain associated with 
inflammatory mediators by the activation of innate immune responses. There 
has been considerable interest in the role of neuroinflammation in directly 
contributing to the progression of AD. Studies in mice and humans have 
identified a role for microglial cells, the resident innate immune cells of the CNS, 
in AD. Activated microglia are a key hallmark of the disease and the secretion 
of pro-inflammatory cytokines by microglia may result in a positive feedback 
loop between neurons and microglia, resulting in ongoing low-grade 
inflammation and associated neurotoxicity. The underlying mechanisms 
however are poorly understood. Here the role of microglia was investigated, 
especially their link to ApoE – the strongest risk factor for late onset Alzheimer’s 
disease – and the relationship between microglia, neurons and 
neuroinflammation. 
 
Target replacement mice were used, where the human ApoE2, ApoE3 or 
ApoE4 allele replaces the mouse ApoE allele. Microglia were activated in a two-
step setup. Initially cells were primed with LPS, followed by a secondary 
stimulus, such as ATP or Aβ. The system was used to characterise the 
cytokines secreted by activated microglia and to assess the impact of 
conditioned medium from stimulated and Aβ treated microglia on neuronal 
morphology. 
 
The first results Chapter (Chapter 3) established the system – mouse microglia 
were isolated from brains of neonatal mice and characterised by CD11b 
staining. Microglia from all three ApoE genotypes were directly compared and 
the data from ELISA and mass spectrometry revealed an enhanced pro-
inflammatory response by ApoE4 microglia and the least efficient at 
internalizing amyloid β.  
Chapter 4 analysed the impact of conditional medium from the microglia ApoE 
variants on neurons and the results showed an ApoE-dependent effect on 
dendrite morphology. Conditioned media from immunostimulated and Aβ 
microglia were incubated with cortical neurons from wt animals. Both the 
dendrite length and number of dendrites were significantly reduced in neurons 
treated with conditioned medium from ApoE4 microglia.  
TNFα was identified as a major cytokine and was responsible for modifying 
neuron morphology in cell assays. Neutralising the cytokine, with an anti-TNFα 
antibody abrogated the majority of morphological changes induced by the 
conditioned media from activated microglia. Hence the data suggests that TNFα 
may have a major role in mediating neuroinflammation.  
 
The third results Chapter (Chapter 5) compared aspects of macrophage 
function with microglia. Here it was shown, that microglia do not require SNX5 
for macropinocytosis, and most likely utilise peripheral mediated 
macropinocytosis as the main form of macropinocytic internalisation. A major 
finding was the ability of sodium chloride to augment a pro-inflammatory 
response not only by immunostimulated macrophages by also microglia. 
Inhibition of the p38 MAPK signalling pathway partially ameliorated the NaCl-
induced inflammatory responses in both macrophages and microglia, together 
with high levels of secreted IL-1β, indicating activation of the NLRP3 
inflammasome. 
 
Overall the studies highlight a role for APoE4 allele to promote an enhanced 
inflammatory response by microglia cells. 
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Chapter 1: Literature review 
 
1.1 Alzheimer’s disease and hallmarks of the disease 
Alzheimer’s disease (AD) was first identified in 1906 by Alois Alzheimer 
who described the characteristic memory loss and confusion, as well as other 
psychological symptoms, in a 51year old female patient. In the same patient’s 
brain, Alzheimer identified plaque formation, neurofibrillary pathology, tangles, 
astrogliosis and neuronal loss (Alzheimer A, 1906).  
AD is now recognized as the most common neurodegenerative disease and is 
characterized by initial short-term memory loss followed by subsequent severe 
deficits attributed to neuronal loss (Probst et al., 1991). An estimate of 46.8 
million people globally were living with dementia in 2015. This number is 
expected to reach 131.5 million by 2050 (Ginhoux et al., 2010). The continuous 
increase in life expectancy results in those rising numbers of dementia patients, 
and goes hand in hand with the increasing economical burden of dementia 
(Westendorp, 2006). The annual cost of dementia care is predicted to increase 
from $600 billion to $1 trillion over the next 15 years (Prince et al., 2014).The 
majority of AD have a late onset (LOAD), whilst a stronger genetic prevalence is 
associated with the early onset AD form (EOAD).  
 
AD is characterized by widespread neuronal degeneration, synaptic loss 
affecting mainly the hippocampus and cortex, resulting in diffuse brain atrophy 
(Braak and Braak, 1991). Accumulation and deposition of amyloid-beta (Aβ) 
peptides and neurofibrillary tangles were long considered the sole major 
hallmarks of AD. However, more recently neuroinflammation has emerged as a 
third hallmark of the disease.  
 
 
1.2 Amyloid precursor protein  
The human amyloid precursor protein (APP) gene was first identified in 
1987 (Kang et al., 1987) and although one of the most studied human proteins, 
the function of APP remains poorly defined. A number of putative physiological 
functions have been assigned to APP, such as regulation of neurite outgrowth, 
cell adhesion, synaptogenesis and cell survival (Vetrivel and Thinakaran, 2010). 
APP, a type 1 membrane protein is synthesized in the ER and transported to 
endosomes and/or the cell surface via the secretory pathway (Sisodia, 1992; 
Thinakaran and Koo, 2008; Toh et al., 2018). Posttranslational modifications of 
newly synthesized APP such as glycosylation, phosphorylation and sulfation 
take place during transit through the Golgi (Wang et al., 2017). Proteolytic 
processing of APP occurs at multiple locations in the cell and results in a variety 
of peptide products, including the pathogenic Aβ peptides, which are then 
secreted from the cell (Tan and Gleeson, 2019). APP is located on 
chromosome 21 and exists in many different isoforms due to alternative splicing 
of the nascent transcript (Rajendran and Annaert, 2012). APP695 is the major 
neuronal isoform. Various mutations of the APP gene are known to cause 
familial AD (FAD) by increasing the extracellular Aβ load or shifting the ratio 
between Aβ1-40 and Aβ1-42 to the less favourable Aβ1-42 (Scheuner et al., 1996). 
The majority of these mutations affect the proteolytic processing by β and α 
secretases (Weggen and Beher, 2012). A reduction of amyloidogenic peptides 
is found in the Icelandic APP mutation (A673T), which confers protection 
against AD, due to reduced β secretase cleavage of APP (Jonsson et al., 
2012).  
Numerous animal models have been developed an in vivo models to gain 
insights into the development of AD. A transgenic mouse model expressing 
high levels of human ‘high-risk’ mutant APP was developed in 1995 (Games et 
al., 1995). Whilst this model expressed the Indiana mutation, various APP 
models have been introduced expressing different APP mutations, including the 
Swedish and Dutch mutation. Furthermore mouse models expressing mutant 
PSEN have been introduced (McGowan et al., 2006). The characterisation of 
these models includes the formation of Aβ. Mouse models for risk genes 
causing LOAD have also been introduced, including ApoE target replacement 
mice, CD33 and TREM2 models. Whilst in vivo models have helped in the 
understanding of AD development, they do not show the dementia comparison.  
 
1.3 β-secretase family 
The generation of Aβ occurs from the processing of APP via membrane-
bound proteases called secretases. Three secretases, α, β and γ, are involved 
in the processing of APP; β and γ secretases have a role in mediating the 
amyloidogenic cleavage of APP, whereas α secretase prevents Aβ generation 
by cleaving APP within the Aβ domain (Haass, 2004).  
 
BACE1 (beta-site APP cleaving enzyme 1) is the major β secretase responsible 
for amyloidogenic cleavage of APP in the brain (Fukumoto et al., 2002). BACE1 
is a 501-residue type 1 transmembrane protease and belongs to the pepsin 
family of aspartyl proteases with optimal activity at acidic pH (Yan et al., 2001; 
Vassar et al., 2009). The protease is synthesized as a larger precursor, 
proBACE1, which is modified by glycosylation and cleaved by a furin-like 
endoprotease in the trans-Golgi network to generate mature BACE1. Like other 
aspartic proteases, BACE1 precursor is a zymogen and is synthesized in the 
endoplasmic reticulum (ER). The maturation of BACE1 increases the catalytic 
activity of the enzyme over that of immature BACE1 (Vassar et al., 2009). An 
increased localization of BACE1 within the ER (which will represent the 
zymogenic non-active form) reduces generation of Aβ, whilst intracellular 
trafficking of BACE1 to the more acidic endosomes enhances Aβ production 
(Vassar et al., 2009). 
 
Mature BACE1 recycles between the plasma membrane and early and 
recycling endosomes (Toh et al., 2018). The recycling is regulated by a 
dileucine motif within the sequence, DISLL, of the cytoplasmic tail at residues 
496-500 (Toh et al., 2018). BACE1 can be phosphorylated on Ser498 within this 
DISLL. The phosphorylation of this motif regulates BACE1 recycling between 
the cell surface and endosomal compartments. There are two mechanisms for 
transport of BACE1 from the early endosomes to the recycling endosome. A 
slow SNX4 (sorting nexin 4) mediated pathway that can transport both non-
phosphorylated and phosphorylated BACE1, and a fast sorting signal mediated 
pathway dependent on the phosphorylation status of the DISLL motif of BACE1. 
Golgi-localized γ-ear containing Arf binding protein 1 (GGA1) recognises the 
phosphorylated DISLL motif of BACE1 and promotes cargo transport to the 
recycling endosomes. Perturbation of the signal sorting pathway by either 
mutation of the Ser in the DISLL motif or by silencing GGA1 or retromer results 
in ~30 % reduction in the transport rate of BACE1 from the early endosomes to 
the recycling endosomes. The phosphorylated DISLL mediated trafficking of 
BACE1 is biologically relevant as elimination of the fast transport of BACE1 
from early endosomes to recycling endosomes results in a three-fold increase in 
Aβ production (Toh et al., 2018). 
 
The analysis of BACE1-/- mice also provides substantial evidence for a crucial 
role of BACE1 in AD. Aβ generation, amyloid pathology and cognitive 
deficiencies are abrogated when BACE1-/- mice are crossed to APP 
transgenics. In AD, BACE1 activity is elevated. BACE activity in AD increased 
by 63 % in the temporal cortex and 13 % in the frontal cortex, but not in the 
cerebellum (Fukumoto et al., 2002). As BACE1 is the only β secretase in the 
brain, BACE1 has been considered a therapeutic target for lowering cerebral Aβ 
levels in AD (Vassar et al., 2009). However, an array of problems and 
challenges have arisen associated with the development of a therapeutic 
BACE1 inhibitor. The issues include the ability to cross the blood brain barrier 
(BBB) and the realisation that there are a large number of physiological 
substrates for BACE1, and inhibition of BACE1 activity will result in off target 
effects (Coimbra et al., 2018). Notably, BACE1 knockout mice have revealed 
defects in synaptic function and behavioural problems (Haass, 2004).  
 
 
1.4 Amyloidogenic and non-amyloidogenic processing of APP 
The ~4 kDa Aβ peptide is one of the hallmarks of AD and is derived from 
APP. BACE1 is responsible for the initial step in Aβ production. The type-1 
transmembrane aspartyl protease needs to be membrane bound and in close 
proximity with APP for cleavage, which highlights the importance of the spatial 
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Figure 1.1. Processing of APP 
(A) In the amyloidogenic pathway, APP undergoes processing by BACE1, 
resulting in the sAPPβ and the C99 fragment. This is further processed by γ-
secretase, resulting in the Aβ monomer. The Aβ monomer can assemble into 
oligomers and fibrils and eventually form the characteristic Aβ plaques.      
(B) In the non-amyloidogenic pathway, the amyloid beta precursor protein 
(APP) undergoes processing by α-secretase, resulting in the sAPPα and the 
C83 fragment, which is cleaved by γ-secretase resulting in the p3 peptide 
fragment. Adapted from Toh and Gleeson (2016). 
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distribution of both APP and BACE1 within the membranes and intracellular 
compartments for processing.  
 
Cleavage of APP by BACE1 results in sAPPβ, a soluble APP luminal domain 
that is subsequently secreted and a membrane bound C99-residue C-terminal 
fragment called C99 or CTFβ. This C99 fragment is cleaved by γ secretase 
resulting in the release of hydrophobic Aβ peptides (Fig. 1.1A).  
 
In an alternate, non-amyloidogenic, pathway, α secretase initially cleaves 
mature APP, resulting in the generation of a soluble luminal domain fragment, 
sAPPα, and a membrane bound fragment C83 or CTFα where the Aβ sequence 
is absent (Fig. 1.1B). Subsequent cleavage of the C83 fragment by γ secretase 
yields a number of short peptides excluding Aβ (Vassar et al., 1999).  
 
 
1.4.1 Secreted Aβ 
Aβ generated from the amyloidogenic pathway is secreted from the cell 
and subsequently aggregates to form amyloid plaques. The majority of secreted 
Aβ peptides are 40 amino acids (Aβ40), and 42 amino acids (Aβ42). The later 
Aβ42 has the propensity to nucleate and drive production of amyloid fibrils 
(Jarrett et al., 1993). Aβ is usually removed from the brain by export into the 
cerebrospinal fluid (CSF), the blood vessels and local degradation by microglia 
(Tarasoff-Conway et al., 2015). Microglia can clear Aβ by uptake and 
degradation or can degrade extracellular Aβ by the release of enzymes such as 
neprilysin. The rapid removal of Aβ released by neurons is imperative as Aβ is a 
hydrophobic peptide with a tendency to aggregate. Thus, there is a fine balance 
between pathways to clear Aβ and the generation of Aβ aggregates, which will 
accumulate. An increase in secreted Aβ concentration by neurons above a 
certain level results in formation of Aβ oligomers and plaques (Scheuner et al., 
1996).  
 
 
1.5 Neurofibrillary tangles 
Neurodegenerative tauopathies, characterized by abnormal tau is 
another characteristic hallmark of AD. Tau is a microtubule-associated protein 
predominantly expressed in neurons and is required for microtubule 
stabilization as well as their assembly (Takemura et al., 1992). Pathological tau 
protein is hyperphosphorylated, and aggregated into insoluble neurofibrillary 
tangles (NFT). Accumulation of toxic intracellular aggregates, together with the 
loss of soluble tau to stabilize microtubules, may synergistically lead to 
compromised neuronal survival accounting for the strong correlation between 
NFT burden and cognitive decline in AD (Iba et al., 2013). Synaptic loss has 
been described with tangle accumulation. Studies of the rTg4510 tauopathy 
mouse model have further revealed that impaired synaptic plasticity also 
contributes to the neurodegenerative process in AD, and both Aβ and tau 
contribute to this degeneration (Crimins et al., 2013). Bussian and colleagues 
have recently shown that tau formation is enhanced by the presence of 
senescent microglia and astroglial cells (Bussian et al., 2018).  
 
 
1.6 Microglia 
There has been considerable recent attention in defining the pathways of 
neuroinflammation and the cell types involved. It has become clear that 
microglial cells are a major contributor to the inflammatory process in the brain, 
and are not just bystanders as originally thought. Microglia have become a 
major focus of neurodegenerative disease research and defining the 
physiological properties of microglia is crucial to understanding their potential 
role in neuronal loss and AD.  
 
Microglia are the resident innate immune cells of the brain, first described as 
migratory phagocytic cells of the central nervous system (CNS) (del Rio-
Hortega, 1932). Microglia account for approximately 10% of cells in the CNS 
and are the most abundant mononuclear phagocytes in this tissue (Ginhoux et 
al., 2010; Colonna and Butovsky, 2017). These resident myeloid cells of the 
CNS control the patterning and wiring of the brain in early development and 
contribute to homeostasis. Erythromyeloid progenitors (EMPs) develop in the 
yolk sac from E8.5 onwards and a subset of these cells become microglia 
progenitors which migrate to the brain from E9.5 onwards. This original pool of 
microglia is the only source of myeloid cells in the healthy brain. However, 
under pathological circumstances other myeloid cells such as bone marrow-
derived monocytes may infiltrate the brain (Kierdorf et al., 2013).  
 
Microglia express chemokine receptors including CXCR4 and CX3CR1, as well 
as integrins such as CD11b, which is constitutively expressed, and CD11c, 
which is upregulated in activated microglia (Färber and Kettenmann, 2005; Roy 
et al., 2006). Chemokine receptors and integrins control the migration and the 
position of microglia within the CNS and enhance their ability to phagocytose 
and eliminate target cells. Pro-and anti-inflammatory cytokines, such as IFNγ, 
TNFα, IL-1β, IL-10 and TGFβ tightly regulate the activity of microglia (Colonna 
and Butovsky, 2017). Furthermore, activated microglia are capable of releasing 
cytotoxicity mediators such as reactive oxygen and nitrogen species, 
arachidonic acid metabolites and histamine, amongst others (Nakajima and 
Kohsaka, 2001). Many studies have shown that the precise profile of the 
neurotrophic or cytotoxic factors released by microglia depends on the specific 
stimulus the microglia has been exposed to (Nakajima et al., 1998; Zhao et al., 
2014). In particular, LPS stimulation is known to result in the secretion of a 
number of pro-inflammatory cytokines (Lee et al., 2010). 
 
Microglia, like macrophages, have previously been classified according to their 
M1 and M2 polarisation. The M1/M2 paradigm has helped conceptualise the 
pathways of microglia activation in vitro, but is now considered inadequate for 
an in vivo understanding as microglia rarely display bias toward either 
phenotype (Ransohoff, 2016). A number of transcriptome studies have revealed 
that microglia activation is both varied and situation-dependent (Hanisch, 2013). 
Different models of neurodegeneration have revealed that microglia express 
both neurotoxic as well as neurotrophic factors (Ransohoff, 2016). Microglia 
under a non-inflammatory environment have a small soma and numerous 
processes extending into the microenvironment. This allows microglia to 
penetrate throughout the parenchyma in the normal adult brain and survey the 
environment, one of their main functions. The term ‘resting’ microglia, 
commonly used in the past, is therefore a misnomer (Nimmerjahn et al., 2005), 
as microglia triggering may occur intermittently even in a healthy environment. 
Additional roles of microglia in healthy conditions include the maintenance of 
homeostasis during neurogenesis, and shaping synaptic fields through synaptic 
pruning (Chen and Trapp, 2016).  
 
Recent GWAS studies have identified immune related pathways as risk factors 
for late onset Alzheimer’s disease (LOAD), identifying microglia as central 
players in disease pathogenesis (Hong et al., 2016).  
 
 
1.6.1 Microglia and Astrocytes in AD 
The precise role of microglia in contributing to chronic disease is 
incomplete. We need to better understand the balance between their protective 
role and one where healthy tissue is destroyed. This scenario is akin to the role 
of macrophages in the development of chronic inflammatory autoimmune 
disease. For microglia, it can be argued that their role is mainly protective, to 
remove cell debris and/or infectious agents (Chen and Trapp, 2016). 
 
Microglia are involved in Aβ clearance (Lee and Landreth, 2010), which is both 
beneficial, to inhibit Aβ build up, and deleterious, when levels of Aβ are 
elevated, as prolonged inflammation will result. Microglia express a range of 
different receptors that can bind Aβ and trigger inflammation, such as different 
TLRs. In turn these can be stimulated by DAMPs such as ATP and induce 
NLRP3 activation (Heneka et al., 2013; Heneka, Carson, et al., 2015). 
Engagement of these receptors induces release of TNFα and IL-1β, which 
mediate neuroinflammation and neurotoxicity and cause sustained low grade 
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Figure 1.2 Differences of microglia function under physiological and pathological 
conditions  
Microglia mediate immune responses by clearing apoptotic cells, debris and Aβ and 
secrete various neurotrophins and cytokine. Under pathological conditions, the 
clearance of Aβ is often impaired, leading to Aβ build up and the secretion of 
neurotrophins, neurotoxins together with pro-inflammatory cytokines.  
inflammation (Heneka, Carson, et al., 2015) (Figure 1.2). Deletion of receptors 
such as TLR4 reduces Aβ induced cytokine production (Fiebich et al., 2018). 
  
In addition to microglia, astrocytes may also play a role in neurodegeneration. 
Astrocytes contribute to synapse formation and synaptic strength regulation 
(Allen, 2014) and, like microglia, are involved in monitoring neuronal activity. 
Astrocytes both sense and modulate synaptic output and may play a role in 
regulating in the overall computing function of the brain (Allen, 2014). Although 
a role for astrocytes in neurodegenerative diseases has been largely ignored in 
the past, potential interactions between microglia and astrocytes are now 
attracting considerable attention. Astrocytes guide microglia to synapses that 
have been pruned via the complement pathway (Lian et al., 2015). Hence 
astrocytes can influence the interaction of microglia with neurons, and thereby 
indirectly affect the delivery of neurotoxic and neurotrophic factors to neurons 
released by microglia.  
 
 
1.6.2 Microglia and other neurodegenerative diseases 
 Microglia involvement has also been associated with several other 
neurodegenerative diseases, in addition to AD, such as amytrophic lateral 
sclerosis (ALS), where the release of pro-inflammatory cytokines by activated 
microglia leads to neuronal damage and neurotoxic activity (Boillee S Kassiotis 
G, 2006). They have further been implicated in Parkinson’s disease as well as 
Huntington’s disease. In these examples, neuroinflammation is the major 
causative neurotoxic effector, demonstrating yet again the relevance of a better 
understanding of the link between microglia activation and its neurotoxic effects 
(Colonna and Butovsky, 2017). 
 
1.7 Neurons and their role in AD 
Neurons are polarised cells with axonal and somatodendritic membrane 
surfaces and are considered the cellular substrate of cognitive abilities of the 
CNS (Nowakowski, 2006; Schmidt and Haucke, 2007). For spatial segregation 
of incoming and outgoing signals, neurons retain an elaborate membrane 
system. Electrical signals are generated and conveyed by axons whilst 
synapses convert them into chemical ones. Neurotransmitter containing 
vesicles undergo exo- and endocytosis at the presynaptical nerve terminal. 
These neurotransmitter molecules bind to receptors at the postsynaptic 
membrane causing ion flux changes and sometimes the generation of an action 
potential. Kinesins are responsible for the transport of membrane vesicles 
containing APP or ApoER2 (apolipoprotein E receptor 2) to the axon (Schmidt 
and Haucke, 2007). APP and BACE1 are predominantly located in the 
somato/dendrites of neurons (Sannerud et al., 2011). 
 
Like microglia, the role of neurons in neuroinflammation was long believed to be 
that of a passive bystander, however they are able to produce inflammatory 
mediators themselves (Heneka et al., 2010). Activation of the complement 
systems plays an important role in AD and neurons are capable of the 
production of most components of the complement cascade (Eikelenboom et 
al., 1989). The complement system can be activated by PAMPS and/or 
DAMPS. C1q can directly bind to molecules like Aβ, hence there is the potential 
for complement to be activated as a consequence of build up of extracellular Aβ 
and/or release of components from dying neurons (Orsini et al., 2014). 
Complement synthesis is low under normal conditions but increased in AD 
(Eikelenboom et al., 1989; Orsini et al., 2014) Neurons are not only involved in 
the production complement cascade components but have also been 
postulated as a source for COX-2 derived prostanoids, a subclass of 
eicosanoids which are vasoactive lipid mediators, and several cytokines such 
as IL-1β, IL-6 and TNFα (Heneka et al., 2010).  
 
Neuronal activity regulates the production and secretion of Aβ by controlling 
APP processing upstream of γ secretase activity. Kamenetz and colleagues 
identified Aβ as a modulator of synaptic strength. This negative feedback role 
for Aβ could suggest Aβ as a player in normal synaptic physiology, not only in 
the processes leading to AD (Kamenetz et al., 2003). Sustained neuronal 
activation is associated with plaque formation. Studies on temporal lobe 
epilepsy patients found plaques in patients as young as 30 years of age 
(Mackenzie and Miller, 1994). Taken together this suggests that neuronal 
activity and Aβ levels are closely interlinked and neuronal hyperexcitability is a 
recognised component of AD. This is most likely due to a mixture of direct and 
indirect effects of Aβ on neurons (De Strooper and Karran, 2016).  
 
 
1.8 Neuroinflammation  
Evidence that inflammation has a causal role in the pathogenesis of AD 
comes both genetic and immunological analysis. Genes for various immune 
receptors such as Trem2 (Triggering receptor myeloid 2) and CD33 are 
associated with AD and microglia have been shown to be capable of binding to 
soluble Aβ oligomers and fibrils via cell surface receptors including CD36, 
CD14, CD47 and Toll-like receptors (TLR2, 4, 6 and 9). Aβ binding to CD36, 
TLR4 or TLR6 results in activation of microglia, to produce pro-inflammatory 
cytokines and chemokines (El Khoury et al., 2003). Pro-inflammatory cytokines 
secreted by activated microglia include TNFα and IL-1β; moreover, these 
cytokines are known to be upregulated in brains of AD patients and in 
transgenic mice with AD-like pathology, and in addition are secreted by primary 
microglia in culture (Grammas and Ovase, 2001). Although mainly pro-
inflammatory an anti-inflammatory role of TNFα and IL-1β is also possible 
(Zheng et al., 2016).  
 
As is the case for innate immune responses in the periphery, cytokines in the 
CNS are key regulators of neuroinflammation. The pro-inflammatory 
environment in the AD brain could directly and indirectly contribute to neuronal 
damage. For example, IL-1β and TNFα may directly impair neuronal function 
(Ye et al., 2013). The rate of progression from mild cognitive impairment to the 
dementia stages of the disease is increased in patients who have elevated 
TNFα levels and decreased TGFβ concentrations in the CSF. Cytokines 
stimulate inducible nitric oxide synthase (iNOS) in microglia and astrocytes and 
iNOS is toxic to neurons at high concentrations. Notably, iNOS has been 
reported to be upregulated in the AD brain (Heneka, Carson, et al., 2015). 
Consistent with this proposal, in vitro experiments have shown that binding of 
microglia to Aβ leads to the production of reactive oxygen species (ROS) (El 
Khoury et al., 2003).  
 
Although Aβ deposition alone may be sufficient to induce an inflammatory 
reaction, risk factors such as systemic inflammation, obesity and traumatic brain 
injury might influence the development of AD through a sustained 
neuroinflammatory drive (Heneka, Carson, et al., 2015). Inflammation preceding 
the development of AD may prime microglia, causing them to be highly 
responsive to further activation (Colton et al., 2006). Subsequent stimulation by 
Aβ could then result in secretion of pro-inflammatory cytokines and 
chemokines, which could trigger neuronal hyperexcitability and synaptic 
dysfunction. Recent studies have demonstrated that neurons are also able to 
produce inflammatory mediators (Heneka et al., 2010). Activation of 
complement systems play an important role in AD and neurons produce most of 
the components of the complement cascade. Moreover, neuronal production of 
complement components is increased in AD (Eikelenboom et al., 1989). 
Neurons have also been postulated to be source of COX-2-derived prostanoids, 
a subclass of eicosanoids which are vasoactive lipid mediators, and several 
cytokines such as IL-1β, IL-6 and TNFα (Heneka et al., 2010).  
 
A number of studies have shown that in vivo LPS treatment results in an 
increase level of Aβ1-42 and a decrease in the level of Aβ1-40 (Lee et al., 2008); 
significantly, Aβ1-42 is the more toxic species. This finding suggests a close 
connection between amyloidogenesis and neuroinflammation. However, the 
mechanisms responsible for LPS-induced amyloidogenesis are unknown. Lee 
et al. reported elevated β and γ secretase activity in cortical and hippocampal 
regions of ICR mice and Sprague-Dawley rats, as well as cell lysates upon LPS 
treatment, hence modified secretase activity could be a potential contributing 

Figure 1.3 Potential positive feedback loop in the diseased brain between microglia and neurons 
(A) In the healthy brain microglia cells clear amyloid β from the CNS microenvironment and secrete 
neurotrophic factors maintaining a healthy neuron population.  
(B) A model illustrating the activation of microglia after DAMP recognition of inflammatory stimuli or 
amyloid β stimulation. Microglia activation induces release of pro-inflammatory cytokines and 
mediates neuroinflammation and neurotoxicity. The resulting increase of amyloid β leads to further 
aggregation and the sustained low grade inflammation found in Alzheimer’s disease.  
factor (Lee et al., 2008). Furthermore, pro-inflammatory cytokines such as 
TNFα and IL-1β have been shown to increase levels of β secretase mRNA, and 
BACE1 protein and enzymatic activity. Lee and colleagues have proposed that 
LPS-induced inflammatory reactions influence APP processing through the 
enhancement of β and γ secretase activity and thereby affect amyloidogenesis 
(Lee et al., 2008).  
 
Unfolded, misfolded and aggregated proteins are recognized by the danger 
associated molecular pattern (DAMP) receptors found on the cell surface of 
innate immune cells. An important finding in the neuroinflammation field is that 
aggregated Aβ acts as a DAMP, resulting in the activation of the innate immune 
system in the brain (Heneka, 2017) with the consequence pro-inflammatory 
cytokine production. Hence, following an initial build up of extracellular 
oligomeric Aβ, there is potential to stimulate an inflammatory response via 
microglia. As the pro-inflammatory response is directed to self-DAMPS, and as 
neurons are in turn impacted by the pro-inflammatory cytokines, a positive 
feedback loop is likely to be established, resulting in enhancing disease 
progression and establishing a chronic, on-going, disease (Figure 1.3). 
 
 
1.9 NLRP3 inflammasome 
The innate immune system engages pattern recognition receptors 
(PRRs), which are expressed by cells fighting against infection and those 
involved in adaptive immune cells, such as macrophages and microglia 
(Schroder and Tschopp, 2010). Different bacteria, fungal and viral molecules 
that contain pathogen associated molecular patterns (PAMPs) or non-microbial 
danger signals (DAMPs), released by damaged cells can activate NOD-like 
receptors (NLRs) (Saresella et al., 2016). 
 
NLRs are characterised by a central nucleotide-binding and oligomerisation 
domain (NACHT), flanked by C-terminal leucine-rich repeats (LRRs) and N-
terminal caspase recruitment (CARD) or pyrin (PYD) domains (Schroder and 
Tschopp, 2010; Horvath et al., 2011). NLRP3 is the best-characterised 
inflammasome and is mainly expressed by myeloid lineage cells. It can be 
induced by stimulation of TLRs, cytokines and other signals (Jo et al., 2016).  
 
Activation of the NLRP3 inflammasome is a two-step process, which depends 
on a priming signal, required for the upregulation of NLRP3 and the production 
of the proinflammtory cytokines pro-IL1β and pro-IL-18. TLR4 stimulation 
initiates MyD88/NFκB signalling (Su et al., 2018). Furthermore p38 MAPK 
signalling has been connected to NLRP3 activation (Li et al., 2018). The 
secondary signal or activation step triggers assembly into the NLRP3 
inflammasome complex. A secondary signal can be extracellular ATP, which 
activates inflammasome assembly via the purinergic receptor P2X7 
(Mariathasan et al., 2006). NLRP3 monomers induce oligomerisation and 
interact with the PYD domain of apoptosis-related speck-like protein (ASC). The 
adaptor ASC then recruits the cysteine protease pro-caspase-1 via a caspase 
recruitment domain (CARD). The resulting autocatalysis and activation of 
caspase-1 leads to maturation and secretion of pro-inflammatory cytokines IL-
1β and IL-18, and under certain conditions the induction of a cell death pathway 
known as pyroptosis (Heneka, Golenbock, et al., 2015; Jo et al., 2016). The 
caspase-1 dependent cell death is inherently inflammatory and is both 
morphologically and mechanistically distinctly different from other forms of cell 
death (Bergsbaken et al., 2009). The resulting increase of IL-1β affects synaptic 
plasticity, as this cytokine is able to disrupt formation of dendritic spines. NLRP3 
inflammasome activation is an important contributor to normal age related 
systemic inflammatory responses as well as brain inflammation (Heneka, 
Golenbock, et al., 2015) (Figure 1.4).  
 
 
1.9.1 NLRP3 inflammasome and its contribution to AD 
The NLRP3 inflammasome plays an important role in AD pathology. 
APP/PS1 mice deficient in NLRP3, casp1 or ASC are largely protected from AD 
(Heneka et al., 2013). In part, protection from AD can be attributed the role of 

Figure 1.4 Activation and assembly of the NLRP3 inflammasome  
The inflammasome is activated by a two-step mechanism. The first signal (priming) is provided by microbial or 
endogenous molecules such as LPS. Recognition by TLR4 in this case leads to an increase in gene 
transcription mediated by the adaptor protein MyD88 (myeloid differentiation factor 88) and then the activation 
of NFκB and p38 MAPK activities. This induces NLRP3 and pro-IL-1β, pro-IL-18 expression. The second signal 
(activation) is triggered by ATP, pore-forming toxins, viral RNA, or particulate matter. Different molecular and 
cellular events have been proposed to trigger NLRP 3 inflammasome activation including K+ efflux, ROS, Ca2+ 
signalling, mitochondrial dysfunction. Upon activation, the NLRP3 inflammasome assembles, and gives rise to 
caspase 1 which cleaves pro-IL-1β and pro-IL-18. IL-1β and IL-18 are secreted and the cell undergoes 
pyroptosis.  
NLRP3 in IL-1β production. IL-1β has been detected in diseased brain tissue in 
multiple studies. IL-1β is released by activated microglia after stimulation with 
Aβ in vitro and elevated levels of IL-1β were detected in microglia surrounding 
Aβ plaques in patients with AD as well as animal models of AD (Griffin et al., 
1989) As described above, IL-1β is synthesized in an inactive form controlled by 
caspase-1, which in turn is controlled by the NLRP3 inflammasome. Halle and 
colleagues have shown that the NLRP3 inflammasome is required for Aβ 
induced activation of caspase-1, release of mature IL-1β and secretion of pro-
inflammatory cytokines as well as potentially neurotoxic cytokines and 
chemokines. These authors also showed that the activation of NLRP3 
inflammasome was initiated after Aβ phagocytosis. Furthermore they have 
demonstrated, using IL-1β ELISA of microglia treated with fibrillar Aβ (10 µM) 
that fibrillar Aβ can induce caspase-1 dependent release of IL-1β (Halle et al., 
2008). Inefficiently cleared pro-inflammatory mediators or Aβ can in turn act as 
DAMPs and upon receptor binding activate NLRs leading to a further increase 
in inflammation. 
 
The notion that the NLRP3 inflammasome plays a key role in 
neuroinflammation is further supported by findings by Saresella and colleagues 
(Saresella et al., 2016). Using patient derived monocytes these authors 
reported an upregulation of inflammasome genes in LPS primed and Aβ 
stimulated monocytes derived from AD patients but not in monocytes from mild 
cognitive impairment (MCI) stage individuals. Furthermore, expression of 
NLRP1, NLRP3 and caspase-8 was greatly increased in AD and MCI stage 
patients, whilst PYCARD, caspase-1 and caspase-5 expression was detected in 
AD but not MCI patients (Saresella et al., 2016). This was also supported by 
Heneka et al (Heneka et al., 2013), who found that caspase-1 expression is 
strongly enhanced in AD and MCI brains. Furthermore, NLRP3 and caspase-1 
KO APP/PS1 mice are largely protected from loss of spatial memory and other 
AD associated symptoms. Reduced brain caspase-1 and IL-1β levels as well as 
enhanced Aβ clearance was found in these mice (Heneka et al., 2013). Not only 
is inflammasome activation linked to AD pathology, Venegas et al. have shown 
that intrahippocampal injections of specks of the adapter protein apoptosis-
assosciated speck-like protein containing a CARD (ASC), result in the 
spreading of Aβ pathology in transgenic double mutant APPSwePSENde9 mice 
(Venegas et al., 2017). NLRP3 inflammasome activation also results in the 
release of assembled ASC specks, which can be taken up by neighbouring 
cells and contribute to the on-going immune response (Franklin et al., 2014). 
Studies using APP/PS1/NLRP3-/- mice, have revealed a protective effect of 
systemic inflammation and additionally revealed the the knockout improves Aβ 
clearance by microglia (Tejera et al., 2019). 
 
 
1.10 Early onset familial form of AD 
EOAD affects approximately 10 % of all AD patients. As the name 
suggest, EOAD results in an earlier onset of the disease, affecting patients 
between 30 and 65 years of age (Prince et al., 2016). Typical clinical 
presentation includes memory impairment, atypical focal cortical symptoms 
such as visual dysfunction, apraxia, and dyscalculia. Whilst the pathological 
features of late onset AD (LOAD) and EOAD are very similar, an atypical 
presentation is reported more frequently seen in EOAD patients (Cacace et al., 
2016). In comparison to LOAD, EOAD is almost entirely genetically determined 
with heritability ranging from 92-100 %. APP, PSEN1 and PSEN2 are the three 
genes mainly responsible for the early onset form of AD (Wingo et al., 2012; 
Cruts et al., 2012). PSEN mutations are inherited in an autosomal dominant 
manner (Cacace et al., 2016). Whilst healthy neurons secrete mainly Aβ1-40, 
many mutations of APP and PSENs either increase Aβ1-42 or the ratio of Aβ1-
40/Aβ1-42 (Borchelt et al., 1996). The Apolipoprotein E4 (ApoE4) is known as the 
major risk factor for LOAD; the e4 allele of the APOE gene also increases the 
risk for EOAD in carriers of only one ApoE4 allele, in carriers with two ApoE4 
alleles, the risk is further increased. The E4 allele may modify the expression of 
other genetic factors contributing to the disease. On the contrary the E2 allele of 
the APOE gene exerts a positive effect and delays age of onset (Corder et al., 
1994; Genin et al., 2011) 
  
1.10.1 Late onset sporadic form of AD 
 LOAD is not only more complex than EOAD but also more common. 
Approximately 65 % of all AD cases are considered sporadic. The sporadic form 
also has APOE as a genetic risk factor and is associated with approximately 40 
% of all cases. However since this leaves 60 % of the cases unexplained for, 
LOAD most likely results from a combination of multiple environmental, dietary 
and lifestyle factors contributing to onset of the disease (Kalaria et al., 2008; 
Piaceri et al., 2013). Illiteracy or low educational achievement has also been 
associated with an increased risk for LOAD, as well as stroke and vascular 
disease (Borenstein et al., 2006). Age however is the most consistent risk factor 
world wide, with women being slightly more likely to develop AD in particular 
with very old age (Kalaria et al., 2008).  
 
 
1.11 AD risk genes- inflammation and membrane trafficking 
For many years ApoE remained the only confirmed risk factor for late 
onset Alzheimer’s disease (LOAD). GWAS studies have now identified 29 risk 
genes (Lambert et al., 2009; Lambert et al., 2013; Jansen et al., 2019). The 
most recent GWAS study confirmed known loci associated with AD from earlier 
GWAS studies and detected 9 novel loci including ADAMTS4 (α secretase) and 
CLNK (a regulator of immunoreceptor signalling) (Jansen et al., 2019). This 
recent study by Jansen and colleagues had a sample size eight-fold larger than 
the previous GWAS (Lambert et al., 2013) and included genetic data of 
>600,000 individuals. Analysis of the identified single nucleotide polymorphisms 
(SNPs) revealed that most of the variants are located in non-coding regions of 
the genome (Jansen et al., 2019).  
 
The identified risk genes for LOAD can be broadly grouped into four categories; 
innate immune response, cholesterol metabolism, endosomal trafficking and 
APP catabolism/processing (summarised in Table 1.1). 
 Examples of innate immune responses include Clusterin (CLU), TREM2 and 
CD33. CLU also known as apoJ, has several SNPs that have been identified 
and shown to confer protection against LOAD. CLU is predicted to function in 
synapse turnover, Aβ aggregation, clearance and toxicity (Bettens et al., 2013). 
TREM2 (triggering receptor expressed on myeloid cells 2) is another example of 
a risk factor identified through GWAS studies, which belongs to the innate 
immune response group. TREMs are a member of the immunoglobulin 
superfamily of receptors encoded by a gene cluster linked to the major 
histocompatibility complex (MHC) (Jay et al., 2015). TREM2 is a receptor 
expressed by myeloid cells, including microglia in the brain. TREM2 stimulates 
phagocytosis and plays a role in the reduction of inflammation by suppressing 
toll-like receptor induced inflammatory cytokines and enhancing anti-
inflammatory cytokine transcription (Jay et al., 2015). TREM2 is also required 
for migration, lipid sensing and ApoE binding (Schlepckow et al., 2017; Ulland 
and Colonna, 2018). The risk associated with TREM2 mutations depends on 
the genetic background, as different populations show differences in their risk of 
developing AD for a given TREM2 mutation. For example, the R47H variant of 
TREM2 confers an increased risk of developing AD similar to that of ApoE4 in 
Caucasians, however there is no association between R47H status and risk of 
developing the disease in East Asian individuals (Ulland and Colonna, 2018). 
 
CD33 has also been identified as a risk factor for LOAD. Two SNPS in the 
CD33 gene have been associated with LOAD. Like TREM2, the CD33 variant 
associated with increased risk has been directly linked to impaired uptake of Aβ 
by microglia cells. CD33 is a member of the sialic acid-binding immunoglobulin-
like lectins (Siglecs) and mediates cell-cell interactions that inhibit or restrict 
immune responses (Griciuc et al., 2013). 
 
 
Table 1.1 Summary of selected genetic risk factors associated with LOAD 
Functional class Risk gene 
Innate immune response Triggering receptor expressed in myeloid cells 2 
(TREM2) (El Khoury et al., 2003) 
Ephrin type-A receptor 1 precursor (EPHA1) 
(Jansen et al., 2019) 
Complement receptor 1 (CR1) (Jansen et al., 
2019) 
SLP Adaptor And CSK Interacting Membrane 
Protein (SCIMP) (Jansen et al., 2019) 
CD33 (Griciuc et al., 2013) 
HLA-DRB1 (Jansen et al., 2019) 
Inositol Polyphosphate-5-Phosphatase D 
(INPPD5) (Jansen et al., 2019) 
ABI family member 3 (ABI3) (Jansen et al., 2019) 
Membrane spanning 4A (MS4A) (Lambert et al., 
2013) 
Cytokine dependent hematopoietic cell linker 
(CLNK) (Jansen et al., 2019) 
Cas scaffolding protein family member 4 (CASS4) 
(Jansen et al., 2019) 
Cholesterol metabolism Apolipoprotein E (ApoE) (Corder et al., 1993) 
Enoyl-CoA Hydratase Domain Containing 
3(ECHDC3) (Jansen et al., 2019) 
Clusterin (CLU) (Lambert et al., 2009) 
ATP binding cassette subfamily A member 7 
(ABCA7) (Lambert et al., 2013) 
Sortilin protein related receptor (SorL1) (Lambert 
et al., 2013)  
Endocytosis Sortilin protein related receptor (SorL1) (Lambert 
et al., 2013) 
Bridging integrator 1 (BIN1) (Lambert et al., 2013) 
Sortin nexin 3 (SNX3) (Lambert et al., 2013)  
Phosphatidylinositol binding clathrin assembly 
protein (PICALM) (Lambert et al., 2013) 
CD2 associated protein (CD2AP) (Lambert et al., 
2013) 
A disintegrin and metalloproteinase with 
thrombospondin motifs 4 (ADAMTS4) (Jansen et 
al., 2019) 
APP processing 
 
A disintegrin and metalloproteinase domain-
containing protein 10 (ADAM10) (Jansen et al., 
2019) 
 Aph-1 Homolog B (APH1B) (Jansen et al., 2019) 
 
 
1.11.2 ApoE 
The major genetic risk factor for AD is the ApoE. The gene is located on 
chromosome 19q13.2 (Strittmatter et al., 1993). ApoE is a 299 amino acid 
lipoprotein and regulator of lipid metabolism and is involved in different roles in 
the CNS such as cholesterol transport and inflammation. Its function in the brain 
remains unclear, despite ApoE being highly expressed in the CNS (Holtzman et 
al., 2012; Piaceri et al., 2013). The ApoE lipoprotein contains two structural 
domains linked by a protease sensitive loop (Wetterau et al., 1988). The N-
terminal domain (aa 1-191) contains the receptor-binding region and forms a 
four helical antiparallel bundle. The C-terminal domain (aa 225-229) contains 
the major lipid binding region (Mahley et al., 2009a). Due to its conformational 
flexibility ApoE can bind to lipoproteins of variable sizes and shapes. ApoE is 
mainly produced by astrocytes and to a lesser extent by microglia under control 
of PPARγ and LXR (Terwel et al., 2011). The three most common alleles of 
ApoE encode the following three isoforms, ApoE2, ApoE3 and ApoE4. 
Weisgraber et al elucidated that single aa substitutions result in the structural 
differences between the isoforms (Weisgraber et al., 1981). The differences of 
aa at residues 112 and 158 distinguishes the isoforms. ApoE3 has cysteine at 
NH2	 COOH	
APOE2	158	Cys	
112	Cys	
NH2	 COOH	
APOE3	158	Arg	
112	Cys	
NH2	 COOH	
APOE4	158	Arg	
112	Arg	
Figure 1.5 Single nucleotide polymorphism gives rise to the three major 
ApoE alleles 
The single AA substitution at position 158 and 112 leads to substitution of 
Cys to Arg and induces binding to other nearby AA via salt bridges which 
dramatically affects the protein structure.  
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position 112 and arginine at 158, whilst ApoE4 has arginines at both sides, and 
ApoE2 cysteines (Weisgraber et al., 1981), as depicted in Figure 1.5.  
 
ApoE allele frequencies in the population differ, with the e3 allele being the 
most common (~65 %), followed by e4 (15-20 %) and e2 the rarest (5-10 %). 
The ApoE genotype determines the risk of developing AD (Mahley et al., 
2009b). Individuals with one ApoE2 allele and one ApoE3 allele are 20 % less 
likely to develop LOAD compared with individuals with one allele of ApoE4. The 
addition of an ApoE4 allele increases the AD risk of an individual by a factor of 
2.84. Thus patients with two ApoE4 alleles are over eight times more likely than 
those without ApoE4 alleles (for example ApoE2/E3 or ApoE3/E3) (Corder et 
al., 1993). ApoE4 is associated with increased deposition of Aβ, 
hyperphosphorylation of tau as well as impairment of neuronal plasticity and is 
also found in senile plaques and intracellular NFTs (Strittmatter et al., 1994; 
Arendt et al., 1997; Piaceri et al., 2013). In early age, the ApoE4 variant confers 
an advantage, as ApoE4 positive individuals performed better in behavioural 
tests executive attention, verbal fluency and memory tasks (Jochemsen et al., 
2012). The beneficial effect of ApoE4 is reversed in old age. This so called 
antagonistic pleiotropy hypothesis could explain ApoE4s persistence in the 
human population (DiBattista et al., 2016).  
 
Not only does ApoE4 constitute the highest risk of developing the disease, it 
also has an effect on the clinical course of the disease, causing earlier onset of 
dementia, increased brain atrophy, thinner cortices as well as faster cognitive 
decline (Jack et al., 1998). In contrast, the ApoE2 isoform has a protective 
effect, manifesting in lower incidences of MCI and AD, later age at onset of the 
disease and a slower cognitive decline (Martins et al., 2005).  
 
Brain regions typically associated with Aβ plaque deposition coincide with 
regions that metabolise glucose by aerobic glycolysis. This process seems to 
be disrupted in AD patients by ApoE4. Studies on patients carrying the ApoE4 
allele revealed reduced cerebral glucose metabolism (Piaceri et al., 2013). 
ApoE binds to Aβ and influences the clearance of soluble Aβ and its 
aggregation. ApoE4 carriers exhibit accelerated and more abundant Aβ 
deposition (Karch and Goate, 2015). Furthermore it was shown that ApoE4 
enhances the oligomerisation of Aβ, suggesting that ApoE4 predisposes AD by 
increasing toxic Aβ oligomers (Huang et al., 2017) and that ApoE4 has an 
impaired ability to facilitate the proteolytic degradation of Aβ by neprilysin and 
insulin degrading enzyme (Du et al., 2009). It has also been shown that ApoE4 
is less effective at inducing cholesterol efflux than ApoE3, suggesting that the 
pathological effects of ApoE4 are related to lipid metabolism (Safieh et al., 
2019).  
 
ApoE has also been associated with neuroinflammation. Ophir and colleagues 
have demonstrated, using human ApoE3 and ApoE4 transgenic mice, that 
following inflammatory stimulation with LPS, ApoE4 mice had an enhanced and 
prolonged neuroinflammatory response (Ophir et al., 2005). The inflammation is 
most likely driven by the effect of ApoE4 on microglial activation and possibly 
enhanced levels of pro-inflammatory cytokines. It was also demonstrated that 
NFκB activation was more pronounced in ApoE4 mice, further suggesting that 
ApoE can regulate inflammatory processes isoform specifically (Ophir et al., 
2005). Interestingly, levels of ApoE in the CSF also differ in an isoform 
dependent manner, suggesting that ApoE concentration may contribute to 
some of the ApoE genotype effects. ApoE4 carriers have lower serum and 
ApoE levels in brain tissue (Martínez-Morillo et al., 2014). 
 
Several studies have shown that ApoE4 does not always increase the risk for 
developing AD. Some populations seem to be protected by other overruling 
factors. Sub-Saharan Africans belong to that group, as well as Caribbean 
Hispanics and African Caribbean people of Jamaican origin, for whom the 
ApoE4 allele is only weakly associated with an increased risk of developing 
LOAD (Kalaria et al., 2008). Differences in populations associated with ApoE4 
and risk of AD suggests genetic interactions with the ApoE4 allele, which 
modulate the risk. 
 1.12 Impact of neuroinflammation on trafficking of APP and BACE and Aβ 
production  
There is evidence that an increase of Aβ production arises as a direct 
result of neuroinflammation (Alasmari et al., 2018). An increase in β and γ 
secretase activities may be one reason for the increased amyloidogensis. In 
addition, neuroinflammatory cytokines have been reported to increase APP 
levels in neuronal cell models, suggesting that the expression of APP is 
upregulated (Alasmari et al., 2018). In addition, another key issue is whether 
neuroinflammation has an effect on the trafficking of APP and BACE and Aβ 
production. 
 
Neuronal BACE1 has been reported to be increased in the proximity of 
activated glia cells (Sastre et al., 2008), hinting the possibility of an 
inflammation dependent BACE1 upregulation. This suggestion was further 
supported by a study using neuronal cultures where exposure to pro-
inflammatory cytokines and under oxidative stress, resulted in an increase in 
BACE1 protein (Sastre et al., 2008). BACE1 has gained a lot of attention as a 
target for therapeutic inhibitors. Whilst BACE inhibition has been shown to 
reduce Aβ levels, many clinical trials failed to rescue cognitive decline (Zhu et 
al., 2018). Selective targeting of BACE1 expression could present a more 
successful approach. An increase of MMP13 has been observed in both human 
AD brains and AD mouse models. The overexpression of MMP13 stimulates 
PI3K (phosphatidylinositide kinase-3) signalling which in turn promotes the 
eukaryotic translation initiation factor 4B (elF4B), which facilitates BACE1 
mRNA translation. Selective targeting of MMP13 decreases elF4B 
phosphorylation and led to a reduction of BACE1 synthesis. These findings 
highlight the potential of both MMP13 and PI3K/Akt signalling as therapeutic 
targets (Zhu et al., 2019). 
 
In order to understand the direct connection between neuroinflammation and Aβ 
production, several studies have investigated the effect of LPS on Aβ 
production. In vivo animal experiments have shown that LPS injections induce 
memory loss and also the generation of Aβ1-42 in the cortex and hippocampus. 
LPS treatment was found to increase both β and γ secretase activities. This 
may be related to the transcriptional upregulation of β secretase mRNA levels 
(Lee et al., 2008). Taken together, these findings indicate that LPS augmented 
inflammatory reactions could influence APP processing through the 
enhancement of β and γ secretase activity thereby affecting amyloidogenesis 
(Lee et al., 2008).  
 
In addition to perturbations in the activity of the membrane-bound secretases, 
defects in membrane trafficking are known to be linked to enhanced Aβ 
production. A number of trafficking machinery genes have been identified as 
LOAD risk genes (Small et al., 2017). The regulation of membrane trafficking 
plays an important role in APP processing and there is an intimate relationship 
between neuron activation and Aβ production. Increased neuronal activity 
results in increased Aβ production (Kamenetz et al., 2003). Aβ production 
resulting from increased neuronal activity has been linked to endosomal 
processing of APP and Aβ release from the cells (Cirrito et al., 2008). Enhanced 
co-localization of exogenously expressed APP and BACE1 was observed 
following glycine-induced N-methyl-D-aspartate receptor (NMDARs) activation 
or potassium activation (Das et al., 2013), findings suggesting that the 
trafficking of APP and BACE1 could be altered under different physiological 
conditions. Of relevance, is that the Gleeson laboratory has demonstrated that 
the phosphorylation of the BACE1 sorting motif, DISLL, is regulated by 
signalling in neurons (Toh et al., 2018) and that the phosphorylation of DISLL 
influences endosomal trafficking of endogenous BACE1 (Toh et al., 2018). 
These studies highlight that external stimuli can induce changes to the 
trafficking itinerary of APP and BACE1 in primary neurons, which can also affect 
Aβ production. The question that arises from these findings is whether 
cytokines secreted from activated microglia can also drive signalling events in 
neurons to influence trafficking and convergence of APP and BACE1. Of 
relevance is that TNFα, a pro-inflammatory cytokine secreted by microglia, has 
been shown to stimulate BACE1 expression and is also linked to enhanced Aβ 
production (Yamamoto et al., 2007). Collectively, these reports suggest that the 
inflammatory environment contributes to Aβ production. This goes in hand with 
the controversy around the validity of the amyloid hypothesis due to the lack of 
successful targeted therapies (Kametani and Hasegawa, 2018). However, the 
amyloid targeted drugs have been tested on later stages of the disease rather 
than testing the impact of amyloid inhibition during the onset of disease or as 
preventative treatment. Evidence of amyloid being the initial driver of the 
disease is very strong. And neuroinflammation appears to be play a crucial role 
in sustaining the disease.  
 
Aβ induced apoptosis is associated with cyclooxygenase-2 upregulation 
through activation of NFκB signalling, or other complementary pathways 
including ERK and p38 MAPK that can intersect with various parts of the NFκB 
pathway. The increase of apoptotic neuronal cell death via elevation of Aβ1-42 
could be an important mechanism in LPS induced memory impairment (Jang 
and Surh, 2005). 
 
In summary, systemic inflammatory stimuli elevate amyloidogenesis through a 
number of likely mechanisms, including activation of β and γ secretases, 
inhibition of α secretase, alterations in membrane trafficking of APP and 
BACE1, leading to elevated Aβ1-42 levels both in vivo and in vitro. The elevated 
inflammation and amyloidogenesis would then be responsible for neuronal cell 
death and thus memory impairment.  
 
 
1.13 Relationship between chronic inflammation in the periphery and AD  
Given the importance of neuroinflammation in AD, it is important to 
consider the potential impact of peripheral chronic inflammation on the 
progression of AD. What do we know about conditions associated with chronic 
inflammation and susceptibility to AD? There is evidence of a correlation 
between systemic chronic inflammation, as determined by elevated C-reactive 
protein (CRP), and AD risk (Tao et al., 2018). Inflammatory conditions are also 
increasingly linked to AD. Oral health and infection, such as periodontitis, is 
correlated with AD (Teixeira et al., 2017). The relationship between chronic 
inflammatory autoimmune diseases, such as Rheumatoid Arthritis (RA), which 
is characterised by both elevated CRP and TNFα, and AD have been studied. 
Whilst one study found that AD was more prevalent among RA patients than 
those individuals not affected by RA (Chou et al., 2016). Kao and colleagues 
claim an inverse correlation between the two diseases (Kao et al., 2016).  
 
Is there any evidence of protection from AD by long term anti-inflammatory 
medication? Several epidemiological studies have provided evidence for a 
reduced prevalence of AD among non-steroidal anti-inflammatory drug (NSAID) 
users (Rogers et al., 1993; Gómez-Isla et al., 2008). The effects appear to be 
strongly dependent on both the duration of treatment and the ApoE genotype. 
Individuals with at least one ApoE4 allele, benefited significantly more from 
NSAID use (Imbimbo et al., 2010). Why ApoE4 carriers benefit more from 
NSAIDs treatment is unclear, it can be hypothesised that this is due to the 
higher risk of Aβ deposition and accumulation. However, whilst some studies 
suggest beneficial effects of NSAIDs such as Ibuprofen, others studies did not 
find a correlation. A more recent report, involving very large cohort of 8.5 million 
participants (Chou et al., 2016), not only confirmed an increased AD risk among 
RA patients, but also indicates there could be an important connection between 
anti-TNFα therapy for RA and reduced risk of AD amongst RA patients. RA 
patients on anti-TNF therapy with Etanercept have a lowered risk of AD (Chou 
et al., 2016). This represents an exciting observation that needs further 
investigation.  
 
 
1.14 Macrophages 
Macrophages are a resident population in non-neuronal tissues that bear 
similarities to microglia. Given the depth of information on macrophages, 
knowledge of the cell biology of this myeloid cell may provide insights into the 
behaviour and biological properties of microglia. 
 
Macrophages are large phagocytic cells that form a resident population in many 
tissues of the body (Gordon, 1986). Mononuclear cells, like macrophages, 
originate from haematopoietic stem cells and develop along distinct 
differentiation pathways (Geissmann et al., 2010). They have variable turnover 
rates and are replaced by cells in the circulation. Postnatally monocytes are 
derived from the bone marrow and can differentiate into macrophages (Roca et 
al., 2009).  
 
Resident macrophages play an important role in tissue homeostasis via 
clearance of apoptotic cells and production of growth factors (Geissmann et al., 
2010). They survey their environment by ingesting dead cells, debris and 
pathogens (Davalos et al., 2005).  
 
Macrophages in non-neuronal tissue reprogram their function in response to 
pathogens and tissue damage. Macrophages can be polarised into at least two 
functional states, M1 and M2. Bacterial stimuli such as LPS polarise 
macrophages to the M1 phenotype. IL-4 or CCL2 drive M2 polarisation (Roca et 
al., 2009). Macrophages activated by LPS and by IL-4 are functionally distinct. 
M1 polarised cells produce pro-inflammatory cytokines and chemokines such as 
IL-12, IL-23, TNFα, CXCL9 and CXCL10 and show enhanced antigen 
presentation capacity (Biswas and Mantovani, 2010). M2 polarised cells 
produce anti-inflammatory cytokines, such as IL-10, and display increased 
phagocytic activity and express scavenger receptors such as CD163 (Biswas 
and Mantovani, 2010). Whilst the concept of polarised M1 and M2 functional 
states is very useful to conceptualise the principles of macrophage activation, it 
is now debated whether it is, like for microglia, an oversimplification of cell 
activation (Yin et al., 2017).  
 
A variety of myeloid populations reside in the brain, including microglia, 
perivascular cells, meningeal macrophages and choroid plexus macrophages, 
sharing a multitude of markers such as IBA1, F4/80 and CX3CR1 (Prinz et al., 
2011). Despite the variety of myeloid cells in the brain, microglia are the only 
myeloid cells that reside behind the BBB (Prinz et al., 2011). The BBB is 
composed of specialised endothelial cells, linked by complex tight junctions 
comprised of adhesion molecules including cadherins (Engelhardt and 
Ransohoff, 2005). The BBB structure limits entry of solutes, and occludes 98 % 
of antibodies and small molecules but at the same time ensuring the efflux of 
others (Bechmann et al., 2007). A second interface, the blood CSF barrier 
(BCSFB), is at the choroid plexus where tight junctions are formed between the 
apical surface of the epithelial cells. A third barrier is formed by the arachnoid 
membrane under the dura mater (Abbott et al., 2010). Following injury to the 
CNS the activation of endothelial cells and associated cells such as astrocytes 
can lead to reduced tight junction integrity facilitating the migration of leukocytes 
across and through the BBB into the brain (Wilson et al., 2010). Under 
pathological conditions, excessively produced Aβ acts as a chemotractant to 
macrophages which then transmigrate across the BBB (Fiala et al., 1998). 
Infiltration of macrophages in the AD brain suggests a systemic immune 
response rather than the originally recognised local immune reaction (Fiala et 
al., 2002; Bechmann et al., 2007). Macrophages are considered to play an 
important role in the reduction of vascular amyloid. A study eliminating 
perivascular macrophages showed an accumulation of vascular amyloid 
(Hawkes and McLaurin, 2009). Interestingly macrophages from healthy 
individuals have been reported to be more efficient at Aβ phagocytosis and less 
susceptible to apoptosis upon Aβ exposure than macrophages from AD 
individuals (Lai and McLaurin, 2012). 
 
 
1.15 Uptake mechanisms  
Phagocytes such as macrophages and microglia are responsible for the uptake 
of cellular debris and elimination of pathogens. In order to do so they utilise 
different endocytic uptake mechanisms, which also allow them to survey their 
environment. Phospholipids play an important role in internalisation processes, 
by directing traffic of individual cellular compartments and the recruitment of 
proteins that control tubulation, fusion and fission events. Unsurprisingly 
dysregulation of phospholipid synthesis and catabolism during endocytosis is 
associated with a multitude of disorders, including infections, and neurological 
pathologies (Bohdanowicz and Grinstein, 2013). Hence, the understanding of 
endocytic pathways is critical to normal brain function.  
 
 
1.15.1 Endocytosis 
Endocytosis is the uptake of particles and cellular debris and involves the 
exchange between different membrane compartments of the cells, including 
plasma membrane, endosomes, lysosomes and the Golgi apparatus (Ryter, 
1985). All endocytic pathways share the requirement for a budding structure on 
the plasma membrane, or membrane ruffles as is the case in macropinocytosis, 
to generate endocytic structures. Endocytic pathways can be classified into two 
categories – clathrin-dependent endocytosis and clathrin-independent 
endocytosis (Doherty and McMahon, 2009). Not all cells perform the entire 
spectrum of endocytic pathways (Kuhn et al., 2014). 
 
 
1.15.2 Clathrin mediated endocytosis 
Clathrin-dependent endocytosis uses clathrin-coated vesicles to facilitate 
the uptake of material into the cell. The name originates from the fact that the 
coat around these vesicles consists of the protein clathrin (Pearse, 1976). 
Vesicle formation is a five-step process; beginning with a membrane pit 
formation and cargo selection by adaptor complexes such as AP-2, which in 
turn recruits clathrin. The small GTPase, dynamin, is then recruited to the 
vesicle and induces membrane scission. After the formation of a clathrin-coated 
vesicle, accessory proteins as well as clathrin are recycled back to the cytosol 
and can be reused. The internalised cargo is then delivered to endosomes 
where it is sorted (McMahon and Boucrot, 2011). 
 
Interestingly clathrin-dependent endocytosis can be used for the uptake of 
particles. One study demonstrated that 40 nm nanoparticles are taken up by 
clathrin mediated endocytosis in macrophages (Kuhn et al., 2014).  
 
 
1.15.3 Clathrin independent endocytosis 
In addition to the classic clathrin-mediated endocytosis, there are several 
rapid internalisation pathways that are clathrin-independent. Clathrin-
independent endocytosis can be further divided into dynamin-dependent and 
dynamin-independent pathways (Mayor and Pagano, 2007). Caveolae-
mediated endocytosis and a pathway dependent on the small GTPase RhoA 
are both dynamin-dependent mechanisms (Lamaze et al., 2001). A dominant 
negative mutant of dynamin was used to demonstrate a dynamin and clathrin 
independent pathway contributing to pinocytosis in HeLa cells (Damke et al., 
1995). Dynamin- and clathrin-independent endocytic pathways are regulated by 
small GTPases such as CDC42 or ARF6 (Mayor and Pagano, 2007). The 
GTPase dynamin pinches off vesicles at the plasma membrane, which is 
required for internalisation. The question therefore arises, how transport carriers 
are budded in dynamin independent endocytosis? Here, internalisation occurs 
via tubular structures, in the absence of a defined coat. Physical tension curves 
the membrane and promotes the spontaneous generation of transport vesicles 
(Mayor et al., 2014; Johannes et al., 2015). 
 
The clathrin-independent pathway(s) provide very rapid endocytosis (~100 ms) 
and can be used to restore the surface area of the membrane after exocytosis, 
as observed in mouse hippocampal neurons and plays an important role in the 
regulation of cell growth and development (Watanabe et al., 2013). 
 
 
1.15.4 Phagocytosis 
Phagocytosis is an actin-dependent pathway used for uptake of large 
particles (>0.5 um), such as apoptotic cells and bacteria, into intracellular 
structures known as phagosomes (Botelho and Grinstein, 2011). Professional 
phagocytic cells such as macrophages, monocytes, neutrophils, dendritic cells 
and microglia, are extremely efficient at surveying their environment and 
provide a first line of defence against infection (Stuart and Ezekowitz, 2005). 
Phagocytes can distinguish between pathogenic components that result in the 
induction of a pro-inflammatory response and apoptotic cells that trigger an anti-
inflammatory response. Pathogen associated components include bacteria, 
which are recognised by TLRs. Apoptotic cells are recognised by the 
expression of phosphatidyl-serine (PS) (Stuart and Ezekowitz, 2005). PS is an 
anionic phospholipid, normally confined to the inner leaflet of the plasma 
membrane of healthy cells (Cocco and Ucker, 2001). The translocation to the 
outer leaflet, exposing it to the cell surface, facilitates removal of cellular debris 
(Elliott et al., 2005). 
 
Phagocytosis is initiated upon receptor recognition on the cell surface following 
ligand binding. Actin polymerisation is induced under the membrane at the site 
of contact and a phagocytic cup, an actin rich membrane extension, then forms 
on the surface membrane that will protrude and curve around the target particle. 
Highly dynamic actin filaments drive the growth of membrane pseudopods that 
encircle the target. The phagosome then closes by fusion of pseudopods from 
both sides of the target particle and detaches from the surface membrane. The 
target can then be internalised and the phagosome matures to become a 
phagolysosome (Aderem, 2003; Botelho and Grinstein, 2011).  
 
 
1.15.5. Pinocytosis 
 Pinocytosis describes both fluid phase uptake and receptor mediated 
endocytosis (or clathrin mediated endocytosis) and includes micropinocytosis 
and macropinocytosis. Macromolecules of a size less than 0.2 µm in diameter 
are internalised by micropinocytosis (Steinman et al., 1983). Macropinocytosis 
on the other hand facilitates the internalisation of large quantities of solutes and 
membrane, due to the large size of macropinosomes, which can be between 
0.2 – 5 µm in diameter. Macropinocytic vesicles have no apparent coat 
structure (Hewlett et al., 1994; Swanson and Watts, 1995). 
 
 
1.15.6 Macropinocytosis 
Compared with other endocytic pathways, the size of vesicles formed by 
macropinocytosis are much larger (Mayor and Pagano, 2007). 
Macropinocytosis is a non-selective, signal-dependent process that can be 
activated by various stimuli including high doses of growth factors, integrin 
substrates, PS containing apoptotic cells, viruses and bacteria (Haigler et al., 
1979; Dharmawardhane et al., 2000; Watanabe and Boucrot, 2017). In the 
immune system, antigen presenting cells such as macrophages not only use 
macropinocytosis to capture antigens from their surrounding as a means of 
surveillance, but they are capable to constitutively do so (Norbury et al., 1995; 
Lim and Gleeson, 2011).  
 
Macropinocytosis begins with actin mediated membrane ruffling of the plasma 
membrane. This can occur both on the peripheral and dorsal surface of the cell 
(Abella 2010, Luo 2014). Ruffle extension and retraction is regulated by the 
phosphorylation and dephosphorylation of phosphoinoisitides. PI5-kinase 
stimulates actin polymerisation for ruffle extensions, whilst PI3-kinase is 
required for closure of the macropinosome (Araki et al., 2000). Rac, a member 
of the Rho family of small GTPases, is activated and leads to the formation of 
lamellipodial extensions (Araki et al., 2000; Araki et al., 2006). 
The so formed lamellipodia fold back onto themselves and fuse with the basal 
membrane creating large vesicles capturing the target. The closed vesicle is 
then internalised. Once formed, the macropinosome undergoes a maturation 
process, by recruiting late endosomal and lysosomal markers, including Rab5 
at the early stages of maturation and later Rab7. The macropinosome initially 
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Figure 1.6 Schematic model of macropinocytosis at the dorsal membrane  
Macropinocytosis is an endocytic pathway that arises from actin mediated membrane ruffling of the plasma membrane. 
Lamellipodia fold back over themselves and fuse with the plasma membrane, capturing the target and creating a large 
vesicle. The vesicle is internalised and the macropinosomes matures.  
acts as a maturing vessel and then fuses with tubular lysosomes (Racoosin and 
Swanson, 1993; Wang et al., 2010) (Figure 1.6).  
 
 
1.15.6.1 Physiological relevance of macropinocytosis 
As macropinocytosis is associated with actin dependent ruffling of the 
plasma membrane it is also implicated with cell motility. Therefore, 
macropinocytosis is not only relevant under physiological but also pathological 
conditions such as tumour progression and metastasis. Macropinocytosis is 
considered important in chemotactic response of highly mobile cells, such as 
neutrophils (Carpentier et al., 1991). This is believed to increase the level of 
pathogen ingestion by neutrophils.  
 
Pathogens such as bacteria, viruses and prions opportunistically exploit 
macropinocytosis to evade and invade the host immune system. The ebola 
virus is a particular interesting example of this, as it primarily enters the host cell 
via macropinocytosis, but has also adapted to an alternative route of entry via 
clathrin mediated endocytosis (Hoffmann et al., 2001; Lim and Gleeson, 2011; 
Aleksandrowicz et al., 2011). 
 
Macropinocytosis is also crucial for the ability of antigen presenting cells to 
sample their immediate environment for antigens (Norbury et al., 1995). 
Macrophages are extremely efficient doing this, as they are able to undergo 
extensive constitutive macropinocytosis, internalising up to 200 % of their 
surface area every hour (Steinman et al., 1976). 
 
 
1.15.6.2 Regulation of macropinocytosis  
A key difference between clathrin-dependent endocytosis and 
macropinocytosis is that the latter requires actin cytoskeleton reorganisation. 
The dynamics of the actin cytoskeleton can be visualised in cells expressing 
fluorescently labelled actin probes (Gaidarov et al., 1999). The actin associated 
protein coronin was identified in playing a key role in the formation of the 
macropinosome (Hacker et al., 1997). In macrophages F-actin was shown to 
associate with dextran positive macropinosomes and decreases when the 
structure matures (Araki et al., 2000; Lee and Knecht, 2002). 
 
 
1.15.6.3 Sorting nexins and macropinocytosis  
Recently members of the sorting nexin (SNX) family have been localised 
to macropinosomes and also implicated in their formation (Merino-Trigo et al., 
2004). SNXs are phox homology (PX) domain containing proteins, which belong 
to a diverse group of cellular trafficking proteins. They have the ability to bind to 
specific phospholipids, through their PX domain, and can form protein-protein 
complexes aiding them in their role in membrane trafficking (Wishart et al., 
2001; Worby and Dixon, 2002). 
 
A number of SNXs have been implicated in the biogenesis of macropinosomes 
including SNX1, SNX5, SNX9, SNX18 and SNX33 (Wang et al., 2010). GFP-
SNX5 expressing HEK cells were used to show that SNX5 colocalises with 
macropinosomes (Merino-Trigo et al., 2004). In a model of HEK-GFP-SNX5 
stable cells an increase in macropinocytosis was observed, which was 
associated with increased formation of macropinosomes. This suggests that 
SNX5 has a role in macropinocytosis regulation. In macrophages SNX5 is 
abundantly present and correlates to high intrinsic macropinocytosic activity 
(Lim et al., 2008). Using SNX5-knockout mice, Lim and colleagues have 
generated both macrophages and dendritic cells and shown that SNX5 plays an 
important role in the biogenesis of macropinsomes from dorsal ruffles. 
Interestingly, the lack of SNX5 did not have an effect on the phagocytic activity 
of these cells. Macrophages deficient in SNX5 have a dramatically reduced 
macropinocytic activity compared to wt macrophages. Whilst SNX5 was found 
both on macropinosomes derived from dorsal and peripheral ruffles, it was 
shown that SNX5 is essential to dorsal-ruffle derived macropinosomes and not 
peripheral mediated macropinsomes (Lim et al., 2012; Lim et al., 2015).  
  
1.16 Aims of this project 
ApoE is well established as one of the strongest risk factors for AD. 
Microglia are known to be key players associated with ApoE risk, but how the 
ApoE alleles affect microglia function remains largely unknown. Many studies 
have performed experiments comparing only two of the three APOE genotypes. 
The aim of this study is to directly compare all three ApoE alleles and 
additionally compare them to wt C57/BL6 microglia, harbouring the single 
isoform wt mouse ApoE allele. Neuroinflammation is a key hallmark of AD. 
Therefore, the first goal to understand the molecular basis for chronic 
inflammation in AD is to assess how microglia from the different genotypes 
respond to immunostimulation, and to determine how they respond to Aβ 
stimulation.  
 
Neurons are another key cell player in AD pathology, but the effect ApoE has 
on primary neurons is not well characterised. In particular, the interplay between 
microglia and neurons and the role of ApoE in such interactions remains an 
open question. Thus, the second aim of this project is to investigate the effect 
immunostimulated, or Aβ treated, microglia from different genetic backgrounds 
on neurons, in particular the impact on neuron morphology.  
 
Thirdly, the characterisation of microglia and comparison between microglia and 
macrophages is relevant to a better understanding of the cell biological 
properties of microglia. There is a wealth of knowledge on macrophages that 
can potentially be utilised to further understand microglia biology and thus 
helping further understand AD pathology. Macrophages, like microglia, are an 
integral part of the innate immune system, in part due to their ability to survey 
their environment by utilising different endocytic mechanisms. Macropinocytosis 
is one of these endocytic pathways. The Gleeson lab had previously shown that 
macropinocytosis in macrophages is SNX5-dependent. There is little known 
about macropinocytosis and the role of SNX5 in microglia, and therefore 
another aim is to assess the role of SNX5 in macropinocytosis in microglia.  
Another potentially relevant property of macrophages is the ability of sodium 
chloride to trigger an inflammatory response, a characteristic, which 
exacerbates inflammation in the periphery. Another component of Aim 3 was to 
examine the impact of sodium chloride on inflammatory responses of microglia. 
 
Chapter 2: Materials & Methods  
 
2.1 Antibodies for immunocytochemistry and immunoblotting  
The following primary antibodies were used at the indicated dilutions: 
MAP2 (1:1500 Rabbit polyclonal antibody, cat. no.: ab32454, Abcam, 
Cambridge, UK), Gm130 (1:300 mouse monoclonal antibody, cat. no.: 610823, 
BD, Franklin Lakes, US), Rabbit anti-mouse SNX5 antibody is as described 
previously (Lim et al., 2012), Phalloidin (1:1000, Sigma, Darmstadt, Germany), 
Integrin αM (1:150, mouse monoclonal antibody, cat. no.: sc-20050, Santa 
Cruz, Santa Cruz, US). Secondary antibodies for immunofluorescence were 
Goat anti-mouse IgG-Alexa Fluor 488 nm, Goat anti-rabbit IgG-Alexa Fluor 488 
nm and Goat anti-rabbit IgG-Alexa Fluor 647 nm. All secondary antibodies were 
diluted in Blocking Solution (5% FCS, 0.02% Sodium Azide in PBS) and 
obtained from Life Technologies. Horse-radish peroxidase (HRP) conjugated 
sheep anti-rabbit Ig and anti-mouse Ig were purchased from DAKO Corporation 
(Carpinteria, US).  
 
 
2.2 General reagents  
2.2.1 Amyloid beta preparation  
Amyloid beta protein (Aβ 1-42) (HFIP-treated) was obtained from 
Bachem (Bubendorf, Switzerland) and prepared following protocol by Nitsch et 
al 2001 (Nitsch, 2001). Aβ was diluted with dPBS and incubated for 30 minutes 
whilst shaking, followed by a further dilution to 250 µM and incubated at 37 °C 
for 84 hours at 1000 rpm.  
 
 
2.3 Animals  
All animals were kept under a temperature (20-24 °C) and humidity controlled 
vivarium in group housing. Both male and female mice were included in the 
study.  
2.3.1 ApoE target replacement mice  
ApoE 2, ApoE 3 and ApoE 4 target replacement mice express the 
human apolipoprotein E (2, 3 or 4 respectively) isoform under the control of the 
murine ApoE regulatory sequence. All animals are on a C57BL/6J genetic 
background. These animals were obtained from Taconic Biosciences (Albany, 
US) and maintained through mating of homozygotes. The original ApoE 2 target 
replacement chimera mouse was backcrossed to C57BL/6 for seven 
generations and twice more (N9) by Taconic, where embryo transfer was 
derived. The colony is since maintained through mating of homozygotes 
(Biosciences, n.d.).  
 
 
2.3.2 SNX5-/- mice  
The SNX5 ‘Knock-out First’ strain was created from ESC clone 
(a2EPD0033_3_D07) and obtained from the NCRR-NIH-supported KOMP 
repository and generated by the CSD consortium for the NIH-funded KOMP 
project. Mice were bred as homozygotes on a C57/BL6 background (Lim et al., 
2015). (University of Melbourne ethics ID: 1613960). 
 
 
2.3.3 Wild type animals 
Wild type C57BL/6J (Charles River, Wilmington, US) animals were used 
as control animals. All animals were maintained in a temperature and humidity 
controlled vivarium.  
 
 
2.4 Mammalian cell methods 
 
2.4.1 Production of L-conditioned medium  
L929 cells (Sigma, Darmstadt, Germany) were cultured in DMEM 
GlutaMAX™ (Gibco, Carlsbad, US) supplemented with 10% FBS (Gibco, 
Carlsbad, US) and 1% Penicillin/Streptomycin (Gibco, Carlsbad, US) at 37 °C, 
5% CO2, humidified air. After 14 days, supernatant was collected, centrifuged at 
1500 rpm for 5 minutes and the supernatant was filtered using a 0.22 µm 
syringe driven filter unit (Merck Millipore, Burlington, US). Supernatants were 
kept at -20 °C until needed.  
L-conditioned medium for macrophage cultures were prepared by culturing 
L929 cells in RPMI (Gibco, Carlsbad, US) supplemented with 10% FBS (Gibco) 
and 1% Penicillin/Streptomycin (Gibco, Carlsbad, US) at 37 °C, 5% CO2. 
Confluent cells were harvested by trypsinisation (5 minutes at 37 °C, 5% CO2 
and cells grown in 2 litre roller bottles in a rotating incubator) on a roller 
incubator for 6 weeks. The medium was centrifuged at 1620 x g for 10 minutes, 
supernatant then filtered using a 0.22 µm syringe driven filter unit (Merck 
Millipore) and stored at -20 °C.  
 
 
2.4.2 Generation of bone marrow derived macrophages 
Eight to twelve-week old mice were killed by CO2 asphyxiation in 
accordance with animal ethics guidelines (University of Melbourne ethics ID: 
1613960). Cells were obtained from the femurs and tibias of mice. Erythrocytes 
were lysed and cells pelleted by centrifugation. Cells were resuspended in 
freezing media (90% FBS, 10% DMSO) and frozen in liquid nitrogen until 
needed. Once thawed, cells were maintained in complete bone marrow medium 
(RPMI supplemented with 15% FCS, 20% L-cell conditioned medium, 100 
units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine) in a 
humidified incubator at 37 °C, 5% CO2. 
 
 
2.4.3 Generation of primary cortical neuron cultures  
Eight to twelve-week old pregnant mice were killed by CO2 asphyxiation 
in accordance with animal ethics guidelines (University of Melbourne ethics ID: 
1613960). Cortical tissue was taken from the brains of E15-17 mouse embryos 
and digested with 0.0125 % (w/v) trypsin (Sigma, Darmstadt, Germany) for 5 
minutes at 37 °C. Tissue was suspended in HBSS (Life Technologies, 
Carlsbad, US) containing 1 mM sodium pyruvate (Life Technologies, Carlsbad, 
US), 10 mM HEPES (Life Technologies, Carlsbad, US), 1.16 mM MgSO4  
(Sigma, Darmstadt, Germany), 7.6 mM D-Glucose (Sigma, Darmstadt, 
Germany), followed by mechanical tituration. Cell viability and density was 
determined using a trypan blue exclusion assay. Cells were plated on poly-D-
lysine (Sigma, Darmstadt, Germany) coated plates or coverslips in complete-
Neurobasal medium (Life Technologies, Carlsbad, US), typically 0.7x10^5 
cells/ml and incubated at 37 °C, 10% CO2 overnight. The following day 50% of 
the medium was replaced with fresh medium and then every three days 50% of 
the medium was changed. 
 
 
2.4.4 Generation of primary microglia cultures 
Microglia were isolated from mouse brains of day 1-3 (P1-3) neonatal 
mice according to Giulian and Baker (Giulian and Baker, 1986). In brief, brains 
were isolated and stripped of their meninges. The tissue was then trypsinised 
(0.25%, Gibco, Carlsbad, US) for 10 minutes and cells were plated on Poly-L-
lysine (Sigma, Darmstadt, Germany) coated flasks and incubated in DMEM 
GlutaMAX™ (Gibco, Carlsbad, US) supplemented with 10% FBS (Gibco, 
Carlsbad, US) and 1% Penicillin/Streptomycin (Gibco, Carlsbad, US) overnight 
at 37 °C, 5% CO2, humidified air. The medium was changed on the following 
day and supplemented with 1.5% (v/v) L929 conditioned medium. Cells were 
harvested after 7-10 days by gently tapping the culture flasks to dissociate the 
microglial cells. The purity of microglia was microscopically assessed by CD11b 
staining (Integrin αM, Santa Cruz, Santa Cruz, US). Typically 98% of cells were 
CD11b positive. Prior to the use of microglia in any assay, microglia were 
serum-starved overnight and the medium supplemented with N2 (Thermo 
Fisher Scientific, Waltham, US). 
 
 
2.5 Indirect immunofluorescence microscopy  
Cells were cultured as monolayers on coverslips and fixed with 4% 
paraformaldehyde (PFA) for 15 min at room temperature, followed by 
quenching in 50 mM NH4Cl/PBS for 10 min at room temperature. Monolayers 
were then permeabilised with 0.1% Triton X-100/PBS for 4 minutes and 
incubated in Blocking Solution (5% FCS, 0.02% Sodium Azide in PBS) for 30 
minuets to reduce non-specific binding. Cell monolayers were incubated with 
primary antibodies diluted in blocking solution for 4 hours or overnight at 4 °C 
and then washed 6 times in PBS. Fluorochrome-conjugated secondary 
antibodies were added at the appropriate dilution and incubated for 1 h at room 
temperature. Following another washing step in PBS, cells were stained with 
DAPI (Life Technologies, Carlsbad, US) for 4 minutes. Coverslips were then 
washed 6 times with PBS, followed by a washing step in milli-Q water, before 
mounting in Mowiol (Calbiochem, SAN Diego, US). Confocal microscopy was 
performed using a Leica SP8 system. Images were collected sequentially for 
multi-colour imaging using a x63/1.4 NA HCX PL APO CS oil immersion 
objective. FITC and Alexa Fluor 488 were excited with the 488 nm line of an 
Argon laser, Alexa Fluor 647 with a 633 nm HeNe laser and DAPI with a 405 
nm UV laser. Images were collected with pixel dimensions of at least 512 x 512.  
 
 
2.5.1 Image analysis  
FIJI (ImageJ, version 2.0.0-rc-59/1.51k, Wayne Rusband, National 
Institute of Health, USA) was used for image analysis. The simple neurite tracer 
plugin was used to measure dendrite length in neurons (Longair M et al, 2011). 
Cells for analysis were carefully chosen and analysis done using a projection 
line of beginning and end of dendrites through a 3D reconstruction of the image. 
Each experiment was repeated at least 3 times.  
 
 
2.6 Treatment of cells  
 
2.6.1 Microglia conditioned media preparation 
Primary microglia were treated with LPS, LPS and ATP, Aβ or LPS and 
Aβ as outlined above and collected after 4 hours. Conditioned media (1.5 ml) 
were collected, spun down at 1200 rpm and snap frozen in liquid nitrogen. 
Conditioned media were stored at -80 °C until used. Primary cortical neurons 
were subjected to microglia supernatants for 72 hours before they were fixed 
and stained as outlined above. At least 3 independent experiments were carried 
out for each treatment condition.  
 
 
2.6.2 Microglia immunostimulation  
Primary microglia were cultured as monolayers, serum starved overnight 
and then stimulated with 150 ng/ml lipopolysaccharide (LPS) from E.coli K12 
(InvivoGen, San Diego, US) for 3 hours, LPS (3 hours) and 1 µM or 10 µM 
Adenosine 5′-triphosphate (ATP) (Sigma, Darmstadt, Germany) for 1 hour, or 
LPS and 10 µM nigericin (Sigma, Darmstadt, Germany) for 1 hour.  
Supernatants were either collected immediately after treatment or medium 
replaced with complete DMEM for 24 hours before supernatant collection. 
 
 
2.6.3 Microglia amyloid beta stimulation  
Primary microglia were cultured in monolayers, serum starved overnight 
and stimulated with 5 µM or 10 µM Ab (Bachem, Bubendorf, Switzerland) for 1 
or 24 hours or pre-stimulated with 150 ng/ml lipopolysaccharide (LPS) from 
E.coli K12 (InvivoGen, San Diego, US) for 3 hours, followed by Aβ stimulation.  
 
 
2.6.4 Neuronal TNFα treatment  
Primary cortical neurons were cultured as monolayers and incubated 
with 2 ng/ml, 1 ng/ml or 500 pg/ml purified mouse TNFα (Sigma, Darmstadt, 
Germany) for 72 hours. The neurons were then fixed and stained as outlined 
above. 
  
2.6.5 Sodium chloride treatment. 
Microglia were cultured overnight in serum-free complete DMEM, in the 
presence of 1% N2 supplement, to render cells quiescent. After a 3 hour 
incubation with LPS (150 ng/ml), cells were treated with an additional 40 mM of 
NaCl, 10 µM Aβ, or 40 mM of NaCl and 10 µM Aβ, for 24 hours. To examine the 
impact of osmolarity and tonicity, experiments were also performed in the same 
manner, with either 80 mM urea or 80 mM mannitol added. 
 
 
2.6.6 Treatment with p38 inhibitor 
p38 MAP Kinase inhibitor (SB203580, InvivoGen, San Diego, US) was 
incubated with cells 1 hour prior to cell treatment. p38 MAP Kinase inhibitor was 
used at a final concentration of 5 µM.  
 
 
2.6.7 TNFα neutralizing antibody  
 TNFα neutralizing antibody (Cell Signalling Technology, Danvers, 
US) was incubated with the supernatants or purified mouse TNFα 1 hour prior 
to the experiment. Mouse TNFα neutralizing rabbit antibody was used at a final 
concentration of 10 ng/ml.  
 
 
2.7 Uptake experiments  
2.7.1 Fluorescently labeled Amyloid uptake in ApoE microglia  
Primary microglia were plated in optical-bottom 96-well plates (Nunc, 
Rochester, US). Cell monolayers were serum starved overnight, washed and 
incubated with Beta Amyloid (1-42) Hi-Lyte Fluor 488 (AnaSpec, Fremont, US) 
for 1-2 hours. The suspension was then removed, and subsequently, 100 µl per 
well of trypan blue suspension (250 µg/ml, pH 4.4) was added for 1 minute to 
quench the extracellular probe. After aspiration of trypan blue, the fluorescence 
was measured at 486 nm excitation and 534 nm emission using a microplate 
reader (Tecan Infinite M200, Magellan™ V6.55). 
Cell number was determined by a 15 minute incubation with H33342 solution 
(25 µg/ml in PBS/ 0.1% TritonX-100) (Sigma, Darmstadt, Germany) followed by 
fluorescence measurement at 360 nm excitation and 418 nm emission using a 
microplate reader (Tecan Infinite M200, Magellan™ V6.55).  
 
 
 
2.7.2 Fluid-phase uptake assays 
 Cells were initially rendered quiescent by culturing primary microglia 
(150,000 cells per well in a 12 well plate) overnight in serum-free DMEM, in the 
presence of 1% N2 supplement and bone marrow derived macrophages 
(180,000 cells per well in a 12 well plate) in RPMI. Cells were stimulated with 
150 ng/ml LPS for 3 hours, followed by incubation with either 500 µg/ml 70kDa 
dextran, Aβ (1-42) Hi-Lyte Fluor 488 (AnaSpec, Fremont, US) for 15 or 45 
minutes. Following the incubation, cells were placed on ice for 5 minutes and 
were washed with ice-cold medium and PBS. Uptake was quantified following 
the method described by Wang et al., using Fiji’s particle analyser (Wang et al., 
2014). For macropinocytosis assays, cells were also pre-treated with the 
inhibitor 5-(N-Ethyl-N-isopropyl) amiloride (Sigma, Darmstadt, Germany) at 100 
µM for 30 mins prior to the addition of 70 kDa dextran. 
 
 
2.8.1 Cytotoxicity assay.  
Cytotoxicity of supernatants were analysed using the Pierce LDH 
Cytotoxicity Assay Kit (Thermo Scientific, Waltham, US) according to the 
manufacturers protocol.  
 
 
2.8.2 Nitric oxide determination 
Nitric oxide released into the cell culture mediums was measured using 
the Griess Reagent System (Promega, Madison, US) according to the 
manufacturer’s protocol. Briefly; sulfanilamide solution was added for 5 minutes, 
followed by a 5 minute incubation with NED solution. Absorbance was then 
measured at 550 nm using a microplate reader (Tecan Infinite M200, 
Magellan™ V6.55/ FLUOstar® Omega, BMG Labtech). The nitrite 
concentration was determined by interpolation using a nitrite standard curve.  
 
 
2.8.3 Quantification of secreted IL-1β and TNFα cytokines  
Conditioned medium collected from treated microglia or macrophages 
was analysed for IL-1β (mouse IL-1β DuoSet ELISA) and TNFα (mouse TNFα 
DuoSet ELISA) using commercially available mouse colorimetric sandwich 
ELISA plates (R&D Systems, Minneapolis, US). Absorbance was measured at 
450 nm using a microplate reader (Tecan Infinite M200, Magellan™ V6.55/ 
FLUOstar® Omega, BMG Labtech). The cytokine concentration was 
determined by interpolation using a standard curve 
 
 
2.8.4 Viability assay 
Cell viability was assessed by an XTT assay kit (XTT Cell Viability Kit, 
Cell Signaling, Danvers, US). Following the treatment of cells, the medium was 
replaced with FluoroBrite DMEM (Gibco, Carlsbad, US) and the tetrazolium salt 
XTT added. Absorbance was measured at 450 nm using a microplate reader 
(Tecan Infinite M200, Magellan™ V6.55). The XTT concentration was 
determined by interpolation using a standard curve. 
The viability of BMDMs and primary microglia treated with NaCl and or Aβ, with 
and without LPS priming was assessed by FACS. Cells were serum starved 
overnight, treated as outlined above and detached using TrypLE™ Express 
(Gibco, Carlsbad, US). Cell supernatants, as well as the trypsinised cells were 
centrifuged at 300 x g for 10 minutes at 4 °C. The cell pellets were resuspended 
in Fixable Viability Dye eFluor™ 780 (Invitrogen, Carlsbad, US) for 30 minutes 
on ice. Following the staining step, cells were centrifuged at 300 x g for 10 
minutes at 4 °C and resuspended in FACS buffer (0.5 % FBS, 0.5 mM EDTA in 
PBS). Cells were then analysed on FACSCanto™ II Cell Analyser (BD 
Bioscience, Franklin Lakes, US). Data was analysed using FlowJo V9.3.2.  
 
 
2.9 Mass Spectrometry  
 
 
2.9.1 Sample preparation  
1.5x106 microglia cells were seeded on 6 well plates and treated as 
outlined above. Supernatants were collected (after 24 hours) and snap frozen in 
liquid nitrogen. The supernatants were stored at -20 °C. Supernatants were 
thawed and acetone precipitated by incubation in ice cold acetone (ratio of 
supernatant to acetone 1:4) for 60 minutes. This was followed by a 10 minute 
centrifugation step at 15,000 x g at 4 °C. Supernatants were decanted and the 
remaining acetone allowed to evaporate for 30 minutes at room temperature. 
The pellet was then resuspended in buffer comprising 2,2,2-Trifluorethanol 
(TFE, Sigma, Darmstadt, Germany), 20 mM Tris(-carboxyethyl)phosphine 
hydrochloride (Tcep, Sigma, Darmstadt, Germany) and 20 mM 
Tetraethylammonium (TEAB, Sigma, Darmstadt, Germany), followed by an 
overnight trypsin digest at 37 °C by the addition of trypsin (1 µg) dissolved in 20 
mM TEAB. The following day samples were centrifuged at 15,000 x g for 5 mins 
and stored at 4 °C until processing. For each genotype 4 samples from 
independent preparations were processed.  
  
 
2.9.2 Technical details 
Samples were analysed by LC-MS/MS using Q-Exactive plus mass 
spectrometer (Thermo Scientific, Waltham, US) fitted with nanoflow reversed-
phase-HPLC (Ultimate 3000 RSLC, Dionex). The nano-LC system was 
equipped with an Acclaim Pepmap nano-trap column (Dionex – C18, 100 Å, 75 
µm × 2 cm) and an Acclaim Pepmap RSLC analytical column (Dionex – C18, 
100 Å, 75 µm × 50 cm). Typically for each LC-MS/MS experiment, 1 µl of the 
peptide mix was loaded onto the enrichment (trap) column at an isocratic flow of 
5 µl/minute of 3% CH3CN containing 0.1% formic acid for 6 minutes before the 
enrichment column was switched in-line with the analytical column. The eluents 
used for the LC were 0.1% v/v formic acid (solvent A) and 100% CH3CN/0.1% 
formic acid v/v. The gradient used was 3% B to 20% B for 95 min, 20% B to 
40% B in 10 min, 40% B to 80% B in 5 min and maintained at 80% B for the 
final 5 min before equilibration for 10 min at 3% B prior to the next analysis. All 
spectra were acquired in positive mode with full scan MS spectra scanning from 
m/z 375-1400 at 70000 resolution with AGC target of 3e6 with maximum 
accumulation time of 50 ms. Lockmass of 445.120024 was used. The 15 most 
intense peptide ions with charge states ≥2-5 were isolated with isolation window 
of 1.2 m/z and fragmented with normalized collision energy of 30 at 17500 
resolution with AGC target of 1e5 with maximum accumulation time of 100ms. 
Underfill threshold was set to 2% for triggering of precursor for MS2. Dynamic 
exclusion was activated for 30s. 
 
 
2.9.3 Mass Spectrometry analysis 
A target list was created including 13 pro- and anti-inflammatory 
cytokines. Many additional proteins overlapped with the predicted masses and 
were included in the analysis. Mascot protein identification search engine 
(Matrix Science, v2.4) was used for Mass Spectometry analysis, using the 
SWISSPROT database. Search parameters used were 10-ppm peptide mass 
tolerance and 0.2-Da fragment ion mass tolerance. Oxidation (M) was set as 
variable modification and 2 missed cleavages were permitted. The search 
taxonomy was restricted to Mus musculus. Peptides with mascot ion scores 
greater than the homology score were considered significant and only those 
that appeared in at least 3 out of 4 independent experiments were included in 
the analysis.  
  
2.10 Statistical analysis 
Data were analysed using, unpaired t-test (for comparison between two 
groups) or one-way ANOVA (for comparison between three groups or more), 
after performing Kolmogorov-Smirnov test with Dallal-Wilkinson-Lilliefor P value 
normality testing using GraphPad Prism 7.0 software (GraphPad Software). 
Data were expressed as mean ± SEM, and levels of significance are indicated 
as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. 
 
 
2.11 Protein methods 
 
2.11.1 Cell lysates 
Equal numbers of cells were lysed in RIPA buffer (50 mM Tris-HCl, ph 
7.3, 150 mM NaCl, 0.1 mM EDTA, 1% [w/v] sodium deoxycholate, 1% (v/v) 
Triton X-100, 0.2% (w/v) NaD and 100 uM Na3VO4) supplemented with 
Complete™ protease inhibitor (Roche). Cell lysates were incubated on ice for 
10 minutes and centrifuged for 10 minutes at 16,000 x g.  
 
 
2.11.2 Bradford assay 
Bradford assay was performed to determine protein concentrations prior 
to SDS PAGE, following the manufacturer’s instructions, using Bio-Rad Protein 
Assay Dye Reagent Concentrate (Bio-Rad, Hercules, US). BSA was used to 
generate a standard curve.  
 
 
2.11.3 Immunoblotting  
Cell lysates from primary cortical neurons were mixed with 4x buffer 
containing β-mercaptoethanol and boiled for 10 min at 100 °C. The samples 
were then resolved on a 4-12% Bis-Tris SDS-PAGE gel (Life Technologies, 
Carlsbad, US) and transferred onto Immnobilon-P polyvinylidene fluoride 
(PVDF) membrane (Millipore, Burlington, US) at 400 mA for 1 hour. Following 
this the membrane was blocked for 1 hour in 5% skimmed milk/ PBS. The 
membrane was incubated with primary antibodies diluted in 1 % BSA/ PBS 
(Sigma, Darmstadt, Germany) overnight at 4 °C and then washed three times 
for 10 minutes each in 0.1 % (v/v) PBS-Tween 20. HRP conjugated secondary 
antibodies were then added to the membrane for 1 hour and washed as above. 
Blots were scanned using ChemiDoc™ Gel Imaging Systems (BioRad, 
Hercules, US). Where reprobing of the membrane was necessary, the 
membrane was stripped using Restore™ PLUS Western Blot Stripping Buffer 
(Thermo Scientific, Waltham, US). Western blot quantification was performed 
using FIJI (ImageJ, version 2.0.0-rc-59/1.51k, Wayne Rusband, National 
Institute of Health, USA).  
Chapter 3: Characterisation of microglia of different ApoE 
genotypes 
 
3.1 Introduction 
Alzheimer’s disease is the most common cause of dementia. Despite 
considerable efforts in understanding the disease and developing treatments, 
there is no cure. Over the past 15 years (between 2000 and 2015) deaths 
resulting from AD have increased by 123 % (Anon, 2018). The three 
pathological hallmarks of AD include Aβ plaques, neurofibrillary tangles and 
neuroinflammation (Ardura-Fabregat et al., 2017). Inflammation is found in the 
AD brain, particularly near Aβ deposits, which are also rich in activated 
microglia. The activated microglial cells release a variety of pro-inflammatory 
mediators including complement components, cytokines, free radicals and nitric 
oxide. These inflammatory mediators then contribute to neuronal dysfunction 
and establish a vicious cycle. Minor signs of neuroinflammation can also be 
found in the normal aging brain. The AD brain however faces a much stronger 
activation of inflammatory systems indicating that an increasing level and/or 
qualitatively different immunostimulants are present (Heneka and O’Banion, 
2007).  
 
Microglia, the resident macrophage-like population in the CNS, play a critical 
role in the initiation as well as the progression of neuroinflammation. Under 
pathological conditions microglia become activated and migrate to locations 
where damaged or dead cells are present, and clear debris from the area. 
Activated microglia up-regulate a variety of surface receptors and upon 
immunostimulation release a variety of pro-inflammatory mediators. Several 
cytokines are implicated in AD progression and include different interleukins, 
TNFα and TGFβ. TNFα in particular is strongly associated with AD pathology 
(Combs et al., 2001).  
 
The three biggest risk factors for LOAD are ageing (Hebert et al., 2010), a 
family history of AD (Fratiglioni et al., 1993) and the ApoE4 variant of the APOE 
gene (Saunders et al., 1993). At least one copy of the ApoE4 allele was found 
in 65 % of AD patients in a study which analysed 1770 pathologically confirmed 
AD cases, highlighting the potential risk factor of ApoE4 allele (Mayeux et al., 
1998).  
 
The APOE gene is considered the strongest genetic risk factor for LOAD 
(Holtzman et al., 2012). The three ApoE alleles contribute fundamental 
differences to the risk of developing the disease. ApoE3 is the most common 
allele, which doesn’t alter the relative risk of developing the disease. ApoE2, 
whilst rare, confers protection against LOAD. ApoE4 increases the risk of 
developing AD (Corder et al., 1993). ApoE functions as a ligand in receptor 
mediated endocytosis of lipoprotein particles and is used to support 
synaptogenesis (Mauch et al., 2001). Aside from ApoE there are other 
apolipoproteins in the CNS including ApoJ (CLU), which is another risk factor 
for LOAD (Lambert et al., 2009), suggesting an important role for 
apolipoproteins in AD pathology.  
 
Furthermore, there is a positive correlation with ApoE4 and Aβ deposition in the 
brain and AD onset (Reiman et al., 2009; Morris et al., 2010). ApoE2 carriers on 
the other hand rarely develop fibrillar Aβ (Morris et al., 2010). Despite efforts to 
determine the underlying mechanism how ApoE influences Aβ aggregation and 
accumulation, it remains unclear. Some studies suggest that ApoE isoforms do 
not influence Aβ production, rather they affect Aβ clearance (Castellano et al., 
2011). This has been suggested to occur by pathways involving ApoE mediated 
enhanced degradation and enzyme facilitated clearance via neprilysin (Jiang et 
al., 2008; Kim et al., 2009).  
 
The effects of ApoE on microglia function are still largely unknown and, in 
particular, studies comparing all three ApoE alleles directly are very limited. The 
aim of this chapter was to compare the three ApoE alleles on microglia function, 
amyloid uptake and cytokine secretion. The results presented in this chapter 
show that the ApoE isotype affects different microglia functions. The strongest 
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Figure 3.1 Experimental setup of microglia treatments  
Primary microglia were extracted from ApoE target replacement mice and 
wt animals. Microglia were then primed with LPS (150 ng/ml) for 3 hours, 
followed by a secondary stimulus for 1 hour (ATP, nigericin or Aβ). (A) 
Assays were then performed on the cells, or with cell culture medium. (B) 
Timeline for stimulation of primary microglia.  
x 
A 
B 
Figure 3.2 Viability of immunostimulated primary microglia  
Primary microglia cells were primed with LPS (150 ng/ml) for 3 hours, with or 
without stimulation by ATP (1 mM, 10 mM) or nigericin (10 µM) for 1 hour. 
Viability was determined by XTT assay. The viability test was performed 
either (A) immediately after treatment or (B) after 24 hours following the 
treatment. Cell viability is presented as percentage (Untreated control set to 
100%). Statistical significance was determined using a 2way ANOVA. Data 
are mean ± SEM and levels of significance are indicated as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001, #p<0.05, ##p<0.01, ###p<0.001 and 
####p<0.0001. # is compared to untreated cells from each genotype.  n=7 
and is from at least 3 independent experiments. 
x 
A 
B 
Figure 3.3 LDH release in microglia culture medium after immunostimulation  
Primary microglia cells were primed with LPS (150 ng/ml) for 3 hours, with or 
without stimulation by ATP (1 mM, 10 mM) or nigericin (10 µM) for 1 hour. 
Cell free supernatants were collected (A) after treatment or (B) 24 hours 
after treatment. LDH secretion was determined and is presented as 
percentage of 100 % lysed cells. Statistical significance was determined 
using a 2way ANOVA. Data are mean ± SEM and levels of significance are 
indicated as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. # is compared 
to untreated cells from each genotype. n=6 from at least 3 independent 
experiments.  
x 
genotype dependent effect was observed in Aβ uptake. Aβ uptake is most 
efficient in ApoE2 followed by ApoE3 with ApoE4 the least efficient. Differences 
in cytokine secretion were also determined; in particular TNFα secretion is 
significantly increased in ApoE4 microglia. Using mass spectrometric analyses, 
a protocol was successfully developed to identify and compare cytokines 
secreted by immunostimulated and Aβ treated microglia of all three genotypes. 
The study demonstrates that mass spectrometry can be utilised to define 
cytokine profiles of different microglia populations.  
 
 
 
3.2 Results 
Microglial activation in vitro is commonly achieved by priming with LPS, 
followed by a secondary stimulus, such as ATP or nigericin for NLRP3 
inflammasome activation (Perregaux et al., 1992). In addition to these stimuli 
we have also examined Aβ as a potential secondary stimulus. Here wt microglia 
from C57/BL6 mice and microglia of different ApoE genotypes were analysed 
after LPS priming treatment alone and also by the classical LPS priming and 
secondary stimulus with ATP or nigericin. ApoE2, 3 and 4 microglia were 
generated from target replacement (TR) mice, where the human ApoE allele 
replaces the mouse allele. This humanised mouse model is commonly used to 
study the effects of the different ApoE alleles (Bour et al., 2008; Hu et al., 
2015). Mouse colonies were established in the facility in Bonn and genotyping 
was performed by PCR from tail DNA to confirm the ApoE genotypes. C57BL/6 
mice carry the murine ApoE form of the gene (Desurmont Caroline et al., 2000). 
The murine ApoE allele most closely resembles the human ApoE 3 allele 
(Fernandez et al., 2019). 
 
The same experimental setup was followed for all experiments in this chapter: 
primary microglia were primed for 3 hours with LPS (150 ng/ml) and treated with 
ATP (1 mM or 10 mM), nigericin (10 µM) or Aβ (5 µM or 10 µM). Assays were 
then performed on cell monolayers or conditioned medium (Fig. 3.1).  
A 
B 
Figure 3.4 IL-1β secretion varies between ApoE genotypes  
A representative example of a standard curve is displayed. (A) Standards 
were measured in duplicates in concentrations ranging from 0 to 1000 pg/ml. 
(B) Primary microglia cells were primed with LPS (150 ng/ml) for 3 hours, 
with or without stimulation by ATP (1 mM, 10 mM) or nigericin (10 µM) for 1 
hour. IL-1β secretion was measured in cell free supernatants by ELISA. 
Statistical significance was determined using a one way ANOVA. Data are 
mean ± SEM and levels of significance are indicated as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. n=7 from at least 3 independent experiments.  
x 
 
 
3.2.1 Viability of immunostimulated microglia is genotype independent. 
Cell viability was determined by assessing metabolic activity using XTT 
(Altman, 1976) and by measuring lactate dehydrogenase (LDH) secretion into 
the culture medium. Both assays were performed either immediately after the 
treatments (4 hours) or 24 hours following the final treatment. Primary microglia 
from wt C57/BL6 mice and ApoE2, 3 and 4 mice were primed with LPS (150 
ng/ml) for 3 hours, followed by treatment with a secondary stimulus (1, 10 mM 
ATP or 10 µM nigericin). Following the 4 hours of total treatment, cell viability as 
assessed by the XTT assay showed no decrease in viability of cells treated with 
LPS alone or LPS and 1 mM ATP. However, there was a 20 - 40 % decrease in 
viability after treatment with LPS and either 10 mM ATP or nigericin. Reduced 
viability was particularly apparent in wt, ApoE 2 and ApoE 3 microglia compared 
to untreated cells. (Fig. 3.2A). At 24 hours after treatment the viability remained 
high for LPS primed and LPS and ATP (1 mM) treated samples (Fig. 3.2B). All 
genotypes showed >90 % viability, which is comparable with untreated control 
samples. However, following LPS priming combined with either a higher ATP 
concentration (10 mM) or nigericin treatment there was a reduction in viability of 
~30 – 45 % compared with untreated control group with the exception of 
ApoE3, which maintained a high viability based on this assay (Fig. 3.2B).  
 
LDH secretion following the treatments was also assessed. The cytoplasmic 
enzyme LDH is released following damage to the cell membrane and thus 
elevated LDH levels in the cell supernatant indicate reduced viability (Decker 
and Lohmann-Matthes, 1988). The maximum level of cellular LDH was 
determined from a supernatant of lysed cells. Very little LDH was detected in 
medium of microglia cell cultures at 4 hours, with the exception of LPS and 
nigericin treatment, where there was ~20 % LDH release from wt C57/BL6 and 
all three genotypes (Fig. 3.3A). These findings are consistent with the 
observations for the XTT assay (Fig. 3.2A). However, 24 hours following 
treatment LDH release is increased to ~40 % in wt and ApoE2 microglia, 
A 
B 
Figure 3.5 Immunostimulated ApoE4 microglia secrete higher levels of TNFα 
than other ApoE genotypes 
(A) A representative example of a standard curve is displayed. Standards 
were measured in duplicates in concentrations ranging from 0 to 2000 pg/ml. 
(B) Primary microglia cells were primed with LPS (150 ng/ml) for 3 hours, 
with or without stimulation by ATP (1 mM, 10 mM) or nigericin (10 µM) for 1 
hour. TNFα secretion was measured in cell free supernatants by ELISA. 
Statistical significance was determined using a  one way ANOVA. Data are 
mean ± SEM and levels of significance are indicated as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. n=5 from at least 3 independent experiments.  
x 
regardless of the treatment and consistently low (<25 %) in ApoE3 and ApoE4 
microglia (Fig. 3.3B). Hence, for ApoE3 and ApoE4 differences were observed 
between the LDH assay and the XTT assay (Fig. 3.2B). LDH release following 
ATP or nigericin treatment is expected, as the microbial toxin is a known NLRP3 
inflammasome inducer (Perregaux et al., 1992). Several independent 
experiments with microglia from independent preparations were assessed by 
the LDH release assay and variations were observed between genotypes and 
the XTT assay. Due to the reduced viability of microglia cell populations at 24 
hours, the subsequent experiments focused on the 4 hour time point. In 
summary, the viability data from both the XTT assay and LDH release shows 
that the treatments had modest effect on viability of microglia preparation over 
the short term of 4 hours, but there was substantial loss of viability over 24 
hours.  
 
 
3.2.2 Cytokine secretion differs between immunostimulated microglia from 
different ApoE genotypes 
Immunostimulation with a priming step to activate the NFκB p38 MAPK 
signalling pathway followed by a secondary stimulus is known to activate the 
NLRP3 inflammasome, which ultimately leads to IL-1β secretion (Sander et al., 
2011). IL-1β secretion is known to be increased in AD. To investigate the effect 
of immunostimulation on microglia and whether the different ApoE alleles 
influence the microglia response, cells were primed with LPS (150 ng/ml) for 
three hours, followed by treatment with ATP or nigericin for 1 hour, as described 
in Figure 3.1. (Perregaux et al., 1992). Priming alone with LPS did not results in 
IL-1β secretion (Fig. 3.4), as expected (Perregaux et al., 1992; Sander et al., 
2011). Whilst microglia from all genetic backgrounds secrete IL-1β in response 
to immunostimulation with 10 mM or nigericin, there are genotype specific 
differences. ApoE4 microglia secrete more than three times more than ApoE3 
microglia, in response to ATP (10 mM) stimulation. After nigericin treatment, IL-
1β secretion is higher in all microglia populations than after 10 mM ATP 
stimulation. In wt C57/BL6 microglia, IL-1β secretion is 1500 pg/ml higher after 
Figure 3.6 Nitrite secretion in primary microglia 
Primary microglia cells were primed with LPS (150 ng/ml) for 3 hours, 
followed by immunostimulation with ATP (1 mM or 10 mM) or nigericin (10 
µM). Nitrite concentration was determined by Griess assay in cell free 
supernatants, which were collected 24 hours after treatment. Dashed line 
represents the detection limit of the assay. Statistical significance was 
determined using a 2way ANOVA. Data are mean ± SEM and levels of 
significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. n=8 from at least 3 independent experiments.  
x 
nigericin treatment than after 10 mM ATP treatment (Fig. 3.4B). The high levels 
of IL-1β secretion following nigericin treatment are consistent with the reduced 
viability of nigericin-treated populations at the 4 hour time point, as NLRP3 
inflammasome activation leads to IL-1β production and pyroptotic cell death.  
 
Like IL-1β, the pro-inflammatory cytokine TNFα is implicated in many 
inflammatory diseases, such as AD (Franchi et al., 2009). To further assess the 
different ApoE alleles on microglial response to immunostimulation, TNFα 
secretion was determined in conditioned media of microglia cell cultures by 
ELISA, following the same setup as outlined above and illustrated in Figure 3.1. 
High levels of TNFα were detected in the conditioned medium at 4 hours 
following LPS treatment in all samples. Of note is that ApoE4 microglia secrete 
almost twice as much TNFα as the other genotypes. TNFα secretion was also 
observed in response to LPS and the secondary stimulus; however, the profiles 
of each ApoE microglia population were very similar to LPS alone. ApoE 2 
microglia secrete more TNFα in response to ATP and nigericin, under primed 
conditions, than ApoE 3 microglia. TNFα follows a genotype dependent pattern, 
with ApoE 4 microglia secreting consistently more TNFα than the other 
genotypes, regardless of the stimulus (Fig. 3.5B).  
 
In summary, the data described here suggests a genotype dependent effect on 
immunostimulated microglia, whereby ApoE 4 microglia have the strongest pro-
inflammatory response and secrete significantly more IL-1β and TNFα than the 
other ApoE genotypes. 
 
 
3.2.3 Nitrite secretion is genotype independent after immunostimulation 
Inflammation in brain tissue is accompanied by increased NO synthesis 
in microglial cells via induction of iNOS. Nitric oxide has been implicated as a 
chemoattractant for activated microglia. Microglia will migrate toward the site of 
injury upon sensing secreted NO (Gutièrrez-Mecinas et al., 2007). Furthermore 
NO is known to be involved in NMDAR mediated neurotoxicity (Yamada et al., 
Figure 3.7 Viability of primary microglia after Aβ treatment  
Primary microglia cells were treated with different concentrations of Aβ (5 
µM, 10 µM) for 1 hour either directly or after 3 hours LPS pre-stimulation. 
Viability was determined by XTT assay. The viability test was performed 
immediately after treatment. Cell viability is presented as percentage 
(Untreated control set to 100%). Statistical significance was determined 
using a 2 way ANOVA. Data are mean ± SEM and levels of significance are 
indicated as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, #p<0.05, 
##p<0.01, ###p<0.001 and ####p<0.0001. # is compared to untreated cells 
from each genotype. n=6 from at least 3 independent experiments.  
x 
Figure 3.8 LDH release in Aβ stimulated primary microglia  
Primary microglia cells were treated with different concentrations of Aβ (5 
µM, 10 µM) for 1 hour, either directly or after 3 hours LPS pre-stimulation. 
Cell free supernatants were collected after treatment and LDH secretion 
determined by LDH cytotoxicity assay. LDH secretion is presented as 
percentage (Technical control = 100 %). Statistical significance was 
determined using a 2way ANOVA. Data are mean ± SEM and levels of 
significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. n=5 from at least 3 independent experiments.  
x 
1997). Here I assessed whether the ApoE genotype has an effect on microglial 
NO secretion. Using the Griess assay for nitrite production, endogenous NO 
formation was measured in the conditioned media of immunostimulated 
microglia. Nitrite secretion is not as rapid as other cellular processes and 
therefore it was necessary to measure nitrite secretion 24 hours after treatment. 
Unsurprisingly, the levels of nitrite detected at the 4 hour time point were below 
the detection limit of the assay (Figure A1 see appendix). Nitrite concentrations 
detected at 24 hours were very low, ranging from 4 to 7 µM (Fig. 3.6). LPS 
primed ApoE 4 microglia secrete more NO than untreated cells. The addition of 
a secondary stimulus however did not result in a further increase in NO. Indeed, 
it has been reported that treatment with the NLRP3 activator nigericin 
(Perregaux et al., 1992) as a secondary stimulus leads to a decrease in nitrite 
secretion, likely due to the increased cytotoxicity.  
 
 
3.2.4 Aβ treatment has no effect on microglia viability 
 To examine the effect of Aβ on microglia responses, I initially assessed 
the viability of microglia following treatment with Aβ (5 µM or 10 µM) for 1 hour 
with or without prior LPS priming for 3 hours (Fig. 3.7). Microglia viability was 
assessed by XTT, measuring the cell’s metabolic activity and by determining 
LDH secretion into the culture medium after 4 hours. The XTT assay revealed 
>90 % viability across all genotypes and treatments (Fig. 3.7). This was 
confirmed by LDH; microglia from all genotypes showed ~10 % LDH in the 
conditioned medium, regardless of the treatment, which is comparable to LDH 
levels of untreated controls (Fig. 3.8). Therefore, it can be concluded that Aβ, 
under these experimental conditions, does not have an effect on viability of 
microglia from the three ApoE isoforms and C57/BL6 wt microglia.  
 
 
3.2.5 Aβ uptake is lower in ApoE4 microglia compared with ApoE3 and ApoE4 
It has been proposed that the increased risk of ApoE4 is partially due to 
reduced Aβ clearance associated with the ApoE4 genotype (Deane et al., 
Figure 3.9 Amyloid beta uptake is genotype dependent  
Primary microglia monolayers were treated with Aβ (5 µM) for 1 hour, either 
directly or after 3 hours LPS priming. Fluorescence emission of internalised 
Aβ was detected using a microplate reader. Statistical significance was 
determined using a 2way ANOVA. Data are mean ± SEM and levels of 
significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. n=5 from at least 3 independent experiments.  
x 
Figure 3.10 IL-1β secretion by microglia treated with amyloid beta 
Primary microglia cells were treated with different concentrations of Aβ (5 
µM, 10 µM) for 1 hour, either directly or after 3 hours LPS pre-stimulation.  
IL-1β secretion was measured in cell free supernatants by ELISA. 
Supernatants were collected immediately after treatment. Statistical 
significance was determined using a 2way ANOVA. Data are mean ± SEM 
and levels of significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. n=3 from 3 independent experiments.  
x 
Figure 3.11 Microglial TNFα secretion is ApoE genotype dependent  
Primary microglia cells were treated with different concentrations of Aβ (5 
µM, 10 µM) for 1 hour, either directly or after 3 hours LPS pre-stimulation. 
TNFα secretion was measured in cell free supernatants by ELISA. 
Supernatants were collected immediately after treatment (A). Statistical 
significance was determined using a 2way ANOVA. Data are mean ± SEM 
and levels of significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. n=3 from 3 independent experiments. Outliers were removed 
based on Grubb’s test for outliers.  
x 
Figure 3.12 Nitrite secretion in primary microglia 
Primary microglia cells were treated with amyloid β, with and without LPS 
pre-stimulation. Nitrite concentration was determined by Griess assay in cell 
free supernatants which were collected 24 hours after treatment. Dashed line 
represents the detection limit of the assay. Statistical significance was 
determined using a 2way ANOVA. Data are mean ± SEM and levels of 
significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. n=4 from at least 3 independent experiments.  
x 
Target	list	 Identified	
TNFα	 	
IL-1β	 	
IFNγ	
CCL2	 	
CD14	 	
CD36	
CD68	
IL-10	
IL-11	
TGFβ	 	
IL-6	 	
Table 3.1 Original target list for MS 
A target list was created for MS as shown. Targets, from that original list 
that were identified by MS are indicated. 
x 
2008). Here, Aβ internalisation by microglia of the three ApoE genotypes, as 
well as microglia wild type animals, was determined by incubating primary 
microglia in the presence of fluorescently labelled Aβ1-42. The uptake of amyloid 
beta was assessed with and without LPS stimulation prior to the assay. The 
data, presented in Fig. 3.9 indicates uptake by microglia of all genotypes. Non-
treated microglia (i.e. no priming) showed abundant Aβ uptake by wt microglia 
and ApoE2, E3, E4 microglia. Interestingly there was no difference in uptake 
between primed and un-primed microglia. ApoE4 microglia were the least 
efficient at Aβ uptake, and ApoE2 microglia together with wt C57/BL6 microglia, 
the most efficient. ApoE 2 microglia showed a 3-4 fold higher uptake of Aβ 
compared with ApoE 4 microglia, and almost twice as much as ApoE 3 
microglia (Fig. 3.9). Overall, this data shows that Aβ uptake by microglia is 
genotype dependent with the corresponding efficiency of uptake as follows, 
ApoE 2 > ApoE 3 > ApoE 4. 
 
 
3.2.7 Pro-inflammatory cytokine secretion is ApoE isoform dependent 
IL-1β secretion was also determined in conditioned medium of Aβ-
treated microglia. Here, microglia were treated with Aβ (5 or 10 µM) for one 
hour, with or without prior LPS priming. IL-1β secretion was observed in primed 
and Aβ treated cells ApoE2 microglia. ApoE2 microglia respond to the 
treatment with large quantities of IL-1β secretion (~1500 pg/ml), whilst very little 
IL-1β was detected in the microglia culture media from the other genotypes 
(<20 pg/ml). No IL-1β secretion was detected from microglia treated with either 
Aβ or LPS alone (Fig. 3.10). Taken together, this suggests that Aβ treatment 
under primed conditions leads to IL-1β secretion in a genotype dependent 
manner, and that ApoE 2 microglia respond the strongest to this treatment. 
 
TNFα secretion by Aβ treated microglia was also determined. As for IL-1β 
secretion, ApoE2 microglia responded strongly to Aβ. Even without priming, Aβ 
induced TNFα secretion of ~1600 pg/ml. Upon LPS priming, all ApoE genotypes 
secreted TNFα, with ApoE4 microglia secreting the highest levels, with ~1.5 
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times higher TNFα compared with ApoE2 microglia and ~3 times higher TNFα 
compared with wt and ApoE3 microglia. A similar trend was observed when 
microglia were primed and treated with Aβ (Fig. 3.11, see also Fig. A2). In 
summary, TNFα secretion is genotype dependent with the corresponding levels 
of TFNα secretion as follows; ApoE4 > ApoE2 > ApoE3.  
 
 
3.2.8 Nitric oxide production is slightly increased upon Aβ treatment in primed 
microglia 
NO production was also assessed in Aβ stimulated microglia. Cells were 
treated with Aβ (5 or 10 µM) for 1 hour, either directly or following LPS priming 
for 3 hours. Cell culture media were replaced with fresh medium after the 
treatment and conditioned medium collected 24 hours following the treatment. 
After LPS priming, small amounts (~ 3 to 5 µM) of nitrite were detected in 
conditional medium from wt and E2 and 3 microglia, but not ApoE4 microglia. 
Nitrite secretion of microglia treated with LPS and Aβ (5 µM) was higher than 
cells only primed with LPS. Upon the addition of 10 µM Aβ, nitrite secretion is 
slightly increased (~ 5-10 µM) in wt, ApoE2 and 3 microglia, but remains below 
the detection limit of the assay for culture medium derived from ApoE4 microglia 
(Fig. 3.12). These results suggest, that nitrite secretion is below the limits of 
detection for ApoE4 microglia, and that Aβ treatment does not induce a strong 
nitrite secretion in any of the genotypes.  
 
 
3.2.9 Mass spectrometry analysis of microglia supernatants 
The production of pro-inflammatory cytokines by activated microglial cells is 
known to lead to neuroinflammation and to contribute to AD. IL-1β and TNFα 
have been implicated in the disease, together with various other pro-
inflammatory cytokines (Akiyama et al., 2000; Smith et al., 2012). The balance 
of pro- and anti-inflammatory cytokines secreted by microglia may influence the 
development and progression of AD. In order to ascertain pro- and anti-
inflammatory cytokines secreted by microglia after immunostimulation and Aβ 
treatment, the conditioned medium from microglia cultures was analysed by 
mass spectrometry (MS). Microglia from wt C57/BL6 and the three ApoE 
isotypes were either left untreated, immunostimulated with LPS and ATP, or 
primed with LPS and treated with Aβ. Culture media was collected after 
treatment and proteins were acetone precipitated for MS analysis. A list of 
potential protein targets was generated based on a literature search of 
cytokines known to be secreted by microglia and with links to AD pathology 
(Table 3.1). The target list included the pro-inflammatory cytokines and 
chemokines; TNFα, IL-1β, IFNγ, CCL2, CD14, CD36, CD68 and the anti-
inflammatory cytokines IL-10, IL-11, TGFβ and IL-6. These targets were 
selected based on their documented involvement in the regulation of 
inflammation by microglia. The MS analysis targeted the mass of the peptides 
predicted from a trypsin digestion of these targets.  
 
A number proteins were identified using this targeted MS approach including 
TNFα, IL-1b, CCL2 and IL-6. The other members of the target list, IFNγ, CD36 
and IL-10 were not detected (Table 3.1). However, a variety of proteins not 
included in the original target list were also identified, due to overlapping 
masses of the tryptic peptide fragments. These additional proteins are 
summarised in Table 3.2. The majority of cytokines were identified across all 
genotypes. The myeloid differentiation antigen CD14 (Haziot et al., 1988) was 
found in all samples, and also the protein kinase CCL2 (Roca et al., 2009). The 
pro-inflammatory cytokine TNFα was found across all genotypes in both 
immunostimulated and Aβ treated samples but not the untreated control. IL-12 
was consistently identified in conditioned media from LPS primed and Aβ 
treated microglia, with the exception of ApoE2 derived samples. IL-12β was 
only found in samples from ApoE3 and ApoE4 microglia that had been primed 
and treated with Aβ. IL-6 was identified in samples from all genotypes. In wt 
C57/BL6 and ApoE2 samples IL-6 was detected after immunostimulation and 
Aβ treatment. In ApoE3 and ApoE4 derived samples, IL-6 was only detected in 
samples from Aβ treated microglia (Table 3.2). The majority of cytokines 
identified were treatment dependent. In addition, ApoE3 and ApoE4 microglia 
display the largest variety of identified cytokines (Table 3.2). Overall, these 
analyses demonstrate that MS can be utilised for identifying cytokine profiles 
from conditioned media of small microglia cultures. Furthermore, the analysis 
has revealed a number of cytokines that can be further investigated.  
 
 
 
3.3 Discussion  
ApoE is the strongest risk factor for LOAD (Strittmatter et al., 1993) but 
how the individual isoforms modify susceptibility to development of AD is still 
unclear. The role of ApoE in acute and chronic neurological pathologies can be 
linked to a glial cell response to brain injury (Laskowitz et al., 2001). However, 
the mechanisms behind this are also unclear. To understand the effect of ApoE 
genotype on microglia function, I performed a number of studies assessing 
microglial responses after immunostimulation and after Aβ treatment. A 
particular focus was on the inflammatory response of the stimulated cells, and 
how the ApoE genotype affects this response. From the studies presented in 
this chapter, it can be summarised that ApoE4 induces the strongest pro-
inflammatory phenotype in response to immunostimulation, in comparison to wt 
C57/BL6, ApoE2 and ApoE3 microglia. Aβ treatment also induces a strong pro-
inflammatory phenotype, which is strongest in ApoE4 but also in ApoE2 
microglia. Furthermore, it was confirmed that Aβ uptake is ApoE genotype 
dependent.  
 
Pro-inflammatory cytokine secretion was determined by ELISA. IL-1β is of 
relevance to AD as it has been proposed to regulate Aβ production and 
promote expression and phosphorylation of tau proteins (Sheng et al., 2000; 
Griffin et al., 2006). In this study, IL-1β secretion was found to be ApoE isoform 
specific, with ApoE4 microglia secreting significantly more (>50 %) IL- 1β, in the 
presence of ATP (10 mM) and nigericin under primed conditions, than the other 
ApoE genotypes (Fig. 3.4B). The increased IL-1β secretion suggests NLRP3 
inflammasome activation, which is characterised by IL-1β secretion and 
pyroptotic cell death (He et al., 2016). The viability data (Fig. 3.2A), however 
does not indicate increased cell death in immunostimulated ApoE4 microglia, 
neither was an increase in LDH secretion detected (Fig. 3.3A). Conos and 
colleagues however propose that caspase-1 mediated IL-1β secretion can be 
cell death independent (Conos et al., 2016). Detecting levels of NLRP3 and 
caspase-1, for example by western blot could confirm NLRP3 inflammasome 
activation.  
 
In addition to IL-1β, secretion of TNFα was also determined. It was shown that 
dimerization of the pro-inflammatory cytokine TNFα can cause IL-1β cleavage 
and its secretion (Conos et al., 2016). TNFα has also been linked to 
neuroinflammation and AD progression in multiple studies and microglia are 
known to release this pro-inflammatory cytokine upon activation. It has been 
reported that biologically relevant concentrations of ApoE2 suppress the 
secretion of TNFα in enriched primary microglia cultures and BV-2 cells, a 
microglial cell line (Laskowitz et al., 2001). Microglia were generated from 
neonatal mice, as this is a standard protocol for high purity microglial cultures 
(Lian et al., 2016). Here primary microglia cells from newborn mice expressing 
the human AopE alleles were used. The data shown here further underlines an 
ApoE genotype dependent effect on TNFα secretion, as ApoE4 microglia 
secreted significantly higher levels (~50 %) of TNFα upon activation (LPS, LPS 
+ ATP, LPS + nigericin) (Fig. 3.5B). This is consistent across the different 
immunostimulatory protocols.  
 
However ApoE2 microglia were found to secrete higher levels of TNFα than 
ApoE3 microglia. Published data on the effect of ApoE on macrophages are in 
line with the findings described here. Using J774A.1 cells (a mouse 
macrophage cell line), Tsoi et al have demonstrated that both ApoE4 and 
ApoE2 cells produce higher amounts of TNFα and attribute these effects to 
modulation of the ERK 1/2 MAPK signalling pathway. They further suggest that 
ApoE isoforms differently modulate the activation of parallel signalling cascades 
triggered by LPS (Tsoi et al., 2007). Importantly, this study extends these 
previous findings from cell lines of macrophages, to primary microglial cells. The 
findings presented here directly demonstrate that different ApoE isoforms 
influence levels of TNFα secreted by stimulate primary microglia. 
 
The study in this Chapter confirms that ApoE4 microglia are the least efficient at 
Aβ clearance (Fig. 3.9). A significant decrease in Aβ uptake is observed 
between ApoE2 and ApoE4 microglia that were left unprimed. Together with the 
elevated TNFα secretion this is in line with the findings by Hickman and 
colleagues suggesting an inverse correlation between cytokine production and 
Aβ clearance in PS1-APP mouse microglia, an established mouse AD model 
expressing both the APP bearing Swedish mutation and PSEN1 mutation 
(Radde et al., 2006; Hickman et al., 2008). Further experiments should aim to 
analyse the degradation of internalised Aβ and whether the ApoE isotype 
influences the level of degradation. One possible limitation to the interpretation 
of the study is that a fluorescent conjugate of Aβ was used for the assay, and it 
is possible that the conjugation has an effect on the properties of Aβ and uptake 
mechanism. 
 
Not only was the uptake of Aβ investigated here, but also the microglial 
response to Aβ treatment. Whilst TNFα secretion was not further increased by 
the addition of Aβ to primed cells, ApoE2 microglia produced elevated TNFα 
secretion in response to Aβ treatment alone. This was not observed in the other 
genotypes. IL-1β secretion was also found to be significantly higher in ApoE2 
microglia, compared with the other genotypes, after LPS priming and Aβ 
treatment (Fig. 3.10). After immunostimulatory treatment, the pro-inflammatory 
response was much lower in ApoE2 microglia compared to the other 
genotypes, suggesting that ApoE has an effect on the response to different 
stimuli. This was further supported by the MS findings, which revealed a more 
diverse range of secreted cytokines were detected by ApoE4 cells compared 
with ApoE2 microglia. Increased pro-inflammatory response to Aβ by ApoE2 
microglia could lead to the recruitment of more microglia to the site of Aβ 
accumulation to clear the Aβ load. This would be consistent with the increased 
Aβ clearance described above.  
 
The MS analysis detected both pro- and anti-inflammatory cytokines. TNFα and 
IL-1β, which had previously been identified by ELISA, were also detected by 
MS. Additionally a variety of pro- and anti-inflammatory were detected, such as 
TGFβ and IL-6, demonstrating that sufficient material can be collected from 
spent cultures for detailed proteomics. Furthermore, the balance between pro- 
and anti-inflammatory cytokines should be further investigated, both in 
response to immunostimulation and Aβ treatment. An imbalance between pro- 
and anti-inflammatory cytokines is most likely the cause of persistent 
neuroinflammation in ApoE4 carriers.  
 
Expanding the MS analysis and performing a quantitative comparison between 
the different genotypes would be well worthwhile in the future. Quantitative MS 
can be performed by isotopic labelling techniques such as isotype-coded 
protein labelling (ICPL) (Schmidt et al., 2005). For this approach the lysine side 
chains and N-termini are labelled with ICPL reagents. (Chahrour et al., 2015). 
ICPL is suitable for different protein samples including body fluids, and would 
be compatible with the experimental setup chosen here (Rainczuk et al., 2013).  
 
Another approach would be to investigate the expression of genes encoding 
pro- and anti-inflammatory cytokines by RNA seq analysis. A previous study 
has identified four genetic profiles at risk for AD by combining the ApoE 
genotypes and genes encoding pro-inflammatory cytokines (Licastro et al., 
2007). This interesting approach allows for the identification of gene variants 
modulating innate immunity and ApoE polymorphism and creating a risk 
prediction for individuals. It further highlights that AD has multiple genetic 
factors in disease development.  
 
In summary, here it was shown that ApoE4 microglia have the strongest pro-
inflammatory response to immunostimulation and that ApoE2 microglia respond 
the strongest to Aβ treatment, whilst also being the most efficient at clearing Aβ. 
These findings are compatible with the role of E4, but not E2, as a risk factor in 
AD. Both immunostimulation and Aβ treatment do not cause ApoE genotype 
specific effects on microglia viability. Furthermore this study demonstrates that 
MS can be utilised for cytokine detection of cell culture media and could provide 
a valuable means to creating large cytokine profiles. However all experiments 
have been performed in vitro and on mouse cells rather than cells of human 
origin.  
 
 
Chapter 4: Effects of primary microglia conditioned media on 
primary cortical neurons 
 
4.1 Introduction 
Alzheimer’s disease is believed to have its onset 2-3 decades before the 
first symptoms of memory loss appear (Selkoe and Hardy, 2016). Hence further 
understanding of the disease progression is crucial. Neuronal degradation and 
loss represents one of the key pathological hallmarks of AD and includes early 
alterations such as synaptic and dendritic injury (DeKosky et al., 1996; Serrano-
Pozo et al., 2011). Several studies have shown that Aβ can impair synaptic 
structure and function. However aside from Aβ, neuroinflammation also 
contributes to neuronal impairment. Immunohistochemical studies support the 
early suspicion by Oskar Fischer, that plaque formation could be the result of an 
inflammatory process in the brain (Fischer, 1907). Neuroinflammation involves 
sustained activation of glial cells (Eikelenboom et al., 2010) and is strongly 
mediated by microglia cells responding to stimuli in their microenvironment by 
the release of pro-inflammatory cytokines. These cytokines then in turn can 
have a detrimental effect on neurons. The secretion of pro-inflammatory 
cytokines such as TNFα and IL-1β mediates neuroinflammation and 
neurotoxicity and causes sustained low grade inflammation (Heneka, 
Golenbock, et al., 2015). TNFα in particular accounts for most of the neurotoxic 
activity secreted by microglia (Combs et al., 2001). However TNFα has also 
been reported to have neuroprotective properties (Akiyama et al., 2000). These 
controversial findings need further investigation and are addressed in this 
Chapter. 
 
Microglia play an important part in the maintenance and plasticity of neuronal 
circuits and thus contribute to synapse remodelling (Ji et al., 2013). The 
interaction between microglia and neurons is considered critical for healthy 
brain function and often impaired during disease (Eyo and Wu, 2013; Tao et al., 
2018). This relationship works in both ways, microglia having an effect on 
neurons and vice versa. Neuronal ageing, for example, can drive microglia 
priming (Heneka, Carson, et al., 2015). This relationship under pathological 
conditions can result in a vicious cycle. Neurons can prime and activate 
microglia, which leads to increased secretion of pro-inflammatory and 
neurotoxic factors and thus more neuronal ageing, secretion of Aβ and further 
microglial activation. Understanding the molecular details of this interaction 
should reveal approaches, which could be used therapeutically.  
 
Similarly, further investigation of the mechanisms, which are responsible for the 
most important genetic risk factor for LOAD, APOE, is important. Studies 
investigating the effects of ApoE alleles on neurons have revealed that human 
ApoE4 cultures secreted two times more Aβ1-42 than ApoE3 cultures. The same 
study also demonstrated that using gene editing to convert ApoE4 to ApoE3 
ameliorated this effect, suggesting an ApoE4 specific effect (Wang et al., 2018). 
In this Chapter, the relationship of ApoE allele and generation of inflammatory 
factors was further expanded on.  
 
The aim of this Chapter was to determine the effects of activated microglia from 
different ApoE backgrounds on primary neurons. Activated primary microglia 
are known to secrete a variety of neurotrophic and neurotoxic factors into their 
culture medium (Nakajima et al., 2001; Heneka, Carson, et al., 2015). Culture 
media were collected and added to primary cortical neuron cultures.  
 
Here, it was shown that immunostimulation and Aβ treatment of microglia cells 
resulted in secreted factors in the culture medium, which have an effect on 
neuron morphology. Moreover, these effects are ApoE genotype dependent. In 
particular, the pro-inflammatory cytokine TNFα was shown to reduce dendrite 
number and length. This can be partially prevented by the addition of an anti-
TNFα antibody. The degree of protection mediated by the anti-TNFα antibody, 
from the morphological changes to neurons is also ApoE genotype dependent.  
 
 
 
4.2 Results 
 
4.2.1 Establishing an experimental setup for neuron treatment 
The aim of this Chapter was to elucidate the effect of microglia culture 
conditioned media on neurons. Primary microglia from the three ApoE isotypes 
(ApoE2, 3 and 4), as well as wt C57/BL6 microglia were immunostimulated (150 
ng/ml LPS and 10 mM ATP) or treated with Aβ 10 µM, either alone or after 
priming with LPS (150 ng/ml). Conditioned medium was then collected and 
added to primary cortical neurons at a 1:2 ratio for 72 hours (Fig.4.1A). Primary 
cortical neurons were cultured in neurobasal medium, whilst primary microglia 
were cultured in DMEM with the addition of N2 supplement, which contains 
growth factors. In order to determine whether the mix of different cell culture 
media would affect neuron viability, neurons were cultured in neurobasal 
medium, or neurobasal medium supplemented with N2 and DMEM. After 72 
hours of incubation, LDH release was measured. The analysis revealed that the 
addition of N2 or DMEM medium does not affect neuron viability (Fig. 4.1B). 
 
 
4.2.2 Conditioned media of microglial cultures affect neuron morphology in an 
ApoE dependent manner . 
Conditioned media from untreated and immunostimulated (150 ng/ml 
LPS for 3 hours and 10 mM ATP for 1 hour) microglia were added to primary 
cortical neurons from DIV 7 (Days in vitro) for 72 hours. Neurons were then 
processed for confocal microscopy by staining for the microtubule associated 
protein 2 (map2). Map2 belongs to a family of phosphoproteins expressed in 
the cell body and dendrites of neurons and was therefore used to assess 
dendrite morphology (Li et al., 2008). Morphological changes were determined 
using Fiji software. Both the number of dendrites per cell and the length of 
dendrites decreased in neurons treated with conditioned medium from 
immunostimulated (LPS and ATP) microglia, compared with conditioned 
medium from untreated microglia, regardless of microglia genotype (Fig 4.2). 
Microscopic images were analysed and the number of dendrites per cell and 
Fig 4.1 Experimental setup for neuron treatment 
Primary microglia from wild type or different ApoE genotypes were either 
immunostimulated with LPS and ATP or treated with Aβ with or without LPS. 
Conditioned media were collected and added to wt primary cortical neurons 
for 72 hours. Neurons were then processed for IFA and changes to neuron 
morphology determined. (A) Schematic representation of the experimental 
setup. (B) Different neuronal culture media (neurobasal medium, 
neurobasal medium supplemented with N2 (added to microglia cultures) 
and conditioned medium from untreated wt C57/BL6 microglia) were tested 
by measuring LDH release after 72 hours of incubation. LDH secretion was 
determined and is presented as percentage of 100 % lysed cells.  
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Figure 4.2 Dendrite morphology changes upon treatment with conditioned 
media from immunostimulated microglia 
Conditioned media from microglia of different genetic backgrounds were 
incubated with primary cortical neurons (DIV 7) for 72 hours and processed 
for immunofluorescence imaging. (A) A representative image is shown for 
untreated neurons and (B) neurons subjected to conditioned media from 
immunostimulated (150 ng/ml LPS for 3 hours + 10 mM ATP for 1 hour) 
ApoE2, 3 and 4 microglia. Dendrites were visualised by staining for map2, 
nucleus by DAPI staining. 
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Figure 4.3. Conditioned media from microglia affect neuron morphology in 
an ApoE dependent manner  
Conditioned media from unstimulated or immunostimulated (150 ng/ml LPS 
for 3 hours + 10 mM ATP for 1 hour) microglia of different genetic 
backgrounds that were incubated with primary cortical neurons (DIV 7) for 72 
hours and then processed for immunofluorescence imaging. (A) ApoE 
dependent changes to neuron morphology were observed based on number 
of dendrites per cell and (B) dendrite length. Untreated medium controls are 
in grey. Data are mean ± SEM and levels of significance were determined by 
two way ANOVA and are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Data are pooled from at least 3 independent experiments. 
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DIV 7 
dendrite length quantified. This allowed for a quantification of morphological 
changes to the cells. Alterations to the cell morphology can have an impact on 
its function (Uylings and Pelt, 2002; Billeci et al., 2009). 
Neurons treated with conditioned medium from untreated wt C57/BL6 microglia 
had an average of ~9 dendrites per cell and an average length of ~55 µm (Fig. 
4.3). Neurons incubated with conditioned media from untreated ApoE3 
microglia, appeared very similar to those incubated with media from wt C57/BL6 
microglia, with ~8 dendrites per cell and an average dendrite length of 50 µm. 
Incubation with conditioned media from untreated ApoE2 microglia resulted in 
slightly more dendrites (~11) that were found to be ~65 µm long. In comparison, 
neurons treated with conditioned media from untreated ApoE4 microglia, have 
~6 dendrites less per cell, which are ~25 µm shorter than those in ApoE2 
treated neurons. There is a significant reduction in dendrite number (~4) 
between neurons incubated with conditioned media from untreated wt C57/BL6 
microglia and untreated ApoE4 microglia. 
 
In addition to these genotype dependent differences in neuron morphology, 
differences were also observed between treatments. Neurons treated with 
conditioned media from immunostimulated (150 ng/ml LPS for 3 hours and 10 
mM ATP for 1 hour) wt C57/BL6 microglia had both significantly fewer (~3) (Fig. 
4.3A) and shorter (~15 µm) (Fig. 4.3B) dendrites. Similarly, the number and 
length of dendrites are reduced, by ~3 dendrites per cell and ~15 µm, in 
neurons treated with conditioned medium from immunostimulated ApoE2 
microglia, compared with neurons treated with conditioned media from 
untreated ApoE2 microglia. A significant reduction in dendrite number and 
length was also observed between neurons incubated with conditioned media 
from immunostimulated ApoE3 and ApoE4 microglia, compared with those 
treated with conditioned media from untreated ApoE3 and ApoE4 microglia.  
 
The same experimental setup was used on neurons at DIV 14. At this time point 
the neuronal cells are more mature and the neuronal density is increased in 
comparison to that of DIV 7 neurons (Cullen et al., 2010). Therefore, the effects 
Figure 4.4 Microglia derived conditioned media affect neuron morphology in 
an ApoE dependent manner  
Conditioned media from unstimulated or immunostimulated (150 ng/ml LPS 
for 3 hours + 10 mM ATP for 1 hour) microglia of different genetic 
backgrounds were incubated with primary cortical neurons (DIV 14) for 72 
hours and then processed for immunofluorescence imaging. (A) ApoE 
dependent changes to neuron morphology were observed based on number 
of dendrites per cell and (B) dendrite length. Untreated medium controls are 
in grey. Data are mean ± SEM and levels of significance are indicated as 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Data are pooled from at 
least 3 independent experiments.  
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of microglia conditioned media were also investigated to elucidate whether the 
more dense neuronal culture would be affected in a similar way as DIV 7 
neurons. Whilst the overall number of dendrites per cell was similar to that 
observed in DIV 7 neurons, the dendrite length was increased in DIV 14 
neurons. In particular in neurons treated with conditioned media from untreated 
ApoE2 microglia, dendrites on DIV14 were ~25 µm longer than dendrites of 
DIV7 neurons. Genotype specific differences were also observed. Neurons 
treated with conditioned media from untreated wt C57/BL6 and untreated 
ApoE2 microglia resulted in significantly more dendrites (~10 per cell) than 
ApoE4 treated neurons (~4 dendrites per cell) (Fig. 4.4A). Similarly, neurons 
subjected to cell culture media from untreated ApoE2 microglia had significantly 
longer dendrites (~55 % longer) than those treated with ApoE4 conditioned 
media (Fig. 4.4B).  
 
As for DIV 7 neurons, there was a significant decrease in both number of 
dendrites and their length between neurons treated with conditioned media from 
untreated microglia and those subjected to conditioned media from 
immunostimulated (150 ng/ml LPS for 3 hours and 10 mM ATP for 1 hour) 
microglia. This was consistent across all genotypes.  
 
In summary, conditioned media from immunostimulated (150 ng/ml LPS for 3 
hours and 10 mM ATP for 1 hour) microglia had an effect on neuronal 
morphology, by decreasing both the dendrite number and length. Whilst this is 
consistently observed with wt C57/BL6 and the three ApoE genotypes, the 
detrimental effect of microglia conditioned media on dendrite morphology is 
genotype dependent with the following ranking (high to low) of conditioned 
medium from microglia, ApoE4 > ApoE3 > ApoE2.  
 
 
4.2.3 TNFα modifies dendrite morphology in a dose dependent manner  
It is well known that TNFα is secreted by activated microglia and, 
furthermore, TNFα has been implicated in AD (Franchi et al., 2009). In the 
previous Chapter it was determined that activated microglia, especially from 
ApoE4 mice, secrete large amounts of TNFα. To determine whether TNFα has 
an effect on dendrite morphology, neurons from DIV 7 were incubated with 
increasing concentrations of purified mouse TNFα (500, 1000 and 2000 pg/ml) 
and in the presence or absence of an anti-TNFα antibody, for 72 hours. 
Measuring dendrite length and number of dendrites per cell provided a read out 
of morphological changes. TNFα significantly reduced both the number of 
dendrites and their length in a dose-dependent manner (Fig. 4.5). Dendrites of 
neurons treated with 2 ng/ml TNFα are less than 50 % as long as dendrites 
from untreated neurons (Fig. 4.5 A and B). The reduction in dendritic length was 
abrogated with anti-TNFα antibody, confirming the morphological changes were 
due to TNFα. Addition of anti-TNFα antibody to TNFα treated neurons 
significantly rescued both dendrite number and length as compared to neurons 
without anti-TNFα treatment. Dendritic length was decreased by ~50 % in 
neurons treated with TNFα (1 or 2 ng/ml) compared with those incubated in the 
presence of anti-TNFα antibody (Fig. 4.5B).  
 
 
4.2.4 TNFα inhibition abrogates morphological changes of cortical neurons, 
induced by conditioned medium from immunostimulated microglia  
 In Chapter 3 it was established that TNFα is secreted by 
immunostimulated microglia in an ApoE isoform dependent manner (Fig. 3.5). 
In order to investigate whether the changes to neuron morphology observed 
here are in part, due to TNFα in the microglia conditioned medium, neurons 
from DIV7 (Fig. 4.6) and DIV14 (Fig. 4.7) were incubated with conditioned 
medium from untreated or immunostimulated microglia as described above, and 
incubated in the presence of a neutralising anti-TNFα antibody. Following anti-
TNFα antibody treatment neurons had more and longer dendrites compared 
with neurons without the anti-TNFα antibody. This effect was observed 
regardless of the genotype of microglia of the conditioned media. On average 
neurons (from DIV7) treated with the anti-TNFα antibody had 2.3 times more 
dendrites than those without TNFα neutralisation (Fig. 4.6A). Dendrite length 
no inhibitor 
TNFα inhibitor 
Figure 4.5 TNFα treatment results in reduction in number and length of 
dendrites 
Primary cortical neurons (DIV 7) were incubated with TNFα for 72 hours, in 
the presence or absence of an anti-TNFα antibody and then processed for 
immunofluorescence imaging. (A) TNFα dependent changes to neuron 
morphology were observed based on number of dendrites per cell and (B) 
dendrite length. Statistical significance was determined using a one-way 
ANOVA. Data are mean ± SEM and levels of significance are indicated as 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Data are pooled from at 
least 3 independent experiments.  
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Figure 4.6 Anti-TNFα antibodies protect neurons from morphological 
changes induced by microglia conditioned medium 
Conditioned media from unstimulated or immunostimulated (150 ng/ml LPS 
for 3 hours + 10 mM ATP for 1 hour) microglia of different genetic 
backgrounds were incubated with primary cortical neurons (DIV 7) for 72 
hours, in the presence or in the absence of anti-TNFα antibody (10 ng/ml) 
and then processed for immunofluorescence imaging and morphological 
changes assessed by determining (A) number of dendrites per cell and (B) 
dendrite length. Statistical significance was determined by t-test. Data are 
mean ± SEM and levels of significance are indicated as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. Data are pooled from at least 3 independent 
experiments.  
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was 2-fold higher in neurons treated with conditioned media from 
immunostimulated microglia with the TNFα neutralising antibody compared with 
those treated without the anti-TNFα antibody (Fig. 4.6B).  
 
Curiously, dendrites of neurons treated with conditioned media from untreated 
microglia were also longer and increased in number in the presence of the anti-
TNFα antibody (Fig. 4.6). Previously it was shown that untreated microglia do 
not secrete detectable levels TNFα (Fig. 3.5); however, in the presence of the 
TNFα antibody the number of dendrites was increased in neurons treated with 
conditioned media from wt C57/BL6 and ApoE4 microglia, and dendrite length 
was increased in neurons incubated with wt C57/BL6, ApoE2 and ApoE3 
microglia derived conditioned media (Fig. 4.6). Interestingly, conditioned media 
from untreated microglia reduced both these measures. An even more drastic 
effect was observed in neurons treated with conditioned media from 
immunostimulated microglia conditioned media. In the presence of the anti-
TNFα antibody, the number of dendrites was increased from ~6 to ~9 in 
neurons subjected to conditioned media from immunostimulated ApoE3 
microglia, and increased by an average of ~4 dendrites per cell in those treated 
with conditioned media derived from immunostimulated ApoE4 microglia (Fig. 
4.6A).  
 
Similar observations were made in neurons from DIV 14. Here the positive 
effects of the anti-TNFα antibody on dendrite morphology were mainly seen in 
neurons incubated with conditioned media from immunostimulated microglia. 
However, the length of dendrites from neurons treated with conditioned media 
from ApoE4 microglia did not increase significantly in the presence of the 
neutralising antibody. This could be due to the large spread of the data from 
DIV14 neurons (Fig. 4.6). Dendrite number and length both increased by ~ 2 
fold in neurons treated with wt C57/BL6 derived conditioned media 
(immunostimulated) (Fig. 4.7). 
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Figure 4.7 Anti-TNFα antibodies protect neurons from morphological 
changes induced by microglia conditioned medium 
Conditioned media from unstimulated or immunostimulated (150 ng/ml LPS 
for 3 hours + 10 mM ATP for 1 hour) microglia of different genetic 
backgrounds were incubated with primary cortical neurons (DIV 14) for 72 
hours, in the presence or absence of an anti-TNFα antibody (10 ng/ml) and 
then processed for immunofluorescence imaging and morphological 
changes assessed by determining (A) number of dendrites per cell and (B) 
dendrite length. Statistical significance was determined by t-test. Data are 
mean ± SEM and levels of significance are indicated as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. Data are pooled from at least 3 independent 
experiments.  
DIV 14 
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In summary, this data suggests that TNFα is a major factor in the conditioned 
microglia media involved in the perturbation of dendrite morphology.  
 
4.2.5 Amyloid beta perturbs dendrite morphology in an ApoE dependent 
manner  
 To determine whether Aβ can stimulate microglia to produce factors that 
affect neuron morphology, primary microglia were also treated with Aβ (10 µM) 
with or without LPS (150 ng/ml) priming. Conditioned media from the Aβ treated 
microglia were added to neuronal cultures (DIV7) at a 1:2 ratio for 72 hours. 
Neurons treated with conditioned media from wt C57/BL6 Aβ alone treated 
microglia had twice as many dendrites as neurons treated with conditioned 
media from LPS primed wt C57/BL6 Aβ treated microglia. A significant 
reduction of dendrite number was also detected between neurons incubated 
with conditioned media from Aβ treated and primed Aβ treated microglia from all 
three ApoE isotypes. On average the number of dendrites increased by at least 
2/cell (Fig. 4.8A). However, it is difficult to assess whether this effect is due to 
Aβ treatment, as the findings from previous experiments (Fig.4.3) suggest 
similar dendrite morphology of neurons treated with conditioned media from 
untreated microglia. In order to determine the extent of the effect Aβ treatment 
of microglia has on neurons, a LPS control would be necessary. Due to the 
large experimental setup and availability of primary neurons, this was not 
included in this current study. 
In addition to this there are also genotype specific differences in dendrite 
numbers. Neurons treated with conditioned media from Aβ alone and primed 
and Aβ treated wt C57/BL6, ApoE2 and ApoE3 microglia had significantly more 
dendrites per cell, than neurons treated with ApoE4 derived conditioned media. 
Neurons incubated with conditioned media from Aβ treated wt C57/BL6 
microglia had 33 %, ApoE2 had 75 % and ApoE3 had 42 % more dendrites 
than ApoE4 treated neurons (Fig. 4.8A). Dendrite length does not vary 
significantly between neurons incubated with conditioned media from Aβ treated 
compared to primed and Aβ treated microglia (Fig. 4.8B). Conditioned media 
from microglia treated with Aβ also affect the dendrite length in a genotype 
Figure 4.8. Conditioned media from Aβ stimulated microglia affect neuron 
morphology in an ApoE dependent manner 
Microglia were treated with Aβ (10 µM), with or without priming with LPS (150 
ng/ml). Conditioned media were collected and incubated with primary cortical 
neurons (DIV 7) for 72 hours. Neurons were then processed for 
immunofluorescence imaging. ApoE dependent changes to neuron 
morphology were observed based on (A) number of dendrites per cell and 
(B) dendrite length. Data for Nbm and DMEM are repeated from Figure 4.3. 
Data are mean ± SEM and levels of significance are indicated as *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. Data are pooled from at least 3 
independent experiments.  
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Figure 4.9. Microglia derived conditioned media affect neuron morphology in 
an ApoE dependent manner 
Microglia were treated with Aβ (10 µM), with or without priming with LPS (150 
ng/ml). Conditioned media were collected and incubated with primary cortical 
neurons (DIV 14) for 72 hours. Neurons were then processed for 
immunofluorescence imaging. ApoE dependent changes to neuron 
morphology were observed based on (A) number of dendrites per cell and 
(B) dendrite length. Data are mean ± SEM and levels of significance are 
indicated as *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Data are 
pooled from at least 3 independent experiments.  
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dependent manner. Those from an ApoE2 background result in the longest 
dendrites ~70 µm, which is comparable to dendrite length of untreated neurons, 
whilst ApoE4 microglia conditioned media decreased the dendrite length both 
after Aβ alone and LPS and Aβ treatment in comparison to wt, ApoE2 and 
ApoE3 derived conditioned media (Fig. 4.8B). 
 
Similar effects, although not as prominent were observed in neurons from DIV 
14. Neurons incubated with conditioned media from Aβ treated wt C57/BL6 
microglia had ~40 % more dendrites than neurons treated with conditioned 
media from ApoE4 microglia. Additionally, treatment dependent effects were 
observed. In the presence of primed and Aβ treated conditioned media from wt 
microglia, 50 % fewer dendrites were detected than in neurons treated with 
conditioned media from Aβ treated microglia. Dendrite number was also 
reduced in neurons incubated with conditioned media from primed and Aβ 
treated ApoE2 (25 %) and ApoE 3 (~40%) microglia compared to neurons 
treated with conditioned media from Aβ treated microglia of the respective 
genotype (Fig. 4.9A). This effect can also be observed in dendrite length (Fig. 
4.9B). Taken together this suggests that both the microglia treatment as well as 
the microglia genotype have an impact on dendrite morphology. However, the 
differences in dendrite morphology between neurons incubated with conditioned 
media from microglia treated with Aβ alone and primed and Aβ treated cells are 
not as apparent as the immunostimulatory treatment.  
 
 
4.2.6 Treatment with anti-TNFα antibody partially prevents dendrite loss 
 The aim was to establish whether the changes in neuron morphology 
observed here are due to TNFα in the microglia conditioned medium, as 
previously described for neurons incubated with conditioned media from 
immunostimulated microglia (Fig 4.6 and Fig 4.7). Incubation in the presence of 
anti-TNFα antibody resulted in an increase of dendrite number compared with 
neurons (DIV 7) incubated with conditioned media from wt C57/BL6 microglia 
(LPS and Aβ treated) by 40 %. There was also a significant difference between 
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Figure 4.10 Primary cortical neurons from DIV 7 incubated with microglia 
conditioned media in the presence and absence of anti-TNFα antibody 
Conditioned media from Aβ stimulated microglia of different genetic 
backgrounds were incubated with primary cortical neurons (DIV 7) for 72 
hours, in the presence or in the absence of an anti-TNFα antibody and then 
processed for immunofluorescence imaging and morphological changes 
assessed by determining (A) number of dendrites per cell and (B) dendrite 
length. Statistical significance was determined by t-test. Data are mean ± 
SEM and levels of significance are indicated as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. Data are pooled from at least 3 independent 
experiments.  
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Figure 4.11 Primary cortical neurons from DIV 14 incubated with microglia 
conditioned media in the presence and absence of anti-TNFα antibody 
Conditioned media from Aβ stimulated microglia of different genetic 
backgrounds were incubated with primary cortical neurons (DIV 14) for 72 
hours, in the presence or absence of an anti-TNFα antibody and then 
processed for immunofluorescence imaging and morphological changes 
assessed by determining (A) number of dendrites per cell and (B) dendrite 
length. Statistical significance was determined by t-test. Data are mean ± 
SEM and levels of significance are indicated as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. Data are pooled from at least 3 independent 
experiments.  
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conditioned media from ApoE2 cells (Aβ treated), by ~25 % and ApoE4 
microglia treated with Aβ as well as LPS and Aβ (>50 %) (Fig. 4.10A).  
Dendrite length was significantly increased in the presence of anti-TNFα 
antibody in neurons subjected to conditioned media from wt (~45 %) and ApoE3 
(~30 %) microglia that have been treated with Aβ, and ApoE4 microglia treated 
with LPS and Aβ. Here the dendrite length is increased almost 2 fold in neurons 
incubated with the anti-TNFα antibody (Fig. 4.10B). In neurons from DIV 14 the 
presence of anti-TNFα antibody significantly increases dendrite length in all 
LPS and Aβ stimulated microglia conditioned medium treated neurons 
regardless of the genotype. Dendrites in the presence of the anti-TNFα antibody 
are increased by >15 µm (Fig. 4.11B).  
Overall the data suggests that the incubation with anti-TNFα antibody, prevents 
dendrite loss in neurons treated with conditioned media from Aβ treated 
microglia, mainly under primed conditions. 
 
 
 
4.3 Discussion 
The interaction and communication between microglia and neurons is 
crucial for normal neuronal regulation. As such, microglia are responsible for 
synaptic pruning (Pósfai et al., 2019). The impact of secretory products from 
microglia on neurons during AD development however remains largely 
unknown. Microglia secrete various neurotoxic and neurotrophic factors that 
can differently affect neurons. Here, microglia from different ApoE genotypes 
and wt C57/BL6, were immunostimulated or treated with Aβ and the conditioned 
medium collected. These culture media were then added to primary cortical 
neuron cultures for 72 hours and effects on neuron morphology studied. An 
ApoE dependent and treatment dependent effect on dendrite morphology was 
observed and could be attributed, at least partially, to TNFα secreted by 
activated microglia. Treatment with an anti-TNFα antibody protected neurons 
from morphological changes. Furthermore, the approach utilised here has 
proven useful to elucidate effects of secretory products from microglia under 
untreated, immunostimulated or Aβ treated conditions.  
 
Activated microglia secrete a plethora of pro-inflammatory proteins (Smith et al., 
2012). Here the effects of immunostimulated (150 ng/ml LPS for 3 hours and 10 
mM ATP for 1 hour) microglia on neurons was demonstrated by changes in 
neuron morphology. Fluorescent immunocytochemistry and confocal 
microscopy revealed that conditioned media from immunostimulated microglia 
resulted in decreased number and length of dendrites, compared with neurons 
incubated with conditioned media from untreated microglia. This effect was 
seen in neurons from DIV 7 (Fig. 4.3) and DIV 14 (Fig. 4.4). Whilst analysis of 
dendrites is easier at DIV 7, neurons from DIV 14 are more representative for 
later developmental stages (Cullen et al., 2010). Overall the more developed 
neuronal cultures from DIV 14 had more and longer neurons. The neurons 
showed similar susceptibility to the microglia conditioned media treatment 
regardless of developmental stage. 
 
The microglia treatment did impact neuron morphology though, indicating that 
immunostimulation (Fig. 4.3, 4.4) and to a lesser extend Aβ treatment (Fig. 4.7, 
4.8) of microglia results in decreased dendrite numbers and length in neurons 
exposed to conditioned media This effect is more pronounced in neurons 
incubated with conditioned media from immunostimulated microglia than Aβ 
treated microglia.  
In the context of Alzheimer’s this is an important observation as it further 
supports the notion of neuroinflammation not only driving the disease but also 
being one of the earliest events in the disease pathogenesis (Cunningham et 
al., 2005; Cardoso et al., 2015). 
 
Some of the effects on neuron morphology outlined here can be attributed to 
TNFα. The pro-inflammatory cytokine, implicated in AD pathology has 
previously been shown by Floden and colleagues to have no effect on neuron 
viability by itself. However coincident stimulation of TNFα and NMDA receptors 
was found to initiate neuronal death, by increasing neuronal iNOS 
immunoreactivity (Floden et al., 2005). Using ERK specific inhibitors it was later 
shown that neuronal death induced by NMDA receptors and TNFα was ERK 
dependent (Jara et al., 2007). 
 
Here it was shown that neuron morphology, as assessed by dendrite number 
and length, are affected by TNFα treatment in a dose dependent manner and 
can be prevented by addition of an anti-TNFα antibody (Fig. 4.5). Microglia 
activation was shown to induce TNFα secretion (Fig. 3.5B). Therefore, the 
effect of TNFα inhibition was also tested on the microglia conditioned media 
treated neurons, using an anti-TNFα antibody. The data shows that overall the 
inhibition of TNFα prevents the dendrite morphology changes described above 
(Fig. 4.6, 4.7, 4.10 and 4.11). This suggests that TNFα in the conditioned media 
is one of the main contributing factors of the changes to neuron morphology 
and further underlines that TNFα is a key player in AD development. Given the 
high levels of secreted TNFα found in conditioned media from LPS primed cells 
of all genotypes, as determined in Chapter 3, the effects here cannot 
conclusively be attributed to immunostimulation or Aβ treatment. LPS may in 
fact be driving this response through the induction of TNFα secretion. To further 
decipher this effect, neurons could be treated with conditioned media from LPS 
primed microglia. 
 
Neurons treated with conditioned media from untreated microglia also displayed 
more and longer dendrites in the presence of the neutralising anti-TNFα 
antibody than those treated with conditioned media from untreated microglia but 
without the addition of the anti-TNFα antibody (Fig. 4.6). However, TNFα was 
undetected in the media from untreated microglia by ELISA (Fig. 3.5B). This 
raises the question why the anti-TNFα antibody had a protective effect on 
dendrite morphology under those treatment conditions? Potentially the anti-TNF
α antibody has non-specific effects. This could be examined using an irrelevant 
Ig isotype control experiment. Although this effect is difficult to explain, it is 
important to note though, that this anti-TNF α  antibody effect was more 
prominent in neuronal cultures from DIV 7 (Fig. 4.6) than DIV 14 (Fig. 4.7), 
suggesting that data from DIV 14 neuronal cultures could be more robust. 
Furthermore, this finding may suggest a hypersensitive reaction by DIV 7 
neuronal cultures to the selected treatments. Aside from this curious effect, the 
data is internally consistent and underlines the role of microglia in a sustained 
pro-inflammatory response and the potential detrimental effects to neurons. In 
addition microglia secrete a multitude of both pro- and anti-inflammatory 
cytokines into their culture media, as determined by MS in Chapter 3. Thus, 
secreted anti-inflammatory cytokines could play a neuroprotective role. Further 
studies could involve longer incubation times, in vivo experiments and rescue 
experiments.  
 
In addition to the treatment dependent differences, genotype dependent 
differences were observed in neurons treated with conditioned microglia media. 
Neurons incubated with culture media from ApoE 4 microglia had significantly 
impaired dendrites in comparison to those treated with ApoE 2 and wt C57/BL6 
microglia derived conditioned media. Differences between ApoE 3 and ApoE4 
treated neurons were not significant but a trend could be observed. Studies 
have suggested that exogenous ApoE3 can stimulate neurite outgrowth, whilst 
ApoE4 has the opposite effect (Nathan et al., 1994). The findings by Nathan 
and colleagues could explain why a reduction in dendrites is seen in neurons 
cultured with untreated ApoE4 microglia derived conditioned media. Microglia 
and astrocytes are the main source of ApoE in the brain (Ji et al., 2003) and 
ApoE secreted by microglia has been shown to have both neurotoxic and 
neuroptrophic effects, depending on the isoform (Qin et al., 2006). The 
reduction of dendrites caused by incubation with conditioned media from 
untreated ApoE4 microglia could be due to the secreted ApoE4. The effect of 
ApoE4 on dendrites could provide a potential explanation for the cognitive 
decline in AD patients expressing ApoE4, which is due to defective neurons. 
The findings presented here are in line with one study that reported a 
correlation of poor spatial learning and memory in ApoE4 TR mice. This was 
attributed to reduced dendritic spine density in the medial entorhinal cortex 
(Rodriguez et al., 2013).  
The underlying mechanism causing ApoE4 induced cognitive deficits as well as 
the changes to neuron morphology remain unknown. However it has been 
demonstrated, that addition of the ApoE mimetics could reduce 
neuroinflammation (Safieh et al., 2019).  
 
Overall I have shown in this Chapter that the effects of microglial secretory 
products on neurons can be determined by incubation of neurons in the 
presence of microglia conditioned media. Whilst this study used morphological 
changes in the neurons as the read out, this approach could also be used for to 
assess biochemical perturbations, including signalling pathways. It would be 
interesting to determine the impact of Aβ secretion by the treated neurons and 
in particular the ratio between Aβ1-42 and Aβ1-40 secretion. This would further 
reveal the downstream effects of ApoE and microglia activation on neurons. 
 
Whilst Jara and colleagues (Jara et al., 2007) showed that TNFα alone does not 
contribute to neuronal death, this current study shows that TNFα affects neuron 
morphology. Additionally, it was shown here that the ApoE genotype has an 
effect on dendrite morphology. These findings contribute to our understanding 
of how ApoE impacts the development of AD. However, it remains to be 
determined how these morphological changes relate to neuronal function. 
Trafficking of APP and BACE1 in the treated neurons, for example, could be 
assessed by fluorescent microscopy. Together with the analysis of Aβ 
production could provide a deeper understanding of perturbations in trafficking 
associated with AD. 
Chapter 5: Analysis of cell biological properties of microglia  
 
5.1 Introduction  
 Macrophages play an important role in immunity and in regulating 
inflammation. There is a wealth of knowledge regarding macrophage function 
that can be used to guide the understanding of microglia function. Like 
macrophages, microglia play a critical role in regulating immune responses and 
represent the main population of innate immune cells of the brain (Rivest, 
2009). Both macrophages and microglia monitor their microenvironments and 
ingest pathogens and cellular debris (Yin et al., 2017). Uptake of pathogens and 
cellular debris occurs via a multitude of endocytic pathways, including 
macropinocytosis (Lim and Gleeson, 2011).  
 
One of the key roles of microglia is the clearance of Aβ. Aβ has been detected 
in endosome-like cellular compartments (Frackowiak et al., 1992). In the brain 
both soluble and fibrillar Aβ are present. Microglia can take up both soluble and 
insoluble Aβ and it has been postulated that soluble Aβ is taken up by 
macropinocytosis, whilst fibrillar Aβ is taken up by phagocytosis (Lee and 
Landreth, 2010). Thus, macropinocytosis is likely to play an important role in Aβ 
clearance. Defining the molecular mechanisms involved in macropinocytosis in 
microglia cells could reveal potential targets for therapeutic intervention.  
 
The Gleeson lab has previously demonstrated that SNX5 is essential for dorsal 
surface-mediated macropinosome biogenesis in macrophages (Lim et al., 
2012). The role of SNX5 in macropinocytosis in microglia has not yet been 
investigated and was one of the aims of this Chapter.  
 
Another property of macrophages is the ability of sodium chloride to trigger a 
pro-inflammatory response (Jantsch et al., 2015; Binger et al., 2015). This could 
be of relevance to AD pathology, as one study has reported elevated Na+ 
concentrations in the brains of AD patients (Graham et al., 2015). Additionally, 
mice on a high salt diet displayed impaired retention of spatial memory, which 
was attributed to increased oxidative stress, induced by the high salt diet (Liu et 
al., 2014). It has been postulated that diet could be a contributing factor to 
neuroinflammation and thus the progression of AD (Husain et al., 2017).  
 
The effect of NaCl on microglia function is unknown and is important to 
investigate as NaCl could provide important insights into how diet can impact 
neuroinflammation and AD. The results presented in this Chapter show that 
NaCl not only induces a pro-inflammatory response in LPS primed 
macrophages, but also in primed microglia. This pro-inflammatory response in 
microglia is regulated by p38 MAPK signalling and results in elevated nitrite 
secretion, as well as IL-1β secretion. In the presence of a p38 inhibitor, these 
microglia pro-inflammatory responses were attenuated. In the presence of Aβ, 
the pro-inflammatory effect mediated by NaCl is further enhanced.  
 
Investigating the role of SNX5 on macropinocytosis, confirmed previous findings 
that SNX5 is necessary for macropinocytosis in macrophages. Here, it was 
demonstrated that macropinocytosis is not SNX5 dependent in microglia cells, 
which highlights a difference between these two innate immune cells.  
 
 
 
5.2 Results 
Microglia and macrophages have the ability to survey their environment 
by utilising different endocytic mechanisms. Here, the role of SNX5 in 
macropinocytosis was investigated using microglia and macrophages from 
SNX5-/- mice. To compare primary microglia and BMDMs, both cell types were 
established in culture and cultured cell populations were initially examined for 
purity by confocal microscopy. BMDMs were stained for F4/80 (Fig. 5.1A) and 
microglia for CD11b (Fig. 5.1B). Based on the staining both BMDMs and 
microglia represented >90 % of the cell population. 
  
 
5.2.1 Macropinocytosis in macrophages and microglia 
The Gleeson lab has previously shown that SNX5 is crucial for dorsal 
ruffle-mediated macropinocytosis in primary macrophages (Lim et al., 2015). 
Here I investigated whether SNX5 is also required for macropinocytosis in 
microglia. First, microglia were isolated from wt and SNX5 knockout mice and 
the absence of SNX5 protein in cells from knockout mice confirmed by Western 
blot (Fig. 5.1C) and confocal microscopy (Fig. 5.1D, E). SNX5 protein levels 
were compared between microglia and macrophages from wt C57/BL6 mice by 
Western blot, which revealed a similar level of SNX5 between the two cell types 
(Fig. 5.1F). 
 
Macropinocytosis was then assessed by the uptake of FITC-labelled 70 kDa 
dextran, a size of dextran which is known to be taken up by macropinocytosis 
but not clathrin mediated endocytosis (Lim and Gleeson, 2011). Dextran uptake 
was determined after 15 minute and 45 minute incubation with FITC-labelled 70 
kDa dextran, in unprimed and LPS primed macrophages and microglia cells, 
and the monolayers examined by confocal microscopy. The number of dextran 
positive structures per cell was determined which revealed that SNX5-/- 
macrophages (<10 dextran positive structures), take up significantly less 
dextran than wt macrophages (~40 dextran positive structures) at the 45 minute 
time point. There was no difference between primed and unprimed cells (Fig. 
5.2A, B). In the presence of the macropinocytosis inhibitor Amiloride, minimal 
dextran was taken up by either wt or SNX5-/- macrophages. In primary microglia 
there was no difference between SNX5-/- and wt cells in the number of dextran 
positive structures (Fig. 5.2C). More dextran positive structures were observed 
in microglia (up to 100) than macrophages (~ 40). Furthermore, the dextran 
positive structures in microglia appeared smaller in size (Fig. 5.2.B, D). The 
ferets diameter (measurement of the ‘maximum diameter’) of the structures was 
measured and revealed that the dextran positive structures in macrophages are 
~2 times larger than those in microglia (Fig. 5.2.E). Amiloride was used as a 
control, confirming the dextran positive structures as macropinosomes. 
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Figure 5.1. Analysis of primary microglia and BMDM cultures from wt and 
SNX5 deficient mice  
Cells were prepared for confocal imaging and (A) BMDM preparations 
stained for F4/80, (B) microglia preparations stained for CD11b 
(representative images out of >10). Figures for (B, C, D) and (E) were 
obtained from microglia cultures. SNX5 knockout was confirmed by (C) 
Western blot and (D, E) confocal imaging. (F) SNX5 levels from western blots 
were quantified from microglia isolated from wt and SNX5-/- mice. The ratio 
of SNX5/GAPDH is presented.  
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Figure 5.2 Dextran uptake is SNX5 dependent in macrophages but not 
microglia 
Quiescent wt and SNX5-/- bone marrow derived macrophages (BMDMs) and 
primary microglia were incubated with 500 µg/ml FITC conjugated 70 kDa 
dextran, with or without LPS pre-stimulation. Cells were fixed and processed 
for confocal imaging. The level of FITC dextran uptake in (A, B) 
macrophages and (C, D) microglia and (E) size of dextran positive structures 
were determined with FIJI software. The macropinocytosis inhibitor Amiloride 
was used as a control. Samples were pre-incubated for 30 minutes with 100 
µM Amiloride and then incubated with 500 µg/ml dextran for 45 minutes. 
Statistical significance was determined by 2way ANOVA (A, C) and unpaired 
t-test (E). Data are mean ± SEM and levels of significance are indicated as 
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Data are pooled from 3 
independent experiments.  
 
Amiloride selectively blocks macropinocytosis and not clathrin dependent 
endocytic pathways, by lowering submembranous pH (Koivusalo et al., 2010) 
 
 
5.2.2 NaCl reduces cell viability of microglia in a p38 MAPK dependent manner 
An important feature of macrophages is the ability of sodium chloride to 
trigger an inflammatory response, a property, which exacerbates inflammation 
in the periphery. The impact of sodium chloride on inflammatory responses of 
microglia is largely unknown and was therefore investigated here.  
 
Macrophages and microglia were primed with LPS (150 ng/ml) for 3 hours, 
followed by 24 hour stimulation with NaCl (40 mM). First, the impact of NaCl on 
cell viability was assessed by flow cytometry. Cells were treated with NaCl (40 
mM) or Aβ (10 µM), or a combination of both, under primed and unprimed 
conditions. Additionally, osmolarity and tonicity controls, namely 80 mM 
mannitol and 80mM urea, respectively, were also tested. Treatment of microglia 
with LPS or NaCl alone did not affect cell viability; neither did Aβ treatment in 
primed microglia, or the mannitol and urea controls (Fig. 5.3B). Treatment with 
LPS and NaCl resulted in a decrease of viability in two samples out of five. 
Treatment with NaCl and Aβ under primed conditions resulted in a decrease in 
viability by ~25 % (Fig. 5.3B). Similar observations were made when assessing 
macrophage viability after the treatment conditions. Viability was ≥80 % in cells 
treated with either LPS, NaCl, mannitol or urea controls. A drop by 40 % of 
viability was found in primed macrophages treated with NaCl. Treatment of LPS 
primed macrophages with NaCl and Aβ reduced viability to ~50 %.  
 
Previous studies on macrophage activation by NaCl have suggested that the 
stimulation by NaCl is regulated via the p38 MAP kinase pathway (Jantsch et 
al., 2015). Therefore, experiments were also performed in the presence of the 
p38 MAPK inhibitor, SB203580. The decrease in viability of LPS and NaCl 
treatment of microglia was prevented by p38 inhibition. However, p38 MAPK 
inhibition did not prevent a decrease in viability of microglia treated with NaCl 
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Figure 5.3 p38 inhibition increases cell viability in NaCl and Aβ treated 
microglia and macrophages 
Primary microglia and BMDMs were pre-treated with LPS (150 ng/ml) for 3 
hours, followed by stimulation with NaCl (40 mM), Aβ (10 µM) or mannitol 
(80 mM), urea (80 mM) for osmolarity and tonicity controls respectively. Cell 
viability was then determined by Fluorescence activated cell sorting (FACS) 
using Fixable Viability Dye eFluor® 780. The gating strategy is shown on a 
representative (A) microglia and (C) macrophage sample. Single cells were 
identified by plotting forward scatter width (FSC-W) against forward scatter 
height (FSC-H); single microglia and macrophages were then separated 
from debris by a forward versus side scatter plot. Finally the percentage of 
viable cells in the population was calculated. Cell viability for each treatment 
was determined and compared between p38 MAPK inhibitor treated and 
untreated samples for both (B) microglia and (D) macrophages. Statistical 
significance was determined by t-test. Data are mean ± SEM and levels of 
significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. n=6 and data are from at least 3 independent experiments.  
and Aβ under primed conditions (Fig. 5.3B). Similar observations were made 
when assessing macrophage viability after the different treatment conditions. A 
reduced viability of ~60 % was found in primed macrophages treated with NaCl. 
In the presence of the p38 inhibitor viability was higher at ~85 %. Treatment of 
LPS primed macrophages with NaCl and Aβ reduced viability to ~50 %, whilst in 
the presence of the p38 inhibitor the viability significantly higher (~70 %) (Fig. 
5.3D). The data suggests, despite some inconsistencies, that reduction in cell 
viability following treatment of primed cells with NaCl can be at least partially 
prevented by inhibition of p38 MAPK.  
 
 
5.2.3 LPS driven nitrite secretion is augmented by NaCl and Aβ 
Previous studies have shown that NaCl augments LPS driven nitrite 
secretion in macrophages (Jantsch et al., 2015). Therefore, the effect of NaCl 
on nitrite production by primed macrophages and microglia was determined by 
measuring secreted nitric oxide in the conditioned media.  
 
Treatment of non-primed macrophages with NaCl or Aβ also did not result in 
nitrite secretion (Fig. 5.4B). Priming of macrophages with LPS resulted in a low 
level of nitrite secretion. However, there was a significant increase in nitrite 
secretion by macrophages treated with both LPS and NaCl, to ~25 µM was 
observed (Fig. 5.4B), consistent with published findings (Jantsch et al., 2015). 
Macrophages treated with LPS and Aβ also secreted nitrite to similar levels as 
LPS and NaCl. Moreover, the combination of NaCl and Aβ together with LPS 
resulted in an increase of secreted nitrite to ~50 µM (Fig. 5.4B). Similar 
observations were observed for nitrite secretion by primary microglia treated 
with NaCl (Fig. 5.4A). Here, either LPS and NaCl treatment or LPS and Aβ 
treatment resulted in ~50 µM nitrite detected in conditioned media. A 
combination of NaCl and Aβ, with LPS, augmented nitrite secretion by an 
additional ~25 µM (Fig. 5.4A). Neither treatment with the osmolarity control 
mannitol, nor with the tonicity control urea resulted in detectable nitrite secretion 
A 
B 
Figure 5.4 NaCl and Aβ augment LPS driven nitrite secretion 
(A) Primary microglia and (B) BMDMs were primed with LPS (150 ng/ml) for 
3 hours, followed by 24 hours of NaCl (40 mM) treatment and/or Aβ (10 µM) 
or osmolarity and tonicity controls; mannitol (80 mM) and urea (80 mM). 
Nitric oxide concentration was determined by Griess assay. Statistical 
significance was determined by one-way ANOVA. Data are mean ± SEM and 
levels of significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Data are pooled from at least 3 independent experiments. n= 
at least 5.  
 
		
in either microglia or macrophages (Fig. 5.4). Therefore, nitrite secretion by 
microglia in response to NaCl is very similar to macrophages. 
 
 
5.2.4 NaCl and Aβ stimulated nitrite secretion is regulated by p38 MAPK 
signalling 
Nitrite secretion was also determined in the presence of a p38 MAPK 
inhibitor, SB203580, to ascertain whether the stimulation resulting in nitrite 
secretion is p38 MAPK dependent. The p38 MAPK inhibitor was initially 
dissolved in DMSO, and diluted in medium with a final low concentration of 
DMSO of 0.04 % (v/v). This is well below toxicity levels of cultured cells, 
including PBMCs (Kloverpris et al., 2010). There was minimum nitrite secretion 
by untreated or NaCl treated microglia and low levels of nitrate secreted by LPS 
primed microglia in the absence of the inhibitor (Fig. 5.5, see also Fig. A3), 
consistent with the previous experiment. In the presence of p38 inhibitor the 
majority of LPS primed microglial samples showed only low levels of nitrate 
secretion compared with controls (Fig. 5.5A). Strikingly, in the presence of the 
p38 MAPK inhibitor, primed microglia treated with NaCl secreted ~50 % less 
nitrite than cells without p38 MAPK inhibition. Primed and Aβ treated microglia 
secreted ~60 % less nitrite upon p38 MAPK inhibition, and primed and NaCl 
and Aβ treated microglia secreted ~80 % less nitrite in the presence of the p38 
MAPK inhibitor (Fig. 5.5A).  
 
Nitrite secretion was also determined in macrophages in the presence and 
absence of the p38 MAPK inhibitor. In the presence of the p38 MAPK inhibitor, 
nitrite secretion was significantly lower compared with samples in absence of 
the inhibitor. This p38 inhibitor dependent reduction in nitrite secretion was 
observed in primed macrophages treated with NaCl, Aβ or NaCl and Aβ. Nitrite 
secretion was reduced by ~50 % in the presence of the p38 MAPK inhibitor 
(Fig. 5.5B). Therefore, the induction of secretion of nitrite following stimulation of 
macrophages or microglia with LPS and either NaCl or Aβ is dependent on the 
MAPK pathway.  
A 
B 
Figure 5.5 NaCl and Aβ augment LPS driven nitrite secretion in a p38 MAPK 
dependent manner 
(A) Primary microglia and (B) BMDMs were primed with LPS (150 ng/ml) for 
3 hours, followed by 24 hours of NaCl (40 mM) treatment and/or Aβ (10 µM) 
or osmolarity and tonicity controls; mannitol (80 mM) and urea (80 mM). p38 
MAPK signalling involvement was examine by using the p38 inhibitor, 
SB203580. Nitric oxide concentration was determined by Griess assay. 
Statistical significance was determined using t-test. Data are mean ± SEM 
and levels of significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Data are pooled from at least 3 independent experiments. n=at 
least 4. Outliers were removed based on Grubb’s test for outliers.  
 
		
  
5.2.5 NaCl treatment of LPS primed cells augments IL-1β secretion but not 
TNFα secretion  
As NaCl enhances nitrite secretion, NaCl may act as a secondary 
stimulus to activate the NLRP3 inflammasome IL-1β is secreted upon 
inflammasome activation (Sander et al., 2011). Therefore, the impact of NaCl 
and Aβ on the secretion of the pro-inflammatory cytokine, IL-1β, was quantified 
in microglia by ELISA. Primed microglia cells treated with NaCl did not show an 
increase in IL-1β secretion, whereas IL-1β secretion was increased in primed 
cells treated with Aβ (>1000 pg/ml) compared with primed cells alone (~500 
pg/ml). The combination of Aβ and NaCl showed a trend for higher levels of IL-
1β secretion, however this was not statistically significantly compared with Aβ 
alone (Fig. 5.6A). 
 
This effect of NaCl and Aβ on IL-1β secretion in macrophages was also 
assessed. NaCl treatment in LPS primed macrophages resulted in an increased 
IL-1β (~280 pg/ml) secretion and higher than any other of the macrophage 
treatments (Fig.5.6B). Overall the pro-inflammatory response to NaCl or NaCl 
and Aβ in macrophages were considerably lower than microglia (Fig. 5.6 A and 
B).  
IL-1β secretion was also assessed in the presence of the p38 MAPK inhibitor to 
determine whether IL-1β is secreted in a p38 dependent manner. IL-1β 
secretion by primed microglia treated with either Aβ alone or the combination of 
Aβ and NaCl was reduced by ~3 fold in the presence of the p38 inhibitor (Fig. 
5.7A). In contrast there was no significant difference in IL-1β secretion between 
macrophages with or without p38 inhibition (Fig. 5.7B). 
 
LPS priming of both microglia and macrophages resulted in a significant 
increase in TNFα secretion (Chapter 3), compared with untreated cells. I also 
assessed whether NaCl promotes and increase in TNFα section by 
macrophages and microglia. However, addition of NaCl to LPS primed cells 
A 
B 
Figure 5.6 IL-1β secretion following sodium chloride treatment 
(A) Primary microglia and (B) BMDMs were incubated with NaCl and/ or 
Aβ, either directly or after LPS priming. IL-1β secretion was determined 
in cell free culture medium by ELISA. Statistical significance was 
determined using one-way ANOVA. Data are mean ± SEM and levels of 
significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Data are pooled from at least 3 independent experiments 
and n=at least 5. 
	
A 
B 
Figure 5.7 IL-1β secretion is reduced in presence of p38 inhibitor in 
microglia but not BMDMs 
(A) Primary microglia and (B) BMDMs were incubated with NaCl and/ or 
Aβ, either directly or after LPS priming, in the presence of p38 inhibitor. 
IL-1β secretion was determined in cell free culture medium by ELISA. 
Statistical significance was determined using t-test. Data are mean ± 
SEM and levels of significance are indicated as *p<0.05, **p<0.01, 
***p<0.001 and ****p<0.0001. Data are pooled from at least 3 
independent experiments and n=at least 4. 
	
does not result in a further increase of TNFα secretion as compared to LPS 
treatment alone (Fig. 5.8).  
 
 
 
5.3 Discussion 
With both microglia and macrophages playing an integral role in innate 
immunity, the well-characterised macrophages provide an opportunity to 
compare the characteristics of the two myeloid cells. In this Chapter, microglia 
were compared to macrophages, revealing both similarities and differences in 
their behaviour.  
Macropinocytosis is utilised by macrophages to carry out important immune 
functions. The Gleeson lab has previously identified SNX5 as a regulator of 
macropinocytosis in macrophages, but not dendritic cells. Upon activation of 
macrophages actin rich ruffles were located on the dorsal surface, which co-
localised with SNX5. In SNX5-/- macrophages, dorsal ruffling was reduced. 
Peripheral ruffling however was unaffected by knock out of SNX5 (Lim et al., 
2015). Here, it was shown that macropinocytosis is SNX5 independent in 
microglia, and the SNX5 dependent dextran uptake in macrophages was 
confirmed (Fig. 5.2). Dextran positive structures in microglia were significantly 
smaller than those in macrophages (Fig. 5.2E) and did appear more rounded 
and less donut like. Whilst the difference between peripheral and dorsal ruffling 
was not determined in this study, the smaller diameter of the dextran positive 
structures in microglia suggests peripheral ruffling to be the predominant route 
for macropinocytic uptake in microglia. Another striking feature of dorsal ruffles 
is their characteristic ring like structure (Hoon et al., 2012; Condon et al., 2018). 
Both the smaller size and the lack of ring like structure support this hypothesis. 
This could be further examined by scanning electron microscopy for 
ultrastructural analysis of the plasma membrane.  
 
The effects of NaCl on microglia function were largely unknown, and may 
provide important insights into how diet could impact neuroinflammation and 
A 
B 
Figure 5.8 NaCl does not augment LPS driven TNFα secretion 
(A) Primary microglia and (B) BMDMs were primed with LPS (150 ng/ml) for 
3 hours, followed by 24 hours of NaCl (40 mM) treatment or osmolarity and 
tonicity controls mannitol (80 mM) and urea (80 mM). Supernatants were 
collected and TNFα levels determined by ELISA. Statistical significance was 
determined using one-way ANOVA. Data are mean ± SEM and levels of 
significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Data are pooled from at least 3 independent experiments. n= 
at least 4. 
	
AD. The results presented in this Chapter show that NaCl not only induces a 
pro-inflammatory response in LPS primed macrophages, but also in primed 
microglia. In the presence of Aβ, the NaCl effect is further enhanced. The pro-
inflammatory response mediated by NaCl is regulated by p38 MAPK signalling 
and results in elevated nitrite secretion, as well as IL-1β secretion. In the 
presence of a p38 inhibitor, these pro-inflammatory responses were attenuated.  
 
The present study demonstrated that high NaCl concentrations induce a strong 
pro-inflammatory phenotype in LPS primed microglia and macrophages. This 
effect is augmented in the presence of Aβ. Previous studies using C57/BL6 
mice and rats have suggested a correlation between high salt and cholesterol 
diet and neuroinflammation and cognitive impairment, (Mogi et al., 2007; 
Husain et al., 2017). These rodent studies assessed a combination of high salt 
and cholesterol. Given the strong pro-inflammatory phenotype observed in this 
current study with salt, my findings suggest that salt alone could contribute to 
neuroinflammation. A high salt diet is considered as an important risk factor for 
several vascular diseases including ischemic stroke (Gardener Hannah et al., 
2012). Additionally, Zhang and colleagues have demonstrated that high salt can 
exacerbate BBB disruption during ischemia. Interestingly this was found to be 
p38 MAPK pathway dependent (T. Zhang et al., 2015). These previous findings 
are consistent with the current study, where I have demonstrated that inhibition 
of p38 MAPK abrogates NaCl and Aβ induced nitrite secretion in LPS primed 
microglia and macrophages (Fig. 5.5). Additionally, in microglia, IL-1β secretion 
was significantly reduced in the presence of the p38 MAPK inhibitor. The data 
obtained for IL-1β secretion by primed macrophages treated with NaCl was 
varied, with data points spread between 0-800 pg/ml. Due to the variation of 
data there is no significant reduction with p38 MAPK inhibition. However, the 
average IL-1β secretion was reduced in the presence of the p38 MAPK inhibitor 
by ~50 % (Fig. 5.7B). Treatment with Aβ did not result in an increase in IL-1β in 
macrophages, unlike microglia. 
The elevated IL-1β secretion by microglia in the presence of NaCl and Aβ 
together with a decrease in viability suggests NLRP3 inflammasome activation 
(He et al., 2016). NaCl could function as a secondary stimulus to NLRP3 
activation in LPS primed cells. Moon and colleagues have demonstrated that 
p38 MAPK knockdown reduces Nlrp3 gene expression in peritoneal 
macrophages (Moon et al., 2015), suggesting p38 dependent NLPR3 activation. 
However, priming and subsequent upregulation of NLRP3 and pro-IL-1β was 
also shown to be regulated by the activation of the transcription factor NFκB (He 
et al., 2016). This could explain why inhibition of p38, which blocks MAPK 
pathway but not NFκB, does not protect from NaCl and Aβ induced reduction of 
viable microglia (Fig. 5.3B). In primed macrophages, treated with NaCl and Aβ, 
cell viability is significantly higher in the presence of the p38 MAPK inhibitor 
than without the inhibitor (Figure 5.3D). 
 
Another study assessing macrophage responses to high salt diet in CNS 
autoimmunity disease also concluded both NFκB and MAPK signalling were 
involved in a NaCl induced pro-inflammatory phenotype (Hucke, Eschborn, et 
al., 2016; Hucke, Wiendl, et al., 2016). Studying the effects of high salt intake in 
a mouse model of MS, namely experimental autoimmune encephalomyelitis 
(EAE), these authors have demonstrated that NaCl promotes a strong pro-
inflammatory phenotype in myeloid cells. This pro-inflammatory response was 
characterised by increased iNOS expression, and upregulation of pro-
inflammatory cytokines. Additionally they showed that the NaCl induced pro-
inflammatory phenotype observed in macrophages was regulated by activation 
of both NFκB and MAPK signalling (Hucke, Eschborn, et al., 2016). 
 
Overall, my study has confirmed and extended previous findings as the data 
demonstrates that high salt induced a pro-inflammatory phenotype in both 
macrophages and microglia. These findings have implications on the 
development and propagation of neuroinflammation in AD. This suggestion is 
further supported by the finding that Aβ enhanced the NaCl induced pro-
inflammatory response in microglia. Thus, NaCl should be further investigated 
as a potential risk factor for neurodegenerative diseases.  
 
Other studies have also suggested that NaCl induced pro-inflammatory 
phenotype in macrophages is regulated by a p38 MAPK signalling pathway 
(Ying and Sanders, 2002; W.-C. Zhang et al., 2015; T. Zhang et al., 2015). On 
the other hand Husain and colleagues demonstrated that inhibition of NFκB 
signalling attenuated high salt and cholesterol diet induced neuroinflammation 
(Husain et al., 2017). To further define the underlying mechanism in microglia, 
inhibitor experiments for both p38 MAPK and NFκB signalling should be 
performed.  
 
In order to confirm NLRP3 inflammasome activation in microglia, analysis of 
caspase1 levels would be useful. Initial attempts to quantify levels of caspase-1 
by immunoblotting were unsuccessful and time constraints precluded resolving 
the technical problems. Another approach to confirm a role for NLRP3 
inflammasome activation in microglia would be the use of microglia derived from 
NLRP3-/- animals.  
 
Taken together, the data presented here suggests a role of NaCl in the 
induction of a pro-inflammatory phenotype, which may be further heightened in 
the presence of Aβ. These findings could be of relevance to neuroinflammation 
and AD and is of particular importance in light of the high salt content in western 
diets, which has already been linked to a pathological T cell response 
contributing to CNS autoimmunity (Hucke, Eschborn, et al., 2016).  
 
Chapter 6: General Discussion 
 
Neuroinflammation has emerged as one of the pathological hallmarks of 
AD and is considered to be the link between Aβ deposition, tauopathy and 
neurodegeneration. Microglia represent the major population of immune cells of 
the CNS and play a key role in driving neuroinflammatory responses under 
pathological conditions (Heneka et al., 2015; Heneka, 2019). A number of the 
AD risk genes are associated with impaired microglia function. The most 
common risk gene for LOAD, APOE is one of them (Holtzman et al., 2012). 
However, the underlying mechanism by which APOE promotes 
neurodegeneration is unknown.  
 
In this study, the effect of ApoE on primary microglia was investigated. Of 
particular interest was the response to immunostimulation (LPS and ATP) and 
Aβ treatment as these conditions model inflammatory conditions and Aβ load, 
respectively, in the AD brain. Using this approach, it was demonstrated that 
ApoE4 microglia elicit the strongest pro-inflammatory response to a variety of 
treatments, as determined by TNFα and IL-1β secretion. ApoE2 microglia also 
displayed a significant pro-inflammatory response, which was particularly 
pronounced after Aβ stimulation under primed conditions. Additionally, an ApoE 
dependent effect on Aβ clearance was demonstrated. 
 
Subsequently, the effects of microglia conditioned media from the different 
ApoE alleles on neurons were determined. Using physiologically relevant 
primary mouse cortical neurons, it was elucidated that ApoE isoforms differently 
affected dendrite morphology with ApoE4-derived conditioned media inducing 
the most detrimental effects. Dendritic morphological changes were also found 
to be dependent on the particular treatment of microglia. TNFα was identified as 
a key contributor to dendrite shortening and loss.  
 
Known macrophage functions were compared to microglia. Here it was 
confirmed that macropinocytosis is SNX5-dependent in macrophages, and 
shown that microgial macropinocytosis is SNX5-independent. The data 
suggests that macropinocytosis in microglia is peripheral-ruffle mediated. 
However, this needs further investigation.  
 
 
6.1  Effect of ApoE genotype on microglia function  
 ApoE is the strongest genetic risk factor for LOAD (Strittmatter et al., 
1993; Corder et al., 1993). The lipid trafficking protein contributes to the relative 
risk of an individual of developing AD and has been proposed to play an 
immunomodulatory role (Shi and Holtzman, 2018). However, the precise 
mechanisms are not well understood. The effects of ApoE on microglia function 
are still largely unknown; studies involving a comparison of all three ApoE 
alleles are rare. Given the different disease-associated risk of ApoE2, ApoE3 
and ApoE4 variants, detailed functional analyses of all three is required to 
identify the relevant mechanism for AD susceptibility. Most studies have 
focused on comparing one allele, either ApoE2 or ApoE4, with the more 
common ApoE3 allele (Guo et al., 2004). In the current study, all three ApoE 
alleles were compared. My studies have demonstrated that stimulation of 
ApoE4 microglia induces the strongest pro-inflammatory response, consistent 
with the role of ApoE4 in propagating a neuroinflammatory situation in the brain 
(Vitek et al., 2009; Gale et al., 2014). The pro-inflammatory response of ApoE4 
is attributed to the response to multiple TLR ligands (Gale et al., 2014), in this 
case induced by TLR4 activation. Whilst a strong pro-inflammatory response is 
associated with ApoE4, ApoE2 microglia were also found to secrete higher 
levels of TNFα than ApoE3 microglia. Anti-inflammatory cytokines including 
TGFβ and IL1RA were also identified by MS analysis. This further highlights the 
importance of not only investigating the pro-inflammatory response but also 
anti-inflammatory mediators. An imbalance of pro- and anti-inflammatory 
cytokines appears the most likely reason for the ApoE4 induced 
neuroinflammatory phenotype (Newcombe et al., 2018). Using mass 
spectrometry (MS), I established a strategy to attempt to identify the cytokine 
profiles of conditioned media from immuno- and Aβ- stimulated microglia. The 
qualitative MS analysis allowed the identification of several cytokines and 
illustrates that MS can be utilised for detection of cytokines in spent culture 
media. The biggest diversity of pro-and anti-inflammatory cytokines was 
identified in conditioned media from ApoE2 microglia. Noteworthy is also that a 
number of studies have suggested dual roles for a variety of cytokines. TNFα, 
IL-6 and TGFβ can function as both pro-and anti-inflammatory (Sanjabi et al., 
2009; Scheller et al., 2011; Zheng et al., 2016). 
 
Additionally, the impact of ApoE on Aβ clearance were investigated. The data 
presented in Chapter 3 showed that Aβ clearance follows an order of clearance 
efficiency; ApoE2 > ApoE3 > ApoE4 and is consistent with the findings from 
Castellano and colleagues, demonstrating that the ApoE isoform determines 
the rate of clearance of Aβ in vivo (Castellano et al., 2011). Moreover, it has 
been demonstrated that ApoE isoform dictates the rate of degradation in 
macrophages, following the same order as described above (Zhao et al., 2009).  
 
 
6.2 Effect of ApoE microglia conditioned media on neurons 
Treating primary neurons with conditioned media from immunostimulated 
and Aβ treated microglia provided a cell based system to analyse the effects of 
ApoE and microglia activation on neurons under pathophysiological conditions. 
The most dramatic change in neuronal morphology was detected with neurons 
treated with conditioned media from ApoE4 microglia that had been 
immunostimulated. This finding further highlights the detrimental effects of 
ApoE4 microglia. Not only is ApoE4 associated with a strong pro-inflammatory 
response by microglia but also the secreted factors from ApoE4 microglia 
drastically impacts dendrite morphology. How the altered morphology of 
neurons affects function remains to be investigated. Of particular interest would 
be to determine the level of Aβ secreted by neurons under the various 
treatments in this assay. ApoE4 microglia was also the ApoE microglia 
population with the highest level of secreted TNFα following stimulation. Of the 
glial cell populations, microglia are the main source of TNFα (Welser-Alves and 
Milner, 2013), which seems to be particularly strong in ApoE4 microglia.  
 
Noteworthy is also that neurons treated with conditioned media from untreated 
ApoE4 microglia had less and shorter dendrites than those treated with 
conditioned media from the other untreated microglia genotypes. This was a 
very reproducible finding and is difficult to explain. The ApoE isoform could be 
affecting the activity of components in the medium even under basal conditions 
ApoE could also have a direct effect on neurons. This could be further 
investigated by treating wt C57/BL6 neurons with purified ApoE proteins. 
Quantitative analysis of ApoE secretion could also be of interest.  
 
The pro-inflammatory response by immunostimulated microglia was particularly 
potent in terms of TNFα secretion. TNFα is a pro-inflammatory cytokine 
implicated in AD (Chang et al., 2017). Furthermore previous studies have 
shown that stimulation TNFα in combination with NMDA receptor (Floden et al., 
2005) is neurotoxic. TNFα on its own however does not result in increased 
neuronal death (Floden et al., 2005). Treating neurons with purified TNFα 
resulted in changes to dendrite morphology that were similar to those observed 
in neurons treated with microglia conditioned media. Neutralising TNFα 
prevented the morphological changes. The concentrations of purified TNFα 
used to treat neurons were chosen to mimic the concentrations detected in 
microglia conditioned media, as described in Chapter 3. Loss of dendrites 
treated with 1 ng/ml TNFα (Fig. 4.5) are most similar to neurons treated with 
conditioned media from ApoE3 microglia (Fig. 4.3), suggesting that the majority 
of dendritic changes mediated by the conditioned media can be accounted for 
by TNFα.  
 
Neutralising TNFα in the microglia conditioned media had protective effects on 
dendrite morphology, suggesting TNFα is one of the key contributors to the 
neuronal changes promoted by the conditioned media. This protective effect 
upon TNFα neutralisation was detected across all three ApoE genotypes as 
well as the wt control. The findings for the different ApoE variants in this study 
are summarised in Table 6.1. 
 
The anti-TNFα antibody also had a protective effect on neurons treated with 
conditioned media from untreated microglia, that is neurons had more and 
longer dendrites. This is curious, as the TNFα ELISA, as well as the MS 
analysis, did not detect TNFα in conditioned media from untreated microglia. 
One possibility is the presence of very low levels of TNFα secreted by untreated 
microglia or alternatively, a non-specific effect of the anti-TNFα antibody in the 
assay, which should be further investigated by inclusion of isotype control 
antibodies in the assay. Studies investigating the effect of Aβ stimulated THP-1 
cell conditioned media on neurons have also reported protective effects of anti-
TNFα antibodies (Combs et al., 2001). The protective effects of anti-TNFα 
antibody treatment are particularly interesting since numerous studies have 
investigated a correlation between TNFα antibody therapies, used in the 
treatment of RA, and AD. Of note is that a connection between anti-TNFα 
therapy for RA and reduced risk of AD amongst RA patients was recently 
reported (Chou et al., 2016). This is an exciting observation that needs further 
investigation. 
 
 
6.3 High salt as an inflammatory modulator  
Several studies have identified a positive correlation between high salt 
and inflammation and demonstrated that a high salt microenvironment can 
induce a pro-inflammatory phenotype in T cells, THP-1 cells and BV-2 cells 
(Kleinewietfeld et al., 2013; Graham et al., 2015; Binger et al., 2015). High salt 
diets have also been associated with cognitive decline (Liu et al., 2014). 
Moreover, a reduction in Aβ clearance was observed in BV-2 and THP-1 cells 
treated with NaCl, suggesting an important role of NaCl in brain function (Cheng 
et al., 2015). Data presented in Chapter 5 suggests an important role for NaCl 
in inducing a strong pro-inflammatory phenotype. My findings suggest that NaCl 
activates the NLRP3 inflammasome, as indicated by the high levels of IL-1β 
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detected upon NaCl treatment of both LPS primed microglia and macrophages. 
Investigating high dietary salt as an environmental risk factor or effector of AD 
could provide new insights into AD development. Studies have also investigated 
the effect of western diet, high in fat and salt, in systemic inflammation and 
determined the NLRP3 inflammasome as a central receptor (Christ et al., 2018). 
My study further supports the hypothesis that NLRP3 inflammasome activation 
could be causative for the strong pro-inflammatory response detected in primed 
and NaCl treated microglia. To confirm whether NaCl activates the NLRP3 
inflammasome, studies could also be carried out with NLRP-/- microglia cells.  
In addition, imaging of AD patients brains has revealed elevated Na+ 
concentrations and a correlation between K+ and Aβ load (Graham et al., 
2015), suggesting an important role in AD. Analysis of dietary salt intake of 
patients in early stages of AD or MCI could be informative.  
 
My results also demonstrate that ApoE4 microglia respond strongly to 
immunomodulatory and Aβ treatment. It would be of interest to determine 
whether the microglia from ApoE4 heterozygotes also respond more strongly to 
high NaCl, using the cell based assays. In addition, studies with ApoE TR mice 
could reveal important insights and determine whether a pro-inflammatory 
response to NaCl is ApoE isotype dependent. Combined with the poor Aβ 
clearance by ApoE4 microglia, these additional approaches could reveal the 
mechanisms by which ApoE4 increases the AD risk of an individual. 
 
Taken together, a system to analyse secreted components of stimulated 
microglia by MS and neuron morphology was successfully established. This 
system could be used for analysis of other secretory components, and also 
after different microglial activation protocols. These could include activation with 
non-bacterial components such as IL-4 or IFNγ (Suzumura et al., 1994; 
Takeuchi et al., 2006). 
 
 
6.4 Future directions 
 Given the relevance of inflammation to the progression and pathology of AD, 
current therapeutic treatments from other chronic inflammatory conditions could 
be exploited. The role of MMPs in AD was mentioned earlier. MMPs play a 
crucial role in the development of osteoarthritis. As for neuroinflammation, in 
osteoarthritis TNFα and IL1β drive the inflammatory process (Schlaak et al., 
1995). Pharmacological inhibition of MMP13 is an effective strategy in mouse 
models of osteoarthritis (Wang et al., 2013). Of relevance, is the selective 
targeting of MMP13 decreases elF4B phosphorylation causing a reduction of 
BACE1 synthesis and studies in a mouse model resulted in attenuated cerebral 
amyloid pathology, rescued learning and memory deficits in an AD mouse 
model (Paumier and Thinakaran, 2019). Hence, these findings provide support 
to investigate strategies for anti-inflammatory treatments in AD.  
 
Another approach is to target the feedback loop between pro-inflammatory 
cytokine release by activated microglia and Aβ production and its dispersal. 
More information is required on how activated microglia affect neurons. In 
addition, exploiting newly emerging 3D models of brain tissue (Cho et al., 2018) 
containing activated microglia and neurons could also aid in defining the key 
events associated with Aβ secretion and turnover, and Aβ neurotoxicity under 
inflammatory conditions. Organoid cultures of neurons, microglia and astrocytes 
from iPSC cells derived from cells from patients with familial mutations could 
provide a powerful approach to understand the impact of disease-causing 
mutations within a cellular environment that mimics the physiological tissue. 
 
In addition to in vitro cell and tissue systems, existing mouse models used by 
immunologists and neurobiologists could be further exploited. For example, 
cytokine reporter mice (Croxford and Buch, 2011), used extensively in 
immunological studies of peripheral responses, could be used for the 
identification of cytokine expressing cells in vivo, and would be particularly 
useful for neuroinflammation studies. Furthermore, use of NLRP3-/- could be 
beneficial to further elucidate the role of the NLRP3 inflammasome in AD.  
 The application of sophisticated imaging technologies with AD mouse models 
would also be beneficial. These may include combining fluorescence labelling 
of proteins of interest and secreted cytokines with cranial windows in AD mouse 
models, to track the events in situ. Also, laser capture microdissection-targeted 
mass spectrometry could also be used to identify inflammatory cytokines and 
other neurotoxic products in defined regions of the brain in AD mouse models. 
A recent study by MacDonald and colleagues (MacDonald et al., 2019) has 
successfully investigated this combined approach. Analysing both human and 
monkey model post mortem they were able to quantify over 200 proteins in 
different cortical layers. This promising approach has the advantage of 
exceptional precision and throughput without losing sensitivity and has the 
potential to generate insights into proteomics of specific brain tissues 
(MacDonald et al., 2019). This approach could potentially be exploited for 
cytokine profile analysis in human post mortem studies. Such approaches 
would provide a spatial map of the events associated with neuroinflammation 
and the impact on neurons. 
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Figure A1 Nitrite secretion in primary microglia. 
(A) Primary microglia cells were immunostimulated for 4h with and without 
LPS pre-stimulation. Nitrite concentration was determined by Griess assay 
in cell free supernatants, which were collected immediately after treatment. 
Dashed line represents the detection limit of the assay. n=2 
x 
Appendix: 
Figure A2 Microglial TNFα secretion  
Primary microglia cells were treated with different concentrations of Aβ (5 
µM, 10 µM) for 1 hour, either directly or after 3 hours LPS pre-stimulation. 
TNFα secretion was measured in cell free supernatants by ELISA. 
Supernatants were collected immediately after treatment (A). Statistical 
significance was determined using a 2way ANOVA. Data are mean ± SEM 
and levels of significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Data are presented without performing outlier analysis. n=3 
and data is from 3 independent experiments.  
x 
Figure A3 Nitrite secretion in primary microglia 
Primary microglia and were primed with LPS (150 ng/ml) for 3 hours, 
followed by 24 hours of NaCl (40 mM) treatment and/or Aβ (10 µM) or 
osmolarity and tonicity controls; mannitol (80 mM) and urea (80 mM). p38 
MAPK signalling involvement was examine by using the p38 inhibitor, 
SB203580. Nitric oxide concentration was determined by Griess assay. 
Statistical significance was determined using t-test. Data are mean ± SEM 
and levels of significance are indicated as *p<0.05, **p<0.01, ***p<0.001 and 
****p<0.0001. Data are presented without performing outlier analysis. Data 
are pooled from at least 3 independent experiments. n=at least 4.  
 
		
